US20080187928A1 - Methods for enhancing exercise performance - Google Patents

Methods for enhancing exercise performance Download PDF

Info

Publication number
US20080187928A1
US20080187928A1 US11/966,851 US96685107A US2008187928A1 US 20080187928 A1 US20080187928 A1 US 20080187928A1 US 96685107 A US96685107 A US 96685107A US 2008187928 A1 US2008187928 A1 US 2008187928A1
Authority
US
United States
Prior art keywords
pparδ
exercise
protein
subject
ampk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/966,851
Inventor
Ronald M. Evans
Vihang A. Narkar
Yong-Xu Wang
Michael Downes
Ruth T. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Howard Hughes Medical Institute
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/966,851 priority Critical patent/US20080187928A1/en
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Assigned to HOWARD HUGHES MEDICAL INSTITUTE reassignment HOWARD HUGHES MEDICAL INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NARKAR, VIHANG A.
Assigned to HOWARD HUGHES MEDICAL INSTITUTE reassignment HOWARD HUGHES MEDICAL INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVANS, RONALD M.
Assigned to SALK INSTITUTE FOR BIOLOGICAL STUDIES reassignment SALK INSTITUTE FOR BIOLOGICAL STUDIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WANG, YONG-XU, DOWNES, MICHAEL, YU, RUTH T.
Assigned to SALK INSTITUTE FOR BIOLOGICAL STUDIES reassignment SALK INSTITUTE FOR BIOLOGICAL STUDIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWARD HUGHES MEDICAL INSTITUTE
Publication of US20080187928A1 publication Critical patent/US20080187928A1/en
Priority to CA2710764A priority patent/CA2710764A1/en
Priority to EP08866040A priority patent/EP2234622A4/en
Priority to JP2010540930A priority patent/JP2011507970A/en
Priority to AU2008345009A priority patent/AU2008345009A1/en
Priority to US12/810,123 priority patent/US9192601B2/en
Priority to PCT/US2008/088466 priority patent/WO2009086526A2/en
Assigned to SALK INSTITUTE FOR BIOLOGICAL STUDIES reassignment SALK INSTITUTE FOR BIOLOGICAL STUDIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWARD HUGHES MEDICAL INSTITUTE
Assigned to HOWARD HUGHES MEDICAL INSTITUTE reassignment HOWARD HUGHES MEDICAL INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NARKAR, VIHANG A., SHAW, REUBEN J., EVANS, RONALD M.
Assigned to SALK INSTITUTE FOR BIOLOGICAL STUDIES reassignment SALK INSTITUTE FOR BIOLOGICAL STUDIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOWNES, MICHAEL, YU, RUTH T.
Priority to US13/899,292 priority patent/US20140005238A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • This disclosure concerns the use of peroxisome proliferator-activated receptor (PPAR) ⁇ agonists for improving exercise performance in a subject, methods for identifying substance-enhanced exercise performance in a subject, and methods for identifying compounds that affect the interaction of PPAR ⁇ with exercise-induced kinases.
  • PPAR peroxisome proliferator-activated receptor
  • Skeletal muscle is an adaptive tissue composed of multiple myofibers that differ in their metabolic and contractile properties including oxidative slow-twitch (type I), mixed oxidative/glycolytic fast-twitch (type IIa) and glycolytic fast-twitch (type IIb) myofibers (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000).
  • Type I muscle fibers preferentially express enzymes that oxidize fatty acids, contain slow isoforms of contractile proteins and are more resistant to fatigue than are glycolytic muscle fibers (Fluck et al., Rev. Physiol. Biochem.
  • Type II fibers preferentially metabolize glucose and express the fast isoforms of contractile proteins (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000).
  • Endurance exercise training triggers a complex remodeling program in skeletal muscle that progressively enhances performance in athletes such as marathon runners, mountain climbers and cyclists. This involves changes in metabolic programs and structural proteins within the myofibers that alter the energy substrate utilization and contractile properties that act to reduce muscle fatigue (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000). Training based adaptations in the muscle are linked to increases in the expression of genes involved in the slow-twitch contractile apparatus, mitochondrial respiration and fatty acid oxidation (Holloszy and Coyle, J. Appl.
  • PPARs are members of the nuclear receptor superfamily of ligand-inducible transcription factors. They form heterodimers with retinoid X receptors (RXRs) and bind to consensus DNA sites composed of direct repeats of hexameric DNA sequences separated by 1 bp. In the absence of ligand, PPAR-RXR heterodimers recruit corepressors and associated histone deacetylases and chromatin-modifying enzymes, silencing transcription by so-called active repression (Ordentlich et al., Curr. Top. Microbiol. Immunol., 254:101-116, 2001; Jepsen and Rosenfeld, J. Cell Sci., 115:689-698, 2002; Privalsky, Ann.
  • RXRs retinoid X receptors
  • Ligand binding induces a conformational change in PPAR-RXR complexes, releasing repressors in exchange for coactivators.
  • Ligand-activated complexes recruit the basal transcriptional machinery, resulting in enhanced gene expression.
  • PPARs bind to lower-affinity ligands generated from dietary fat or intracellular metabolism. In keeping with their roles as lipid sensors, ligand-activated PPARs turn on feed-forward metabolic cascades to regulate lipid homeostasis via the transcription of genes involved in lipid metabolism, storage, and transport.
  • PPAR ⁇ is expressed in most cell types with relative abundance (Smith, Biochem. Soc. Trans., 30(6):1086-1090, 2002), which led to early speculation that it may serve a “general housekeeping role” (Kliewer et al., Proc. Natl. Acad. Sci. U.S.A., 91:7355-7359, 1994).
  • PPAR ⁇ transgenic mouse models and discoveries aided by the development of high-affinity PPAR ⁇ agonists have revealed PPAR ⁇ as a key transcriptional regulator with effects in diverse tissues including fat, skeletal muscle, and the heart (for review see, e.g., Barish et al., J. Clin. Invest., 116(3):590-597, 2006).
  • PPAR ⁇ receptor VP16-PPAR ⁇
  • VP16-PPAR ⁇ constitutively active PPAR ⁇ receptor
  • the observed PPAR ⁇ -mediated reprogramming of muscle fibers involved the increased expression of genes related to fatty acid oxidation, mitochondrial respiration, oxidative metabolism, and slow-twitch contractile apparatus (Wang et al., PLoS Biol., 2:e294, 2004).
  • PPAR ⁇ agonists e.g., GW1516
  • exercise-induced effects such as to improve exercise endurance (e.g., running endurance) even more than may be achieved by exercise alone.
  • exercise endurance e.g., running endurance
  • the expression of one or more genes and/or proteins that are uniquely regulated by the combination of exercise and PPAR ⁇ agonist administration can be used to identify subjects using drugs to enhance exercise performance.
  • the newly identified protein complexes including PPAR ⁇ and exercise-induced kinases (such as AMPK ⁇ 1 and/or AMPK ⁇ 2), can be used to identify agents that have potential to affect PPAR ⁇ -regulated gene networks and the corresponding downstream biochemical and/or physiological effects.
  • exercise-induced kinases such as AMPK ⁇ 1 and/or AMPK ⁇ 2
  • FIG. 1A is a series of bar graphs showing the effects of orally administered PPAR ⁇ agonist (GW1516) on mRNA expression levels of three biomarkers of fatty acid oxidation, uncoupling protein 3 (UCP3), carnitine palmitoyl-transferase I (mCPT I), and pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4), in quadriceps muscle isolated from sedentary vehicle-treated (V), sedentary GW1516-treated (GW), sedentary VP16-PPAR ⁇ transgenic (TG), and sedentary wild-type littermates of VP16-PPAR ⁇ transgenic mice (WT).
  • V sedentary vehicle-treated
  • GW1516-treated sedentary VP16-PPAR ⁇ transgenic
  • WT sedentary wild-type littermates of VP16-PPAR ⁇ transgenic mice
  • FIG. 1B-D are a series of bar graphs showing the regulation of oxidative genes UCP3, mCPT I, and PDK4 by GW1516 (GW) in wild-type (WT) and PPAR ⁇ null (KO) primary muscle cells. * represents statistical significance between V and indicated groups (p ⁇ 0.05, One Way ANOVA; post hoc: Dunnett's Multiple Comparison Test)
  • FIG. 1E is a series of bar graphs showing running endurance of vehicle-treated sedentary (V; open bars) and GW1516-treated sedentary (GW; black bars) mice before (Week 0) and after (Week 5) treatment.
  • FIGS. 2A-C show the effects of administration of a PPAR ⁇ agonist, GW1516, on the gastrocnemius muscle of sedentary (V or GW) or trained (Tr or Tr+GW) mice.
  • FIG. 2A shows digital images of representative meta-chromatically stained frozen cross-sections of gastrocnemius muscle from vehicle-treated, sedentary (V), GW1516-treated, sedentary (GW), vehicle-treated, exercised (Tr) and GW1516-treated, exercised (Tr+GW) mice.
  • Type I slow oxidative
  • Data in (B) and (C) are presented as mean ⁇ SEM.
  • * represents a statistical difference between V and the group(s) indicated by asterisk (p ⁇ 0.05, One-Way ANOVA; post hoc: Dunnett's Multiple Comparison Test).
  • FIGS. 3A-C are a series of bar graphs showing gene expression in quadriceps muscle isolated from V, GW, Tr and Tr+GW groups.
  • FIG. 3A shows the relative gene expression levels of biomarkers for fatty acid oxidation (UCP3, mCPT I, PDK4; from left to right).
  • FIG. 3B shows the relative gene expression levels of biomarkers for fatty acid storage (SCD1, FAS, SREBP1c).
  • oxidative biomarkers myoglobin, UCP3, CYCS, SCD1
  • tubulin loading control
  • FIG. 7A is a series of Western blot images showing AMPK activation by exercise.
  • FIG. 7B is a series of Western blot images showing AMPK activation by VP16-PPARd over-expression.
  • the levels of phospho-AMPK (phospho-AMPK) and total-AMPK in quadriceps muscle of sedentary wild-type or transgenic mice (Sed/WT or Sed/TG) are shown.
  • FIGS. 8A-B show the synergistic regulation of muscle gene expression by PPAR ⁇ and AMPK.
  • FIGS. 10A-L demonstrate the AMPK-PPAR ⁇ interaction.
  • A-D show the expression of metabolic genes in wild type and PPAR ⁇ null (KO) primary muscle cells treated with V, GW, AI and GW+AI (bars from left to right) for 24 hours.
  • E-F, J AD293 cells were transfected with PPAR ⁇ +RXR ⁇ +Tk ⁇ PPRE along with control vector, AMPK ⁇ 1, ⁇ 2 and/or PGC1 ⁇ as indicated above.
  • E Induction of basal PPAR ⁇ transcriptional activity by AMPK ⁇ 1 or ⁇ 2.
  • GenBank accession number Nucleic acid and amino acid sequences may be referred to herein by GenBank accession number. It is understood that the sequences given such GenBank accession numbers are incorporated by reference as they existed and were known as of Dec. 29, 2006.
  • a subject physical activity such as aerobic exercise (e.g., running)
  • a PPAR ⁇ agonist e.g., GW1516
  • the exercise effect that is enhanced can be, for example, improved running endurance (such as, improved running distance or improved running time or a combination thereof, increased fatty acid oxidation in at least one skeletal muscle of the subject, and/or body fat (e.g., white adipose tissue) reduction).
  • a subject is a mammal (such as a racing mammal, like a horse, a dog, or a human), and/or an adult, and/or an exercise-trained subject.
  • the PPAR ⁇ agonist is administered on the same day(s) on which the physical activity is performed.
  • administration of the PPAR ⁇ agonist is by oral administration, intravenous injection, intramuscular injection, and/or subcutaneous injection.
  • the effective amount of the PPAR ⁇ agonist is from about 1 mg per day to about 20 mg per day in a single dose or in divided doses.
  • Also disclosed herein are methods for identifying the use of performance-enhancing substances in an exercise-trained subject which include determining in a biological sample taken from an exercise-trained subject (e.g. a skeletal muscle biopsy) the expression of the molecules listed in Table 2 or listed in Table 4, or a subset thereof, such as expression of at least 1, at least 5, at least 10, at least 20, at least 40 of the molecules listed in Table 2 or in Table 4.
  • expression is upregulated in one or more of (such as at least 5, at least 10, at least 20, at least 35, or all of) adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2
  • Exemplary methods for identifying the use of performance-enhancing substances in an exercise-trained subject involve determining protein expression and/or determining expression of a gene encoding the protein. Such methods are routine in the art. In some examples, the level of protein or nucleic acid expression is quantified.
  • Such methods can include (i) providing a first component comprising a PPAR ⁇ receptor or an AMPK-binding fragment thereof; (ii) providing a second component comprising an AMP-activated protein kinase (AMPK), AMPK ⁇ 1, AMPK ⁇ 2, or a PPAR ⁇ -binding fragment of any thereof; (iii) contacting the first component and the second component with at least one test agent under conditions that would permit the first component and the second component to specifically bind to each other in the absence of the at least one test agent; and (iv) determining whether the at least one test agent affects the specific binding of the first component and the second component to each other.
  • An effect on specific binding of the first component and the second component to each other identifies the at least one test agent as an agent having potential to enhance exercise performance in a subject.
  • a third component i.e., a PPAR ⁇ agonist (e.g., GW1516) is involved and the first component, second component, and third component are contacted as described above.
  • a PPAR ⁇ agonist e.g., GW1516
  • Gene expression The process by which the coded information of a nucleic acid transcriptional unit (including, for example, genomic DNA or cDNA) is converted into an operational, non-operational, or structural part of a cell, often including the synthesis of a polypeptide.
  • Gene expression can be influenced by external signals; for instance, exposure of a cell, tissue or subject to an agent that enhances gene expression.
  • Expression of a gene also may be regulated anywhere in the pathway from DNA to RNA to polypeptide. Regulation of gene expression occurs, for instance, through controls acting on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization or degradation of specific protein molecules after they have been made, or by combinations thereof.
  • Gene expression for example expression of one or more of the genes listed in Tables 2 and 4 can be measured at the RNA level or the protein level and by any method known in the art, including, without limitation, Northern blot, RT-PCR, Western blot, or in vitro, in situ, or in vivo protein activity assay(s).
  • the expression of a nucleic acid may be modulated compared to a control state, such as at a control time (for example, prior to administration of a substance or agent that affects regulation of the nucleic acid under observation) or in a control cell or subject, or as compared to another nucleic acid.
  • modulation includes but is not necessarily limited to overexpression, underexpression, or suppression of expression.
  • modulation of nucleic acid expression may be associated with, and in fact may result in, a modulation in the expression of an encoded polypeptide or even a polypeptide that is not encoded by that nucleic acid (such as downstream regulated polypeptide(s)).
  • the expression of a polypeptide also may be modulated compared to a control state, such as at a control time (for example, prior to administration of a substance or agent that affects expression of a nucleic acid encoding or regulating the polypeptide) or in a control cell or subject, or as compared to another polypeptide.
  • Modulation of polypeptide expression includes, but is not limited to, overexpression or decreased expression of the polypeptide, alteration of the subcellular localization or targeting of the polypeptide, alteration of the temporally regulated expression of the polypeptide (such that the polypeptide is expressed when it normally would not be, or alternatively is not expressed when it normally would be), alteration in the stability of the polypeptide, alteration in the spatial localization of the protein (such that the polypeptide is not expressed where it would normally be expressed or is expressed where it normally would not be expressed).
  • Isolated An “isolated” biological component (such as a polynucleotide, polypeptide, or cell) has been purified away from other biological components in a mixed sample (such as a cell or tissue extract).
  • a mixed sample such as a cell or tissue extract.
  • an “isolated” polypeptide or polynucleotide is a polypeptide or polynucleotide that has been separated from the other components of a cell in which the polypeptide or polynucleotide was present (such as an expression host cell for a recombinant polypeptide or polynucleotide).
  • purified refers to the removal of one or more extraneous components from a sample.
  • the polypeptides are purified by, for example, the removal of host cell proteins thereby increasing the percent of recombinant polypeptides in the sample.
  • the polynucleotide is purified by, for example, the removal of host cell polynucleotides thereby increasing the percent of recombinant polynucleotide in the sample.
  • Isolated polypeptides or nucleic acid molecules typically, comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or even over 99% (w/w or w/v) of a sample.
  • Polypeptides and nucleic acid molecules are isolated by methods commonly known in the art and as described herein. Purity of polypeptides or nucleic acid molecules may be determined by a number of well-known methods, such as polyacrylamide gel electrophoresis for polypeptides, or agarose gel electrophoresis for nucleic acid molecules.
  • Sequence identity The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences.
  • NCBI National Center for Biotechnology Information
  • BLASTTM Basic Local Alignment Search Tool
  • the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method.
  • Specific binding refers to the particular interaction between one binding partner (such as a binding agent) and another binding partner (such as a target). Such interaction is mediated by one or, typically, more noncovalent bonds between the binding partners (or, often, between a specific region or portion of each binding partner). In contrast to non-specific binding sites, specific binding sites are saturable. Accordingly, one exemplary way to characterize specific binding is by a specific binding curve.
  • a specific binding curve shows, for example, the amount of one binding partner (the first binding partner) bound to a fixed amount of the other binding partner as a function of the first binding partner concentration. As the first binding partner concentration increases under these conditions, the amount of the first binding partner bound will saturate.
  • Exercise is known to have many effects on subjects that perform it.
  • Exercise effects at the molecular, biochemical, and/or cellular levels e.g., modified regulation of genes and/or gene networks and corresponding proteins involved in energy substrate utilization and contractile properties of muscle
  • form the basis of physiological effects that are observed at the tissue, organ, and/or whole body levels e.g., increased cardiorespiratory endurance, muscular strength, muscular endurance, and/or flexibility, and/or improvements in body appearance.
  • methods for enhancing one or more exercise effects by combining, at least, physical activity with administration of one or more PPAR ⁇ agonists.
  • physical activity is replaced with administration of an AMPK activator (e.g., AICAR).
  • AICAR AMPK activator
  • exercise is the performance of some physical activity.
  • a single episode (also referred to as a bout) of physical activity is performed for a particular duration and at a particular intensity. If more than one bout of exercise is performed, separate bouts of exercise may have the same or different durations and/or the same or different intensities.
  • a single bout of exercise may last for up to 30 minutes, up to 45 minutes, up to 60 minutes, up to 90 minutes, up to 2 hours, up to 2.5 hours, up to 3 hours, or even longer.
  • repeated episodes of physical activity are needed to achieve an exercise-induced effect (such as, increased aerobic capacity or increase running endurance).
  • bouts of physical activity may be repeated within a single day; for instance, up to 2 bouts of exercise per day, up to 3 bouts of exercise per day, up to 4 bouts of exercise per day, up to 5 bouts of exercise per day, or even more bouts per day.
  • Some professional athletes or racing mammals may exercise in repeated bouts for a total of 8 hours or more a day.
  • bouts (or repeated bouts) of exercise are performed on a daily basis, 6 times per week, 5 times per week, 4 times per week or 3 times per week.
  • exercise may continue for at least 2 weeks, for at least 4 weeks, for at least 6 weeks, for at least 3 months, for at least 6 months, for at least 1 year, for at least 3 years, or indefinitely (for the lifetime of the subject).
  • Exercise generally is performed at an intensity that is more than the usual (e.g., average, median, normal standard, or normoactive) activity for a subject, and/or at or less than the maximum activity achievable by a subject performing a particular exercise.
  • Any known indicator of physical performance can be used to determine whether a subject is performing more than a usual amount of activity, including, for instance, measuring heart rate, repetition rate (e.g., revolutions per second, minutes per mile, lifts per minute, and many others), and/or force output.
  • a bout of exercise is performed at sub-maximal intensity; for instance, at about 10% maximal intensity, 25% maximal intensity, 50% maximal intensity, or 75% maximal intensity.
  • a bout of exercise is performed at 40%-50% maximal heart rate, 50%-60% maximal heart rate, 60%-70% maximal heart rate, or 75%-80% maximal heart rate, where maximum heart rate for a human subject is calculated as: 220 bps ⁇ (age of the subject).
  • Exercise is generally grouped into three types: (i) flexibility exercise (such as, stretching), which is believed to, at least, improve the range of motion of muscles and joints; (ii) aerobic exercise; and (iii) anaerobic exercise (such as, weight training, functional training or sprinting) which is believed to, at least, increase muscle strength and mass.
  • flexibility exercise such as, stretching
  • aerobic exercise such as, aerobic exercise
  • anaerobic exercise such as, weight training, functional training or sprinting
  • Aerobic exercise refers to a physical activity in which oxidative or aerobic metabolism (as compared to glycolytic or anaerobic metabolism) substantially predominates in exercised skeletal muscles.
  • a subject performs one or more aerobic exercises.
  • Exemplary aerobic exercises include, without limitation, aerobics, calisthenics, cycling, dancing, exercise machines (rowing machine, cycling machine (e.g., inclined or upright), climbing machine, elliptical trainers, and/or skiing machines), basketball, football, baseball, soccer, footbag, housework, jogging, martial arts, massage, pilates, rowing, running, skipping, swimming, walking, yoga, boxing, gymnastics, badminton, cricket, track and field, golf, ice hockey, lacrosse, rugby, tennis, or combinations thereof.
  • the disclosed methods contemplate enhancing any known or observable effect of exercise (such as an aerobic exercise, like walking or running).
  • running endurance e.g., running distance and/or running time
  • Enhancing an exercise effect means that such effect is improved in a subject more than would have occurred by exercise alone.
  • an enhanced exercise effect is determined by discontinuing administration of a PPAR ⁇ agonist in the subject and observing (e.g., qualitatively or quantitatively) a reduction in the exercise effect of interest (e.g., aerobic endurance, such as running endurance).
  • an exercise effect of interest the PPAR ⁇ -enhanced portion of which is lost upon discontinuance of PPAR ⁇ administration, will be reduced by at least about 5%, by at least about 10%, by at least about 20%, by at least about 30%, or by at least about 50% as compared to the magnitude of the effect with exercise alone.
  • PPAR ⁇ agonists Preferably such agonist would be non-toxic in the subject to which it is administered.
  • exemplary PPAR ⁇ agonists include GW1516, L-165041 (as described by, e.g., Leibowitz et al., FEBS Lett., 473(3):333-336, 2000), any one or more compounds described in PCT Publication Nos.
  • WO/2006/018174 WO/2005/113506, WO/2005/105754, WO/2006/041197, WO/2006/032023, WO/01/00603, WO/02/092590, WO/97/28115, WO/97/28149, WO/97/27857, WO/97/28137, WO/97/27847, and/or WO/98/27974, and/or a published U.S. national phase application or issued U.S. patent corresponding to any of the foregoing (each of which is expressly incorporated herein by reference).
  • other PPAR ⁇ agonists can be identified using the methods described, for example, in PCT Publication No. WO/1998/049555 or any corresponding published U.S. national phase application or issued U.S. patent (each of which is expressly incorporated herein by reference).
  • the PPAR ⁇ agonist is GW1516 (also referred to in the art as GW501516).
  • GW1516 is (2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfanyl)phenoxy)acetic acid as has been shown to be is bioactive in humans (Sprecher et al., Arterioscler. Thromb. Vasc. Biol. 27(2): 359-65, 2007).
  • GW1516 is administered orally, for example 1 mg-20 mg/day, such as 2.5 mg or 10 mg per day.
  • a subject is a living multi-cellular vertebrate organism (e.g., human and/or non-human animals).
  • a subject is a mammal (including humans and/or non-human mammals such as veterinary or laboratory mammals) or, in more particular examples, a racing mammal (such as a horse, a dog, or a human).
  • a subject is an adult, an exercise-trained subject, or a healthy subject. Some representative adult, human subjects are 16 years old or old, 18 years old or older, or 21 years old or older.
  • Some representative exercised-trained subjects have performed physical activity (such described in detail above) for at least 4 weeks, for at least 6 weeks, for at least 3 months, or for at least 6 months.
  • the subject is healthy, for example, is a subject in which no known disease or disorder has been diagnosed or would be apparent after reasonable inquiry to an ordinarily skilled physician in the field to which the disease or disorder pertains.
  • the disclosed methods envision the use of any method of administration, dosage, and/or formulation of PPAR ⁇ agonist that has the desired outcome of enhancing an exercise effect in a subject receiving the formulation, including, without limitation, methods of administration, dosages, and formulations well known to those of ordinary skill in the pharmaceutical arts.
  • Modes of administering a PPAR ⁇ agonist (or a formulation including a PPAR ⁇ agonist) in a disclosed method include, but are not limited to, intrathecal, intradermal, intramuscular, intraperitoneal (ip), intravenous (iv), subcutaneous, intranasal, epidural, intradural, intracranial, intraventricular, and oral routes.
  • a PPAR ⁇ agonist is administered orally.
  • a PPAR ⁇ agonist or a formulation including a PPAR ⁇ agonist
  • routes for administration of a PPAR ⁇ agonist include for example, infusion or bolus injection, topical, absorption through epithelial or mucocutaneous linings (for example, oral mucosa, rectal and intestinal mucosa, and the like) ophthalmic, nasal, and transdermal.
  • Administration can be systemic or local.
  • Pulmonary administration also can be employed (for example, by an inhaler or nebulizer), for instance using a formulation containing an aerosolizing agent.
  • a PPAR ⁇ agonist may be desirable to administer a PPAR ⁇ agonist locally.
  • This may be achieved by, for example, local or regional infusion or perfusion, topical application (for example, wound dressing), injection, catheter, suppository, or implant (for example, implants formed from porous, non-porous, or gelatinous materials, including membranes, such as sialastic membranes or fibers), and the like.
  • a pump such as a transplanted minipump
  • a PPAR ⁇ agonist or a formulation including a PPAR ⁇ agonist
  • a PPAR ⁇ agonist or a formulation including a PPAR ⁇ agonist
  • a PPAR ⁇ agonist is delivered in a vesicle, in particular liposomes (see, e.g.
  • a PPAR ⁇ agonist can be delivered in a controlled-release formulation.
  • Controlled-release systems such as those discussed in the review by Langer ( Science 249, 1527 1990), are known.
  • polymeric materials useful in controlled-released formulations are known (see, e.g. Ranger et al., Macromol. Sci. Rev. Macromol. Chem. 23, 61, 1983; Levy et al., Science 228, 190, 1985; During et al., Ann. Neurol. 25, 351, 1989; Howard et al., J. Neurosurg. 71, 105, 1989).
  • a PPAR ⁇ agonists may be coupled to a class of biodegradable polymers useful in achieving controlled release of a compound, including polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a compound, including polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • PPAR ⁇ agonist or formulation containing the same
  • Dosage forms are commonly known and are taught in a variety of textbooks, including for example, Allen et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems , Eighth Edition, Philadelphia, Pa.: Lippincott Williams & Wilkins, 2005, 738 pages.
  • Dosage forms for use in a disclosed method include, without limitation, solid dosage forms and solid modified-release drug delivery systems (e.g., powders and granules, capsules, and/or tablets); semi-solid dosage forms and transdermal systems (e.g., ointments, creams, and/or gels); transdermal drug delivery systems; pharmaceutical inserts (e.g., suppositories and/or inserts); liquid dosage forms (e.g., solutions and disperse systems); and/or sterile dosage forms and delivery systems (e.g., parenterals, and/or biologics).
  • solid dosage forms and solid modified-release drug delivery systems e.g., powders and granules, capsules, and/or tablets
  • semi-solid dosage forms and transdermal systems e.g., ointments, creams, and/or gels
  • transdermal drug delivery systems e.g., ointments, creams, and/or gels
  • pharmaceutical inserts e
  • Particular exemplary dosage forms include aerosol (including metered dose, powder, solution, and/or without propellants); beads; capsule (including conventional, controlled delivery, controlled release, enteric coated, and/or sustained release); caplet; concentrate; cream; crystals; disc (including sustained release); drops; elixir; emulsion; foam; gel (including jelly and/or controlled release); globules; granules; gum; implant; inhalation; injection; insert (including extended release); liposomal; liquid (including controlled release); lotion; lozenge; metered dose (e.g., pump); mist; mouthwash; nebulization solution; ocular system; oil; ointment; ovules; powder (including packet, effervescent, powder for suspension, powder for suspension sustained release, and/or powder for solution); pellet; paste; solution (including long acting and/or reconstituted); strip; suppository (including sustained release); suspension (including lente, ultre lente, reconstituted); syrup (including
  • a dosage form is a formulation of an effective amount (such as a therapeutically effective amount) of at least one active pharmaceutical ingredient (such as a PPAR ⁇ agonist) with pharmaceutically acceptable excipients and/or other components (such as one or more other active ingredients).
  • active pharmaceutical ingredient such as a PPAR ⁇ agonist
  • pharmaceutically acceptable excipients and/or other components such as one or more other active ingredients.
  • pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and, more particularly, in humans.
  • Excipients for use in exemplary formulations include, for instance, one or more of the following: binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, colorings, preservatives, diluents, adjuvants, and/or vehicles. In some instances, excipients collectively may constitute about 5%-95% of the total weight (and/or volume) of a particular dosage form.
  • Pharmaceutical excipients can be, for instance, sterile liquids, such as water and/or oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • Water is an exemplary carrier when a formulation is administered intravenously.
  • Saline solutions, blood plasma medium, aqueous dextrose, and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Oral formulations can include, without limitation, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • Excipients may also include, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like.
  • compositions include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
  • a formulation if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • a dosage regimen utilizing a PPAR ⁇ agonist is selected in accordance with a variety of factors including type, species, age, weight, sex and physical condition of the subject; the route of administration; and/or the particular PPAR ⁇ agonist formulation employed.
  • An ordinarily skilled physician or veterinarian can readily determine an effective amount of a PPAR ⁇ agonist (or formulation thereof) useful for enhancing an exercise effect in a subject.
  • oral dosages of a PPAR ⁇ agonist will generally range between about 0.001 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, and such as about 0.01-10 mg/kg/day (unless specified otherwise, amounts of active ingredients are on the basis of a neutral molecule, which may be a free acid or free base).
  • a neutral molecule which may be a free acid or free base.
  • an 80 kg subject would receive between about 0.08 mg/day and 8 g/day, such as between about 0.8 mg/day and 800 mg/day.
  • a suitably prepared medicament for once a day administration would thus contain between 0.08 mg and 8 g, such as between 0.8 mg and 800 mg.
  • formulation including a PPAR ⁇ agonist may be administered in divided doses of two, three, or four times daily.
  • a suitably prepared medicament as described above would contain between 0.04 mg and 4 g, such as between 0.4 mg and 400 mg. Dosages outside of the aforementioned ranges may be necessary in some cases. Examples of daily dosages that may be given in the range of 0.08 mg to 8 g per day include 0.1 mg, 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1 g, 2 g, 4 g and 8 g. These amounts can be divided into smaller doses if administered more than once per day (e.g., one-half the amount in each administration if the drug is taken twice daily).
  • a subject would receive an injected amount that would deliver the active ingredient in approximately the quantities described above.
  • the quantities may be adjusted to account for differences in delivery efficiency that result from injected drug forms bypassing the digestive system.
  • Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day.
  • a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, such as for example 0.1 mg/ml, 0.3 mg/ml, or 0.6 mg/ml, and administered in amounts per day equivalent to the amounts per day stated above.
  • a concentration of active ingredient of between about 0.01-1.0 mg/ml, such as for example 0.1 mg/ml, 0.3 mg/ml, or 0.6 mg/ml, and administered in amounts per day equivalent to the amounts per day stated above.
  • an 80 kg subject receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day.
  • a PPAR ⁇ agonist (or a formulation thereof) can be administered at about the same dose throughout a treatment period, in an escalating dose regimen, or in a loading-dose regime (for example, in which the loading dose is about two to five times a maintenance dose).
  • the dose is varied during the course of PPAR ⁇ agonist usage based on the condition of the subject receiving the composition, the apparent response to the composition, and/or other factors as judged by one of ordinary skill in the art.
  • long-term administration of a PPAR ⁇ agonist (or formulation thereof) is contemplated, for instance in order to effect sustained enhancement of an exercise effect (such as aerobic endurance, e.g., running endurance).
  • the particular genes (and/or proteins encoded thereby) were not affected by the combined treatment but were up- or down-regulated by one or both intervention when practiced alone.
  • the unique regulation of these genes (and/or the encoded proteins) makes them useful markers (either alone or in any combination) for identifying exercising subjects who are taking (or receiving) PES.
  • a PES is any substance taken in nonpharmacologic doses specifically for the purpose of improving sports performance (e.g., by increasing strength, power, speed, or endurance (ergogenic) or by altering body weight or body composition).
  • exemplary PES include the following: (i) pharmacologic agents (prescription or nonprescription) taken in doses that exceed the recommended therapeutic dose or taken when the therapeutic indication(s) are not present (e.g., using decongestants for stimulant effect, using bronchodilators when exercise-induced bronchospasm is not present, increasing baseline methylphenidate hydrochloride dose for athletic competition); (ii) agents used for weight control, including stimulants, diet pills, diuretics, and laxatives, when the user is in a sport that has weight classifications or that rewards leanness; (iii) agents used for weight gain, including over-the-counter products advertised as promoting increased muscle mass; (iv) physiologic agents or other strategies used to enhance oxygen-carrying capacity, including erythrop
  • the biomarkers of substance-induced performance enhancement identified herein and useful in a disclosed method include one or more (or any combination of) the genes (and/or proteins encoded thereby) listed in Table 2, and in some examples listed in Table 4.
  • at least 2, at least 3, at least 5, at least 7, at least 10, at least 15, at least 20, at least 30, or at least 40 of the genes (and/or proteins encoded thereby) listed in Table 2 (or Table 4) are detected in a disclosed method.
  • at least one gene (and/or protein encoded thereby) from each class listed in Table 2 e.g. cytokines, fat metabolism
  • upregulated expression is detected for one or more of the following genes (or proteins encoded thereby): adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; protein tyrosine
  • downregulated expression is detected in one or more of the following genes (and/or proteins encoded thereby): gamma-glutamyl carboxylase; 3-oxoacid CoA transferase 1; solute carrier family 38, member 4; annexin A7; CD55 antigen; RIKEN cDNA 1190002H23 gene; fusion, derived from t(12;16) malignant liposarcoma (human); lysosomal membrane glycoprotein 2; and/or neighbor of Punc E11.
  • downregulation of at least 2, at least 3, at least 5, or at least 7 of the foregoing genes (and/or proteins encoded thereby) are detected in a disclosed method.
  • a combination of upregulated genes (and/or proteins encoded thereby) and downregulated genes (and/or proteins encoded thereby) as described above is detected in a sample from a subject (such as, an exercised or exercise-trained subject).
  • Yet other method embodiments involve the detection in a sample of a combination of the above-described upregulated genes (and/or proteins encoded thereby) and/or the above-described downregulated genes (and/or proteins encoded thereby), and/or the above-described exercise-regulated genes that are not affected by exercise combined with PPAR ⁇ administration.
  • a subject is a living multi-cellular vertebrate organism (e.g., human and/or non-human animals).
  • a subject is a mammal (including humans and/or non-human mammals) or, in more particular examples, a racing mammal (such as a horse, a dog, or a human).
  • a subject is an exercise-trained subject. Some representative exercised-trained subjects have performed physical activity (such described in detail above) for at least 4 weeks, for at least 6 weeks, for at least 3 months, or for at least 6 months. Other exercise-trained subjects may be student athletes and/or professional athletes (including, in some examples, non-human professional athletes, such as race horses and/or racing dogs).
  • sample from a subject e.g., a biological sample
  • a sample in which can be detected one or more genes and/or proteins uniquely regulated by exercise in combination with PPAR ⁇ agonist intake (as described in detail throughout this specification) is contemplated for use in a disclosed method.
  • exemplary samples for use in a disclosed method include blood, saliva, urine, muscle biopsy (e.g., skeletal muscle biopsy), cheek swab, fecal sample, sweat, and/or sperm.
  • expression of one or more genes identified herein can be detected by any method of nucleic acid amplification (such as, polymerase chain reaction (PCR) or any adaptation thereof, ligase chain reaction, transcription-based amplification systems, cycling probe reaction, Q ⁇ replicase amplification, strand displacement amplification, and/or rolling circle amplification), solid-surface hybridization assays (such as Northern blot, dot blot, gene chips, and/or reversible target capture), solution hybridization assays (such as MAP technology (which uses a liquid suspension array of 100 sets of 5.5 micron probe-conjugated beads, each internally dyed with different ratios of two spectrally distinct fluorophores to assign it a unique spectral address)), and/or in situ hybridization.
  • nucleic acid amplification such as, polymerase chain reaction (PCR) or any adaptation thereof, ligase chain reaction, transcription-based amplification systems, cycling probe reaction, Q ⁇ replicase amplification, strand displacement amplification,
  • expression of one or more proteins encoded by corresponding genes identified herein can be detected by Western blot, immunohistochemistry, immunoprecipitation, antibody microarrays, ELISA, and/or by functional assay (e.g., kinase assay, ATPase assay, substrate (or ligand) binding assay, protein-protein binding assay, or other assay suitable for measuring a particular protein function).
  • functional assay e.g., kinase assay, ATPase assay, substrate (or ligand) binding assay, protein-protein binding assay, or other assay suitable for measuring a particular protein function.
  • the pattern of expression identified in the test subject is similar to that shown in Table 2 (e.g. the genes shown as upregulated and downregulated in Table 2 are observed in the subject to be upregulated and downregulated, respectively), this indicates that the subject is taking a PES, such as a PPAR ⁇ agonist (e.g. GW1516).
  • a PES such as a PPAR ⁇ agonist
  • the pattern of expression identified in the test subject is different to that shown in Table 2 (e.g. the genes shown as upregulated and downregulated in Table 2 are observed in the subject to be not differentially expressed or show a different pattern of regulation)
  • this indicates that the subject is not taking a PES, such as a PPAR ⁇ agonist (e.g. GW1516).
  • This disclosure identifies a previously unknown protein-protein interaction between PPAR ⁇ and particular exercise-induced kinases (e.g., AMPK, such as the AMPK ⁇ 1 and/or AMPK ⁇ 2 subunit(s) of AMPK).
  • AMPK exercise-induced kinases
  • the interaction between PPAR ⁇ and AMPK may have important functional outcomes, such as enhancing exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject.
  • agents e.g., having potential to enhance exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject.
  • agents that affect e.g., enhance, weaken, or substantially disrupt
  • agents that affect e.g., increase, decrease, or substantially eliminate
  • AMPK-dependent phosphorylation of a PPAR ⁇ complex are identified.
  • agent is any substance or any combination of substances that is useful for achieving an end or result; for example, a substance or combination of substances useful for modulating a protein activity (e.g., AMPK-dependent phosphorylation of a PPAR ⁇ complex), or useful for modifying or affecting a protein-protein interaction (e.g., PPAR ⁇ -AMPK interaction). Any agent that has potential (whether or not ultimately realized) to modulate any aspect of the PPAR ⁇ -AMPK interaction disclosed herein is contemplated for use in the screening methods of this disclosure.
  • Exemplary agents include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries (see, e.g. Lam et al., Nature, 354:82-84, 1991; Houghten et al., Nature, 354:84-86, 1991), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g.
  • antibodies including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab′) 2 and Fab expression library fragments, epitope-binding fragments thereof), small organic or inorganic molecules (such as, so-called natural products or members of chemical combinatorial libraries), molecular complexes (such as protein complexes), or nucleic acids.
  • Libraries useful in the disclosed methods include, but are not limited to, peptide libraries (see, e.g. U.S. Pat. No. 5,010,175; Furka, Int. J. Pept. Prot. Res., 37:487-493, 1991; Houghton et al., Nature, 354:84-88, 1991; PCT Publication No. WO 91/19735), encoded peptides (e.g. PCT Publication WO 93/20242), random bio-oligomers (e.g. PCT Publication No. WO 92/00091), benzodiazepines (e.g. U.S. Pat. No.
  • Libraries useful for the disclosed screening methods can be produce in a variety of manners including, but not limited to, spatially arrayed multipin peptide synthesis (Geysen, et al., Proc. Natl. Acad. Sci., 81(13):3998-4002, 1984), “tea bag” peptide synthesis (Houghten, Proc. Natl. Acad. Sci., 82(15):5131-5135, 1985), phage display (Scott and Smith, Science, 249:386-390, 1990), spot or disc synthesis (Dittrich et al., Bioorg. Med. Chem.
  • Libraries may include a varying number of compositions (members), such as up to about 100 members, such as up to about 1000 members, such as up to about 5000 members, such as up to about 10,000 members, such as up to about 100,000 members, such as up to about 500,000 members, or even more than 500,000 members.
  • members such as up to about 100 members, such as up to about 1000 members, such as up to about 5000 members, such as up to about 10,000 members, such as up to about 100,000 members, such as up to about 500,000 members, or even more than 500,000 members.
  • high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (e.g., affectors of AMPK-PPAR ⁇ protein-protein interactions). Such combinatorial libraries are then screened in one or more assays as described herein to identify those library members (particularly chemical species or subclasses) that display a desired characteristic activity (such as increasing or decreasing an AMPK-PPAR ⁇ protein-protein interaction).
  • the compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.
  • pools of candidate agents may be identify and further screened to determine which individual or subpools of agents in the collective have a desired activity.
  • PPAR ⁇ forms a protein-protein interaction with AMPK or one or more of its subunits (such as AMPK ⁇ 1 and/or AMPK ⁇ 2).
  • Agents that affect (e.g., increase or decrease) an AMPK-PPAR ⁇ interaction or AMP-dependent phosphorylation of a PPAR ⁇ complex may have the effect of enhancing exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject and, therefore, are desirable to identify.
  • tissue samples, isolated cells, isolated polypeptides, and/or test agents can be presented in a manner suitable for high-throughput screening; for example, one or a plurality of isolated tissue samples, isolated cells, or isolated polypeptides can be inserted into wells of a microtitre plate, and one or a plurality of test agents can be added to the wells of the microtitre plate.
  • test agents can be presented in a high-throughput format, such as in wells of microtitre plate (either in solution or adhered to the surface of the plate), and contacted with one or a plurality of isolated tissue samples, isolated cells, and/or isolated polypeptides under conditions that, at least, sustain the tissue sample or isolated cells or a desired polypeptide function and/or structure.
  • Test agents can be added to tissue samples, isolated cells, or isolated polypeptides at any concentration that is not lethal to tissues or cells, or does not have an adverse effect on polypeptide structure and/or function. It is expected that different test agents will have different effective concentrations. Thus, in some methods, it is advantageous to test a range of test agent concentrations.
  • PPAR ⁇ or AMPK such as AMPK ⁇ 1 or AMPK ⁇ 2
  • PPAR ⁇ ligand optionally is included (or is omitted) in disclosed methods.
  • a “direct association” between two or more polypeptides is characterized by physical contact between at least a portion of the interacting polypeptides that is of sufficient affinity and specificity that, for example, immunoprecipitation of one of the polypeptides also will specifically precipitate the other polypeptide; provided that the immunoprecipitating antibody does not also affect the site(s) involved in the interaction.
  • a direct association between polypeptides also may be referred to as a “protein-protein interaction.”
  • the binding of one polypeptide to another in a protein-protein interaction is considered “specific binding”.
  • Agents that affect an AMPK-PPAR ⁇ interaction can be identified by a variety of assays, including solid-phase or solution-based assays.
  • PPAR ⁇ or an AMPK-binding fragment thereof and AMPK or a subunit thereof (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) or a PPAR ⁇ -binding fragment thereof are mixed under conditions in which PPAR ⁇ and AMPK (or its subunit(s) or functional fragments) normally interact (e.g., co-immunoprecipitate).
  • One of the binding partners is labeled with a marker such as biotin, fluoroscein, EGFP, or enzymes to allow easy detection of the labeled component.
  • the unlabeled binding partner is adsorbed to a support, such as a microtiter well or beads. Then, the labeled binding partner is added to the environment where the unlabeled binding partner is immobilized under conditions suitable for interaction between the two binding partners.
  • One or more test compounds such as compounds in one or more of the above-described libraries, are separately added to individual microenvironments containing the interacting binding partners. Agents capable of affecting the interaction between the binding partners are identified, for instance, as those that increase or decrease (e.g., increase) retention or binding of the signal (i.e., labeled binding partner) in the reaction microenvironment, for example, in a microtiter well or on a bead for example.
  • combinations of agents can be evaluated in an initial screen to identify pools of agents to be tested individually, and this process is easily automated with currently available technology.
  • solution phase selection can be used to screen large complex libraries for agents that specifically affect protein-protein interactions (see, e.g., Boger et al., Bioorg. Med. Chem. Lett., 8(17):2339-2344, 1998); Berg et al., Proc. Natl. Acad. Sci., 99(6):3830-3835, 2002).
  • each of two proteins that are capable of physical interaction for example, PPAR ⁇ (or AMPK-binding fragments thereof) and AMPK or AMPK ⁇ 1 or AMPK ⁇ 2 (or PPAR ⁇ -binding fragments of any thereof) are labeled with fluorescent dye molecule tags with different emission spectra and overlapping adsorption spectra.
  • FRET fluorescence resonance energy transfer
  • Interactions between PPAR ⁇ (or AMPK-binding fragments thereof) and AMPK or AMPK ⁇ 1 or AMPK ⁇ 2 (or PPAR ⁇ -binding fragments of any thereof) also can be determined (e.g., quantified) by co-immunoprecipitation of the relevant component polypeptides (e.g. from cellular extracts), by GST-pull down assay (e.g., using purified GST-tagged bacterial proteins), and/or by yeast two-hybrid assay, each of which methods is standard in the art.
  • Conducting any one or more such assays in the presence and, optionally, absence of a test compound can be used to identify agents that improve or enhance (or, in other embodiments, decrease or inhibit) the interaction between PPAR ⁇ (or AMPK-binding fragments thereof) and AMPK or AMPK ⁇ 1 or AMPK ⁇ 2 (or PPAR ⁇ -binding fragments of any thereof) in the presence of a test compound as compared to in the absence of the test compound or as compared to some other standard or control.
  • one or more AMPK (such as AMPK ⁇ 1 and/or AMPK ⁇ 2)-binding fragments of PPAR ⁇ and/or one or more PPAR ⁇ -binding fragments of AMPK (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) are used.
  • Polypeptide fragments having the desired binding activities can be identified by making a series of defined PPAR ⁇ fragments and/or AMPK (such as AMPK ⁇ 1 or AMPK ⁇ 2) fragments using methods standard in the art.
  • cDNA encoding the protein(s) of interest can be serially truncated from the 3′ or 5′ end (provided that a start codon is engineered into 5′ truncations) using conveniently located restriction enzyme sites (or other methods) and leaving intact (or otherwise correcting) the proper reading frame.
  • a nucleic acid sequence encoding an epitope tag (such as a FLAG tag) is placed in frame with (and substantially adjacent to) the truncated protein-encoding sequence to produce a nucleic acid sequence encoding an epitope-tagged protein fragment.
  • the epitope-tagged protein fragment can be expressed in any convenient expression system (such as a bacterial expression system), isolated or not, and mixed with a sample containing a protein or other protein fragment to which the epitope-tagged protein fragment may bind.
  • An antibody specific for the tag (or other region of the protein fragment) can be used to immunoprecipitate the fragment of interest together with any protein(s) or protein fragment(s) that bind to it.
  • Protein(s) or protein fragment(s) that bind to the epitope-tagged protein fragment of interest can be particular identified, e.g., by Western blot.
  • a PPAR ⁇ -AMPK such as AMPK ⁇ 1 and/or AMPK ⁇ 2
  • complex including complexes including one or both of PPAR ⁇ -binding AMPK fragments and/or AMPK-binding PPAR ⁇ fragments
  • the affinity of PPAR ⁇ (or AMPK-binding fragments thereof) and AMPK (or PPAR ⁇ -binding fragments thereof) for each other is increased when the amount of such complex or the binding affinity is at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 100% or at least 250% higher than a control measurement (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent).
  • a control measurement e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent.
  • the formation of a PPAR ⁇ -AMPK (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) complex (including complexes including one or both of PPAR ⁇ -binding AMPK fragments and/or AMPK-binding PPAR ⁇ fragments) or the affinity of PPAR ⁇ (or AMPK-binding fragments thereof) and AMPK (or PPAR ⁇ -binding fragments thereof) for each other is decreased when the amount of such complex or the binding affinity is at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 100% or at least 250% lower than a control measurement (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent).
  • a control measurement e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent.
  • AMPK e.g., AMPK ⁇ 1 and/or AMPK ⁇ 2
  • Agents that affect AMPK-dependent phosphorylation of the PPAR ⁇ complex can be identified by a variety of assays, such adaptations of solid-phase- or solution-based assays described above, where the end point to be detected is phosphorylation of one or more components of the PPAR ⁇ complex.
  • phosphorylated protein e.g., phosphorylation of one or more components of the PPAR ⁇ complex
  • stains specific for phosphorylated proteins in gels.
  • antibodies specific phosphorylated proteins can be made or commercially obtained.
  • Antibodies specific for phosphorylated proteins can be, among other things, tethered to the beads (including beads having a particular color signature) or used in ELISA or Western blot assays.
  • a PPAR ⁇ complex (or a fragment thereof containing an AMPK phosphorylation site) and AMPK or one or more of it subunits (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) or functional fragments thereof that are capable of phosphorylation are mixed under conditions whereby a PPAR ⁇ complex is phosphorylated by AMPK.
  • a PPAR ⁇ complex is adsorbed to a support, such as a microtiter well or beads.
  • AMPK or its one or more subunits (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) or phosphorylation-capable fragments thereof) is added to the environment where the complex is immobilized.
  • a phosphate donor typically is also included in the environment.
  • the phosphate to be donated can be labeled.
  • One or more test compounds such as compounds in one or more of the above-described libraries, are separately added to the individual microenvironments.
  • Agents capable of affecting AMPK-dependent phosphorylation are identified, for instance, as those that enhance (or inhibit) phosphorylation of immobilized PPAR ⁇ complex.
  • phosphorylation of immobilized PPAR ⁇ complex can be determined by retention or binding of a labeled phosphate in the reaction microenvironment, for example, in a microtiter well or on a bead for example.
  • PPAR ⁇ complex can be isolated from the solution (e.g., by immunoprecipitation with PPAR ⁇ -specific or phosphate-specific antibodies), and its level of phosphorylation in the presence (and, optionally, absence) of one of more test agents determined as previously discussed.
  • the phosphorylation of a PPAR ⁇ complex is increased when such posttranslational modification is detectably measured or when such posttranslational modification is at least 20%, at least 30%, at least 50%, at least 100% or at least 250% higher than control measurements (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent, or in a comparable test system in the absence of AMPK).
  • the phosphorylation of PPAR ⁇ complex is decreased when such posttranslational modification is detectably reduced or when such posttranslational modification is at least 20%, at least 30%, at least 50%, at least 100% or at least 250% lower than control measurements (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent, or in a comparable test system in the absence of AMPK).
  • a PPAR ⁇ polypeptide useful in a disclosed screening method is any known PPAR ⁇ receptor. Also useful in the disclosed screening methods are homologs, functional fragments, or functional variants of a PPAR ⁇ that retains at least AMPK-binding activity as described herein for a prototypical PPAR ⁇ polypeptide (see Example 6).
  • amino acid sequences of prototypical PPAR ⁇ polypeptides are well known.
  • Exemplary PPAR ⁇ amino acid sequences and PPAR ⁇ -encoding nucleic acid sequences are described, for instance, in U.S. Pat. No. 5,861,274, and U.S. Pat. Appl. Pub. No. 20060154335 (each of which is expressly incorporated herein by reference), and in GenBank Accession Nos.
  • NP — 035275 (GI:33859590)( Mus musculus amino acid sequence); NM — 011145.3 (GI:89001112)( Mus musculus nucleic acid sequence); NP — 006229 (GI:5453940)( Homo sapiens amino acid sequence); NM 006238.3 (GI:89886454)( Homo sapiens nucleic acid sequence); NP — 037273 (GI:6981384)( Rattus norvegicus amino acid sequence); NM — 013141.1 (GI:6981383)( Rattus norvegicus nucleic acid sequence); NP — 990059 (gi45382025)( Gallus gallus amino acid sequence) or NM — 204728.1 (GI:45382024)( Gallus gallus nucleic acid sequence).
  • a PPAR ⁇ homolog or functional variant shares at least 60% amino acid sequence identity with a prototypical PPAR ⁇ polypeptide; for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity with an amino acid sequence as set forth in U.S. Pat. No. 5,861,274, U.S. Pat. Appl. Pub. No. 20060154335, or GenBank Accession No.
  • a PPAR ⁇ homolog or functional variant has one or more conservative amino acid substitutions as compared to with a prototypical PPAR ⁇ polypeptide; for example, no more than 3, 5, 10, 15, 20, 25, 30, 40, or 50 conservative amino acid changes compared to an amino acid sequence as set forth in U.S. Pat. No.
  • NP — 035275 (GI:33859590)( Mus musculus amino acid sequence);
  • NP — 006229 GI:5453940)( Homo sapiens amino acid sequence);
  • NP — 037273 (GI:6981384)( Rattus norvegicus amino acid sequence); or
  • NP — 990059 (gi45382025)( Gallus gallus amino acid sequence).
  • the following table shows exemplary conservative amino acid substitutions:
  • a PPAR ⁇ functional fragment such as an AMPK-binding fragment
  • a PPAR ⁇ functional fragment can be any portion of a full-length known PPAR ⁇ polypeptide, including, e.g., about 20, about 30, about 40, about 50, about 75, about 100, about 150 or about 200 contiguous amino acid residues of same; provided that the fragment retains a PPAR ⁇ function of interest (e.g., AMPK binding).
  • PPAR ⁇ encompasses known functional motifs (such as ligand-binding domain, a DNA-binding domain, and a transactivation domain).
  • AMPK Mammalian AMP-activated kinase
  • An AMPK (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) polypeptide useful in a disclosed screening method is any known AMPK protein or subunit thereof (such as AMPK ⁇ 1 and/or AMPK ⁇ 2). Also useful in the disclosed screening methods are homologs, functional fragments, or functional variants of an AMPK protein or subunit thereof (such as AMPK ⁇ 1 and/or AMPK ⁇ 2) that retains at least PPAR ⁇ -binding activity as described herein (see Example 6).
  • amino acid sequences of prototypical AMPK subunits such as AMPK ⁇ 1 and/or AMPK ⁇ 2
  • nucleic acids sequences encoding prototypical AMPK subunits such as AMPK ⁇ 1 and/or AMPK ⁇ 2
  • Exemplary AMPK ⁇ 1 amino acid sequences and the corresponding nucleic acid sequences are described, for instance, in GenBank Accession Nos.
  • NM — 206907.3 (GI:94557298)( Homo sapiens transcript variant 2 REFSEQ including amino acid and nucleic acid sequences); NM — 006251.5 (GI:94557300)( Homo sapiens transcript variant 1 REFSEQ including amino acid and nucleic acid sequences); NM — 001013367.3 (GI:94681060)( Mus musculus REFSEQ including amino acid and nucleic acid sequences); NM — 001039603.1 (GI:88853844)( Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM 019142.1 (GI: 11862979)( Rattus norvegicus REFSEQ including amino acid and nucleic acid sequences).
  • Exemplary AMPK ⁇ 2 amino acid sequences and the corresponding nucleic acid sequences are described, for instance, in GenBank Accession Nos. NM — 006252.2 (GI:46877067)( Homo sapiens REFSEQ including amino acid and nucleic acid sequences); NM — 178143.1 (GI:54792085)( Mus musculus REFSEQ including amino acid and nucleic acid sequences); NM — 001039605.1 (GI:88853850) ( Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM — 214266.1 (GI:47523597)( Sus scrofa REFSEQ including amino acid and nucleic acid sequences).
  • a homolog or functional variant of an AMPK subunit shares at least 60% amino acid sequence identity with a prototypical AMPK ⁇ 1 and/or AMPK ⁇ 2 polypeptide; for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity with an amino acid sequence as set forth in the GenBank Accession Nos. NM 206907.3; NM — 006251.5; NM — 001013367.3; NM — 001039603.1; NM — 019142.1; NM — 006252.2; NM — 178143.1; NM — 001039605.1; or NM — 214266.1.
  • a homolog or functional variant of an AMPK subunit has one or more conservative amino acid substitutions as compared to a prototypical AMPK ⁇ 1 and/or AMPK ⁇ 2 polypeptide; for example, no more than 3, 5, 10, 15, 20, 25, 30, 40, or 50 conservative amino acid changes compared to an amino acid sequence as set forth in as set forth in GenBank Accession Nos. NM 206907.3; NM — 006251.5; NM — 001013367.3; NM — 001039603.1; NM — 019142.1; NM — 006252.2; NM — 178143.1; NM — 001039605.1; or NM — 214266.1.
  • Exemplary conservative amino acid substitutions have been previously described herein.
  • Some method embodiments involve a functional fragment of AMPK or a subunit thereof (such as AMPK ⁇ 1 and/or AMPK ⁇ 2), including a PPAR ⁇ -binding fragment or a fragment with PPAR ⁇ phosphorylation activity.
  • Functional fragments of AMPK or a subunit thereof can be any portion of a full-length or intact AMPK polypeptide complex or subunit thereof (such as AMPK ⁇ 1 and/or AMPK ⁇ 2), including, e.g., about 20, about 30, about 40, about 50, about 75, about 100, about 150 or about 200 contiguous amino acid residues of same; provided that the fragment retains at least one AMPK (or AMPK ⁇ 1 and/or AMPK ⁇ 2) function of interest (e.g., PPAR ⁇ binding and/or PPAR ⁇ phosphorylation activity).
  • an AMPK PPAR ⁇ -binding fragment includes a functional fragment encompassing (or consisting of) the catalytic core domain of an alpha subunit of AMPK (such as AMPK ⁇ 1 and/or AMPK ⁇ 2).
  • PPAR ⁇ activation by pharmacological treatment did not modify fiber-type composition of skeletal muscle, nor improve running endurance in non-transgenic, sedentary (also referred to as “non-exercised” or “untrained”) mice.
  • mice Male C57B/6J mice (8 wks old) were obtained from Jackson Laboratory and housed in the Salk Institute animal care facility. The animals were acclimated to their surroundings for one week prior to experimentation, and had access at all times to standard mouse chow and water ad libitum.
  • mice were acclimated to moderate treadmill running (10 m/min for 15 min) every other day for 1 week. After acclimation, basal running endurance was determined by placing each mouse on a treadmill, gradually increasing the speed from 0 to 15 m/min, and maintaining 15 m/min until the mouse was exhausted. The time and distance run until exhaustion were recorded as the basal endurance values (Week 0).
  • mice then were treated once per day for 4 weeks with vehicle or the PPAR ⁇ agonist, GW1516 (5 mg/kg). Treatments were administered orally. During the treatment period, mice were housed in standard laboratory cages and received only the amount of physical activity that could be had by normal movements about such cage.
  • QPCR Real time quantitative PCR
  • Fiber type proportions in skeletal muscle are believed to be determined by heredity and environmental factors, such as physical activity level (Simoneau and Bouchard, FASEB J., 9(11):1091-1095, 1995; Larsson and Ansved, Muscle Nerve, 8(8):714-722, 1985).
  • Endurance exercise training is known to remodel the skeletal muscle by increasing type I slow-twitch fibers, oxidative enzymes, and mitochondrial density, which progressively alter performance (Holloszy et al., J. Appl. Physiol. 56:831-8, 1984; Booth et al., Physiol Rev. 71:541-85, 1991; Schmitt et al., Physiol. Genomics.
  • Meta-chromatic staining was used, following a routine myofibrillar ATPase reaction, to demonstrate quantitative differences in phosphate deposition among different skeletal muscle fiber types and, thereby, differentiate skeletal muscle fiber types (Doriguzzi et al., Histochem., 79(3):289-294, 1983; Ogilvie and Feeback, Stain Technol., 65(5):231-241, 1990).
  • muscle fibers with high ATPase activity e.g., type I (slow oxidative) muscle fibers
  • type I slow oxidative
  • FIG. 2A there was no significant difference in the proportion of type I (slow, oxidative) muscle fibers in the gastrocnemius muscles of vehicle- and GW1516-treated sedentary mice.
  • hindlimb muscles of VP16-PPAR ⁇ transgenic mice exhibited an increased number of type I muscle fibers when assayed by monochromatic staining.
  • GW1516 increased the proportion of type I fibers (by 38%) compared to the vehicle-treated sedentary mice ( FIGS. 2A and 2B ).
  • a PPAR ⁇ agonist e.g., GW1516
  • GW1516 a PPAR ⁇ agonist
  • administration of a PPAR ⁇ agonist does not significantly affect the number of type I (slow-twitch, oxidative) muscle fibers in hindlimb muscles, but can increase the number of type I muscle fibers in hindlimb muscles of trained subjects.
  • GW1516 treatment in sedentary mice increased the expression of MHC I (a marker of slow-twitch, oxidative muscle fibers) and decreased the expression of MHC IIb (a marker of fast-twitch, glycolytic muscle fibers) as compared to vehicle-treated, control mice.
  • MHC IIa a marker of fast-twitch oxidative/glycolytic muscle fibers
  • This example illustrates that the genetic or pharmacologic activation of the PPAR ⁇ regulatory program in skeletal muscles of adult, sedentary subjects does not have the same outcome.
  • the ability to genetically manipulate skeletal muscle specification by activation of the PPAR ⁇ receptor in a transgenic mouse from early development in the absence of exercise is not necessarily predictive of the result of pharmacologically activating the PPAR ⁇ program in the sedentary, normal adult.
  • the cellular “template” for PPAR ⁇ effects on skeletal muscle is very different in a normal subject as compared to a genetically engineered transgenic subject.
  • PPAR ⁇ -regulated program For example, in a normal adult, muscle fiber specification of individual muscle groups is already determined and the connections between muscle fibers and spinal motor neurons are established prior to pharmacological activation of the PPAR ⁇ -regulated program.
  • the constitutively active PPAR ⁇ transgene is active all the while muscle fiber specification is being determined and connections between muscle fibers and motor neurons are being made.
  • the effects of activation of endogenous PPAR ⁇ receptor by a single daily dose of a PPAR ⁇ agonist which is expect to have a transient peak exposure followed by clearance, likely are much different from the effects of the constitutive activation of a VP16-PPAR ⁇ transgene.
  • mice Male C57B/6J mice (8-10 wks old) were randomly divided into four groups (nine per group): (i) vehicle-treated and sedentary (V), (ii) GW1516-treated and sedentary (GW), (iii) vehicle-treated and exercise trained (Tr) and (iv) GW1516-treated and exercise trained (GW+Tr). Mice in all groups were acclimated to moderate treadmill running and basal running endurance was determined as described in Example 1.
  • mice in the exercise-trained groups received four weeks (5 days/week) of exercise training on a treadmill inclined at 5 degrees. Intensity and time of training were gradually increased. At the end of four weeks, all exercise-trained mice were running for 50 min/day at 18 m/min. Vehicle or GW1516 was administered to the respective exercise-treated or sedentary groups as described in Example 1. Unless otherwise noted, V, GW, Tr and GW+Tr subjects described in this and the examples below were similarly treated. At the end of the drug treatment and/or training protocol (Week 5) 6 mice per group were subjected to the running test. These interventions do not affect body weight and food intake in mice. RNA was prepared real time quantitative PCR performed as described in Example 1.
  • This interesting response profile includes a series of genes involved in the regulation of fatty acid storage [such as steroyl-CoA-desaturase (SCD1), fatty acyl coenzyme A synthase (FAS) and serum response element binding protein 1c (SREBP1c)] and fatty acid uptake [such as the fatty acid transporter (FAT/CD36) and lipoprotein lipase (LPL)] adding a new set of target genes to exercise and drug treated mice ( FIGS. 3B , 3 C and 6 A-C).
  • SCD1 steroyl-CoA-desaturase
  • FAS fatty acyl coenzyme A synthase
  • SREBP1c serum response element binding protein 1c
  • fatty acid uptake such as the fatty acid transporter (FAT/CD36) and lipoprotein lipase (LPL)
  • protein expression was determined for selective oxidative biomarkers including myoglobin, UCP3, cytochrome c (CYCS) and SCD1, using Western blotting.
  • Protein homogenates were prepared from quadriceps muscle, separated by SDS polyacrylamide gel electrophoresis, transferred to blotting membrane and probed with antibodies specific for myoglobin (Dako), UCP3 (Affinity Bioreagents), cytochrome c (Santacruz) SCD1 (Santacruz), and, as a loading control, tubulin (Sigma).
  • a robust up regulation of myoglobin, UCP3, cytochrome c, and SCD1 protein expression was observed with combined exercise and GW1516 treatment in comparison to treatment with the PPAR ⁇ agonist or exercise alone ( FIG. 3D ).
  • mTG Muscle triglyceride
  • FIG. 4 Muscle triglyceride (mTG) content was measured as previously described (Wang et al., PLoS Biol., 2:e294, 2004) using a kit from Thermo Electron Corporation. As shown in FIG. 4 , mTG content was comparable between vehicle and GW1516-treated sedentary mice and was substantially increased in muscle of mice receiving only exercise training. In contrast, dramatic increase in triglycerides in exercised muscle was completely reversed in GW1516-treated exercise trained mice, indicating increased fat utilization ( FIG. 4 ).
  • Gene and/or protein expression that is induced by a combination of exercise and drug treatment (e.g., PPAR ⁇ agonist administration) but not by either input alone is believed to be a new discovery.
  • This type of response can be used to further characterize the intersection of pharmacologic and physiologic genetic networks.
  • one or more genes and/or proteins uniquely regulated by one or more drugs (e.g., PPAR ⁇ agonists) and exercise can be used as markers, for instance, of illicitly boosting performance in professional and/or amateur athletes.
  • Example 3 GW1516 treatment induces wide-spread genomic changes associated with oxidative metabolism, nonetheless alone it failed to increase running endurance. This finding was unexpected because it was known that constitutive activation of the PPAR ⁇ gene network (in the VP16-PPAR ⁇ transgenic mouse) lead to a distance-running phenotype (familiarly, a “marathon mouse”).
  • PPAR ⁇ agonist e.g., GW1516 treatment in conjunction with exercise produced an enriched remodeling program that included a series of transcriptional and post-translational adaptations in the skeletal muscle. This indicates that exercise training serves as a trigger to unmask a set of PPAR ⁇ target genes.
  • This Example provides methods used to demonstrate that administration of a PPAR ⁇ agonist (e.g., GW1516) surprisingly improves physical performance in exercised (trained) subjects.
  • mice Male C57B/6J mice (8-10 wks old) were randomly divided into four groups (nine per group): (i) vehicle-treated and sedentary (V), (ii) GW1516-treated and sedentary (GW), (iii) vehicle-treated and exercise trained (Tr) and (iv) GW1516-treated and exercise trained (GW+Tr), acclimated to moderate treadmill running as described in Example 1, and exercise-trained as described in Example 3. At the end of the drug treatment and/or training protocol (Week 5) 6 mice per group were subjected to the running test.
  • V vehicle-treated and sedentary
  • GW1516-treated and sedentary GW1516-treated and sedentary
  • Tr vehicle-treated and exercise trained
  • GW+Tr GW1516-treated and exercise trained
  • FIGS. 5A and 5B the same dose and duration of GW1516 treatment that failed to alter running endurance in sedentary mice, when paired with 4 weeks of exercise training, increases running time by 68% and running distance by 70% over vehicle-treated trained mice ( FIGS. 5A and 5B , compare Week 5). Comparison of running time and distance before (week 0) and after (week 5) exercise and drug treatment revealed a 100% increment in endurance capacity for individual mice, underscoring the robustness of the combination paradigm ( FIGS. 5A and 5B ). In contrast, the same exercise protocol without concurrent GW1516 treatment did not significantly increase running endurance in C57B1/6J mice.
  • Hematoxylin and eosin (H&E) staining of white adipose tissue paraffin sections was performed as previously described (Wang et al., PLoS Biol., 2:e294, 2004; Wang et al., Cell, 113: 159-70, 2003).
  • GW1516 treatment in combination with exercise produced a significant (32%) reduction in the epididymal fat to body weight ratio, which was further evident in the decreased cross-sectional area of the adipocytes in the same group ( FIG. 5D ). Therefore, the combined effects of GW1516 and exercise are not restricted to muscle.
  • Example 2 Using the methods described in Example 2, it was also demonstrated that the combination of GW1516 treatment and exercise training significantly increased the number of type I muscle fibers in exercised muscle. However, combining GW1516 treatment with exercise did not induce additional changes in MHC I and MHC IIb expression. Therefore, although orally administered PPAR ⁇ agonist (GW1516) alone is capable of inducing the expression of at least some of the contractile proteins in the PPAR ⁇ -regulated gene network (see Example 5) the transcriptional effect observed was not sufficient to induce a post-transcriptional change in fiber-type composition as was observed by meta-chromatic staining in GW1516-treated, exercised mice.
  • GW1516 orally administered PPAR ⁇ agonist
  • PPAR ⁇ agonist e.g., GW1516 treatment unexpectedly augments the performance of aerobic exercise (e.g., running distance and endurance) in an exercised subject.
  • Endurance exercise is known to channel extra-muscular fat to muscle triglyceride stores by inducing adipose tissue lipolysis to meet increased oxidative demands (Despres et al., Metabolism, 33:235-9, 1984; Mauriege et al., Am. J. Physiol., 273:E497-506, 1997; Mader et al., Int. J. SportsMed., 22:344-9, 2001; Schmitt et al., Physiol.
  • a comprehensive study of the skeletal muscle transcriptional program in V, GW, Tr and Tr+GW mice was conducted using microarray analysis.
  • AffymetrixTM high-density oligonucleotide array mouse genome 430A 2.0 chips were used. Preparation of in vitro transcription products, oligonucleotide array hybridization, and scanning were performed in conformance with AffymetrixTM-provided protocols. To minimize discrepancies due to variables, the raw expression data were scaled by using AffymetrixTM MICROARRAY SUITETM 5.0 software, and pairwise comparisons were performed. The trimmed mean signal of all probe sets was adjusted to a user-specified target signal value (200) for each array for global scaling. No specific exclusion criteria were applied.
  • the 130 genes regulated by the combination of GW1516 treatment and exercise training and a classification of each such gene are shown in Table 1.
  • the 130 regulated genes included 30 fat metabolism genes, 5 oxygen carriers, 5 mitochondrial genes, 3 carbohydrate metabolism genes, 15 signal transduction genes, 16 transcription genes, 10 transport genes, 3 steroid biogenesis genes, 5 heat shock genes, 2 angiogenesis genes, 5 proliferation and apoptosis genes, 2 cytokines, and 29 others.
  • the majority of the genes in the exercise-trained/GW1516-treated (GW+Tr) gene signature shown in Table 1 were induced (109/130).
  • the 109 upregulated genes are shown in non-bold font in Table 1 (final column>1).
  • Down-regulated genes are shown in bold italics in Table 1 (final column ⁇ 1).
  • a predominance of genes involved in oxidative metabolism is selectively up-regulated by combined exercise and drug treatment (see unbolded genes in Tables 1 and 2).
  • several stress-related genes activated by either intervention including heat shock proteins, metallothioneins and other stress biomarkers (Table 3) are not changed by the combination possibly reflecting a potential lessening of exercise-based damage.
  • fatty acid biosynthesis/storage e.g., FAS, SCD 1 & 2
  • uptake e.g., FAT/CD36, fatty acid binding proteins (FABP) and LPL] and oxidation [e.g., adiponectin, hormone sensitive lipase (HSL), PDK4, UCP3]
  • carbohydrate metabolism e.g., fructose bisphosphate 2 (FBP2), phosphoenolpyruvate carboxykinase 1 (PEPCK1), lactate dehydrogenase B]
  • FBP2 fructose bisphosphate 2
  • PEPCK1 phosphoenolpyruvate carboxykinase 1
  • lactate dehydrogenase B lactate dehydrogenase B
  • fatty acyl-CoA oxidase and medium chain acyl-CoA dehydrogenase were not represented in the signature. All but four of these metabolic genes were induced, which indicated a general increase in oxidative capacity of skeletal muscle in exercise-trained subjects that received GW1516 treatment.
  • genes regulated in quadriceps muscle by the combination of exercise and GW1516 treatment encoded proteins involved in pathways such as angiogenesis (e.g., angiopoietin-like 4 protein/also a known regulator of lipid metabolism), (e.g., adrenergic receptor ⁇ 3, insulin-like growth factor, insulin-like growth factor binding protein 5), transcription (e.g., C/EBP ⁇ , Reverb ⁇ , NURR1) and substrate transport (e.g., transferrin, chloride channel 5) (Nagase et al., J. Clin. Invest. 97:2898-904, 1996; Singleton and Feldman, Neurobiol. Dis. 8:541-54, 2001; Adams, J. Appl.
  • angiogenesis e.g., angiopoietin-like 4 protein/also a known regulator of lipid metabolism
  • transcription e.g., C/EBP ⁇ , Reverb ⁇ , NURR1
  • substrate transport e.g.
  • Genes and/or proteins uniquely affected (e.g., up-regulated or down-regulated or not substantially regulated) by exercise in the presence of one or more pharmaceutical agents can be used as markers, for instance, of “drug doping” in exercise-trained subjects (e.g., athletes). It is expected that the unique set of 48 genes regulated by GW+Tr, but not GW1516 treatment or exercise training alone, can be used to identify exercised subjects who have received a variety performance-enhancing drugs.
  • PPAR ⁇ Directly Interacts with Exercise-Activated Kinases, p44/42 MAPK and AMPK
  • Exercise training is known to activate kinases, such as p44/42 MAPK and AMPK, which regulate gene expression in skeletal muscle (Chen et al., Diabetes, 52:2205-12, 2003; Goodyear et al., Am. J. Physiol., 271:E403-8, 1996).
  • AMPK affects skeletal muscle gene expression and oxidative metabolism (Chen et al., Diabetes. 52: 2205-12, 2003, Reznick et al., J. Physiol. 574: 33-9, 2006).
  • the interaction between exercise-regulated kinases and PPAR ⁇ signaling is described in this Example.
  • the levels of phospho-p44/42 MAPK and phospho-AMPK ⁇ subunit and total AMPK were determined in protein homogenates of quadriceps muscle by Western blot.
  • Antibodies specific for phospho-p44/42 MAPK, phospho- and total-AMPK ⁇ 1 antibodies were obtained from Cell Signaling.
  • the phospho-specific AMPK ⁇ c1 antibody recognizes the key activating threonine in the activation loop.
  • FIG. 8A which includes target genes associated with translation, protein processing, amino acid metabolism, fat metabolism, oxygen carriers, carbohydrate metabolism, signal transduction, transcription, transport, steroid biogenesis, heat shock response, angiogenesis, proliferation and apoptosis, cytokines, contractile proteins, stress, and others) that shares 40% of the genes with that of combined GW1516 treatment and exercise ( FIG. 8B ).
  • Classification of the 52 genes common to the two signatures (combined PPAR ⁇ activation and exercise or PPAR ⁇ and AMPK co-activation) (listed in Table 4) revealed that the majority of the targets were linked to oxidative metabolism.
  • PPAR ⁇ and exercise synergistically regulate running endurance.
  • kinase activation may influence PPAR ⁇ signaling during exercise in establishing an “endurance gene expression signature” that effectively enhances performance.
  • Example 6 The genetic synergism described in Example 6 indicates that AMPK directly regulates the transcriptional activity of PPAR ⁇ in skeletal muscles. To demonstrate this, an analysis of the effects of GW1516 and AICAR on gene expression in primary muscle cells isolated from wild type and PPAR ⁇ null mice was performed.
  • RNA expression of UCP3, PDK4, LPL, and HSL was determined using real time quantitative PCR as described in Example 1.
  • synergism is dependent on PPAR ⁇ and lost in the null cells. Similar synergistic regulation of gene expression by GW1516 and AICAR was also observed in differentiated C2C12 cells. These results show that AMPK activation may enhance ligand-dependent transcriptional effects of PPAR ⁇ in muscles.
  • AD 293 cells were cultured in DMEM containing 10% serum and an antibiotic cocktail.
  • Cells were transfected with one or more of CMX-Flag, CMX-Flag PPAR ⁇ , CMX-Tk-PPRE, or CMX- ⁇ GAL, or an hAMPK ( ⁇ 1 and ⁇ 2 subunits, Origene) expression vector using LipofectamineTM 2000 in accordance with the manufacturer's instructions.
  • Anti-Flag antibody-conjugated beads were incubated overnight at 4° C. with lysates from transfected cells.
  • Flag-tagged protein or protein complexes were immunoprecipitated by separating the beads from non-bound materials.
  • the beads were washed in ice-cold lysis buffer followed by extraction in Laemmli buffer. For co-immunoprecipitation experiments SDS was excluded from the lysis buffer. Western blotting was performed with antibodies specific for the Flag tag or AMPK ⁇ subunit(s).
  • AD 293 cells were transfected with PPAR ⁇ and hAMPk ( ⁇ 1 or ⁇ 2 subunit) expression vectors as described above. Forty-eight hours after transfection, the cells were washed three times with phosphate-free DMEM and incubated with 32 P-orthophosphate in phosphate-free DMEM for 20 hours (100 ⁇ Ci/5 ml). Cells were washed three times with ice-cold phosphate-free DMEM and lysed in ice-cold lysis buffer.
  • the portion of the PPAR ⁇ -exercise signature that is independent of PPAR ⁇ -AMPK interaction may depend on cross-talk between the receptor and other exercise signal transducers such as MAPK, calcineurin/NFAT and SIRT 1.
  • This example describes methods that can be used to increase or enhance an exercise in a healthy mammalian subject. Although specific conditions are described, one skilled in the art will appreciate that minor changes can be made to such conditions.
  • Healthy adult human subjects perform aerobic exercise (e.g., running) for at least 30 minutes (e.g., 30-90 minutes) for at least 3-4 days per week (e.g., 3-7 days per week) for at least 2 weeks (e.g., at least 4-12 weeks).
  • the exercise is performed at 40%-50% maximal heart rate, 50%-60% maximal heart rate, 60%-70% maximal heart rate, or 75%-80% maximal heart rate, where maximum heart rate for a human subject is calculated as: 220 bps ⁇ (age of the subject).
  • the subjects are orally administered GW1516 [(2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfanyl)phenoxy)acetic acid] at a dose of 1 to 20 mg per day, such as 2.5 or 10 mg per day.
  • Subjects can continue to perform aerobic exercise while receiving GW1516.
  • the subject can receive GW1516 for a period of at least 2 weeks, such as at least 4 weeks.
  • the exercise effect achieved in the treated subjects can be compared to such an effect in untreated subjects.
  • Exercise effect can be measured using methods known in the art, such as measuring aerobic or running endurance (for example measuring distance run until exhaustion or amount of time to run a particular distance).
  • the exercise effect of interest is increased in treated subjects by at least 5%, such as at least 10% as compared to untreated subjects.
  • This example describes methods that can be used to identify performance-enhancing substances in an exercised-trained subject.
  • a biological sample obtained from a healthy adult human is analyzed to determine if the subject is taking a PES (e.g., GW1516) by analyzing expression of one or more of the molecules (nucleic acids or proteins) listed in Table 2 or Table 4.
  • Suitable biological samples include samples containing genomic DNA or RNA (including mRNA) or proteins obtained from cells of a subject, such as those present in peripheral blood, urine, saliva, tissue biopsy, or buccal swab.
  • a biological sample of the subject can be assayed for a change in expression (such as an increase or decrease) of any combination of at least four molecules (nucleic acids or proteins) listed in Table 2 or 4, such as any combination of at least 10, at least 20, at least 30, or at least 40 of those listed in Table 2 or 4, for example all of those listed in Table 2 or 4.
  • a change in expression such as an increase or decrease
  • any combination of at least four molecules (nucleic acids or proteins) listed in Table 2 or 4 such as any combination of at least 10, at least 20, at least 30, or at least 40 of those listed in Table 2 or 4, for example all of those listed in Table 2 or 4.
  • nucleic acid molecules from a biological sample are routine, for example using PCR to amplify the molecules from the sample, or by using a commercially available kit to isolate mRNA or cDNA.
  • nucleic acids need not be isolated prior to analysis.
  • Nucleic acids can be contacted with an oligonucleotide probe that will hybridize under stringent conditions with one or more nucleic acid molecule listed in Table 2 or 4.
  • the nucleic acids which hybridize with the probe are then detected and quantified.
  • the sequence of the oligonucleotide probe can bind specifically to a nucleic acid molecule represented by the sequences listed in Table 2 or 4.
  • Increased or decreased expression of the molecules listed in Table 2 or 4 can be detected by measuring the cellular levels of mRNA.
  • mRNA can be measured using techniques well known in the art, including for instance Northern analysis, RT-PCR and mRNA in situ hybridization. Details of mRNA analysis procedures can be found, for instance, in provided examples and in Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
  • Oligonucleotides specific to sequences listed in Table 2 or 4 can be chemically synthesized using commercially available machines. These oligonucleotides can then be labeled, for example with radioactive isotopes (such as 32 P) or with non-radioactive labels such as biotin (Ward and Langer et al., Proc. Natl. Acad. Sci. USA 78:6633-57, 1981) or a fluorophore, and hybridized to individual DNA samples immobilized on membranes or other solid supports by dot-blot or transfer from gels after electrophoresis.
  • radioactive isotopes such as 32 P
  • non-radioactive labels such as biotin (Ward and Langer et al., Proc. Natl. Acad. Sci. USA 78:6633-57, 1981) or a fluorophore
  • Proteins in the biological sample can also be analyzed. In some examples, proteins are isolated using routine methods prior to analysis.
  • SELDI-TOF mass spectrometry is used to detect changes in differential protein expression, for example by using the ProteinChipTM (Ciphergen Biosystems, Palo Alto, Calif.). Such methods are well known in the art (for example see U.S. Pat. No. 5,719,060; U.S. Pat. No. 6,897,072; and U.S. Pat. No. 6,881,586).
  • SELDI is a solid phase method for desorption in which the analyte is presented to the energy stream on a surface that enhances analyte capture or desorption.
  • the chromatographic surface includes antibodies that recognize proteins listed in Table 2 or 4. Antigens present in the sample can recognize the antibodies on the chromatographic surface. The unbound proteins and mass spectrometric interfering compounds are washed away and the proteins that are retained on the chromatographic surface are analyzed and detected by SELDI-TOF. The MS profile from the sample can be then compared using differential protein expression mapping, whereby relative expression levels of proteins at specific molecular weights are compared by a variety of statistical techniques and bioinformatic software systems.
  • the availability of antibodies specific to the molecules listed in Table 2 or 4 facilitates the detection and quantification of proteins by one of a number of immunoassay methods that are well known in the art, such as those presented in Harlow and Lane ( Antibodies, A Laboratory Manual , CSHL, New York, 1988). Methods of constructing such antibodies are known in the art. Any standard immunoassay format (such as ELISA, Western blot, or RIA assay) can be used to measure protein levels. Immunohistochemical techniques can also be utilized for protein detection and quantification.
  • a tissue sample can be obtained from a subject, and a section stained for the presence of the desired protein using the appropriate specific binding agents and any standard detection system (such as one that includes a secondary antibody conjugated to horseradish peroxidase).
  • any standard detection system such as one that includes a secondary antibody conjugated to horseradish peroxidase.
  • expression in the test sample can be compared to levels found in cells from a subject who has not taken a PES.
  • the pattern of expression identified in the test subject can be compared to that shown in Table 2 or 4.
  • test sample shows a pattern of expression similar to that in Table 2 or 4 (e.g. the genes shown as upregulated and downregulated in Table 2 or 4 are observed in the subject to be upregulated and downregulated, respectively)
  • a PES such as a PPAR ⁇ agonist
  • the pattern of expression identified in the test subject is different to that shown in Table 2 or 4 (e.g. the genes shown as upregulated and downregulated in Table 2 or 4 are observed in the subject to be not differentially expressed or show a different pattern of regulation)
  • a significant increase in the non-bolded proteins listed in Table 2 in the cells of a test subject compared to the amount of the same protein found in normal human cells is usually at least 2-fold, at least 3-fold, at least 4-fold or greater difference.
  • Substantial overexpression of the non-bolded proteins listed in Table 2 in the subject's sample can be indicative of the subject taking a PES.
  • a significant decrease in the bolded proteins listed in Table 2 in the cells of a test subject compared to the amount of the same protein found in normal human cells is usually at least 2-fold, at least 3-fold, at least 4-fold or greater difference.
  • Substantial underexpression of the bolded proteins listed in Table 2 in the subject's sample can be indicative of the subject taking a PES.

Abstract

Disclosed herein are methods for enhancing one or more effects of exercise in a subject by administering a PPARδ agonist (e.g., GW1516) to the subject in combination with an exercise program. Also disclosed are gene expression profiles unique to the combination of agonist-induced PPARδ activation and exercise. Such profiles are useful, at least, in methods for identifying the use of performance-enhancing drugs in exercised subjects (such as, professional or athletes). Direct interactions between PPARδ and exercised-induced kinases (e.g., AMPK or its subunits, AMPK α1 and/or AMPK α2) also are disclosed. Such protein-protein interactions provide new targets for identification of useful compounds.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 60/882,774 filed Dec. 29, 2006, herein incorporated by reference.
    • ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
  • This work was supported by National Institutes of Health Grant No. 1 F32 AR053803-01 (NRSA Fellowship). Therefore, the Government of the United States has certain rights in this invention.
    • FIELD
  • This disclosure concerns the use of peroxisome proliferator-activated receptor (PPAR)δ agonists for improving exercise performance in a subject, methods for identifying substance-enhanced exercise performance in a subject, and methods for identifying compounds that affect the interaction of PPARδ with exercise-induced kinases.
    • BACKGROUND
  • Skeletal muscle is an adaptive tissue composed of multiple myofibers that differ in their metabolic and contractile properties including oxidative slow-twitch (type I), mixed oxidative/glycolytic fast-twitch (type IIa) and glycolytic fast-twitch (type IIb) myofibers (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000). Type I muscle fibers preferentially express enzymes that oxidize fatty acids, contain slow isoforms of contractile proteins and are more resistant to fatigue than are glycolytic muscle fibers (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000). Type II fibers preferentially metabolize glucose and express the fast isoforms of contractile proteins (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000).
  • Endurance exercise training triggers a complex remodeling program in skeletal muscle that progressively enhances performance in athletes such as marathon runners, mountain climbers and cyclists. This involves changes in metabolic programs and structural proteins within the myofibers that alter the energy substrate utilization and contractile properties that act to reduce muscle fatigue (Fluck et al., Rev. Physiol. Biochem. Pharmacol., 146:159-216, 2003; Pette and Staron, Microsc. Res. Tech., 50:500-509, 2000). Training based adaptations in the muscle are linked to increases in the expression of genes involved in the slow-twitch contractile apparatus, mitochondrial respiration and fatty acid oxidation (Holloszy and Coyle, J. Appl. Physiol., 56:831-838, 1984; Booth and Thomason, Physiol. Rev., 71:541-585, 1991; Schmitt et al., Physiol. Genomics, 15:148-157, 2003; Yoshioka et al., FASEB J, 17:1812-1819, 2003; Mahoney et al., FASEB J, 19:1498-1500, 2005; Mahoney and Tarnopolsky, Phys. Med. Rehabil. Clin. N. Am., 16:859-873, 2005; Siu et al., J. Appl. Physiol., 97:277-285, 2004; Garnier et al., FASEB J, 19:43-52, 2005; Short et al., J. Appl. Physiol., 99:95-102, 2005; Timmons et al., FASEB J, 19:750-760, 2005). Such exercise training-related adaptations can improve performance and protect against obesity and related metabolic disorders (Wang et al., PLoS Biol., 2:e294, 2004; Koves et al., J. Biol. Chem., 280:33588-33598, 2005). Moreover, skeletal muscles rich in oxidative slow-twitch fibers are resistant to muscle wasting (Minnaard et al., Muscle Nerve. 31: 339-48, 2005).
  • PPARs are members of the nuclear receptor superfamily of ligand-inducible transcription factors. They form heterodimers with retinoid X receptors (RXRs) and bind to consensus DNA sites composed of direct repeats of hexameric DNA sequences separated by 1 bp. In the absence of ligand, PPAR-RXR heterodimers recruit corepressors and associated histone deacetylases and chromatin-modifying enzymes, silencing transcription by so-called active repression (Ordentlich et al., Curr. Top. Microbiol. Immunol., 254:101-116, 2001; Jepsen and Rosenfeld, J. Cell Sci., 115:689-698, 2002; Privalsky, Ann. Rev. Physiol., 66:315-360, 2004). Ligand binding induces a conformational change in PPAR-RXR complexes, releasing repressors in exchange for coactivators. Ligand-activated complexes recruit the basal transcriptional machinery, resulting in enhanced gene expression. PPARs bind to lower-affinity ligands generated from dietary fat or intracellular metabolism. In keeping with their roles as lipid sensors, ligand-activated PPARs turn on feed-forward metabolic cascades to regulate lipid homeostasis via the transcription of genes involved in lipid metabolism, storage, and transport.
  • Three PPAR isotypes exist in mammals: α (also known as NR1C1), γ (also known as NR1C3), and β (also known as β or NR1C2). PPARδ is expressed in most cell types with relative abundance (Smith, Biochem. Soc. Trans., 30(6):1086-1090, 2002), which led to early speculation that it may serve a “general housekeeping role” (Kliewer et al., Proc. Natl. Acad. Sci. U.S.A., 91:7355-7359, 1994). More recently, PPARδ transgenic mouse models and discoveries aided by the development of high-affinity PPARδ agonists have revealed PPARδ as a key transcriptional regulator with effects in diverse tissues including fat, skeletal muscle, and the heart (for review see, e.g., Barish et al., J. Clin. Invest., 116(3):590-597, 2006).
  • Targeted expression of a constitutively active PPARδ receptor (VP16-PPARδ) transgene in rodent skeletal muscle promoted remodeling of skeletal muscle to an oxidative phenotype and increased running endurance in unexercised adult mice (Wang et al., PLoS Biol., 2:e294, 2004). The observed PPARδ-mediated reprogramming of muscle fibers involved the increased expression of genes related to fatty acid oxidation, mitochondrial respiration, oxidative metabolism, and slow-twitch contractile apparatus (Wang et al., PLoS Biol., 2:e294, 2004). These VP16-PPARδ transgenic mice, who had a phenotype similar to endurance-trained athletes, but who had had no exercise training, suggest that pharmacological activation of endogenous PPARδ in an adult, sedentary subject might provide an exercise effect without the actual exercise. Given the numerous benefits of exercise on general health, identification of orally active agents that mimic the effects of exercise is a long standing, albeit elusive medical goal.
    • SUMMARY
  • This disclosure illustrates that, despite expectations to the contrary, pharmacological activation of endogenous PPARδ in adult, sedentary subjects did not promote remodeling of skeletal muscle to an oxidative phenotype or increase running endurance in such subjects. Surprisingly, however, pharmacological activation of PPARδ in combination with at least sub-maximal exercise synergistically modified skeletal muscle architecture (e.g., induced fatigue resistant type I fiber specification and mitochondrial biogenesis) and increased exercise performance (e.g., running endurance). In addition, agonist-induced activation of endogenous PPARδ in combination with exercise led to a unique “gene expression signature” in skeletal muscle, which was distinct from the gene expression profile obtained by either exercise or drug intake alone, and revealed direct interactions between PPARδ and exercise-induced kinases (such as AMPK α1 and/or AMPK α2).
  • These and other discoveries described herein serve as the basis for disclosed methods. For example, it can now be appreciated that PPARδ agonists (e.g., GW1516) used in combination with exercise can enhance exercise-induced effects, such as to improve exercise endurance (e.g., running endurance) even more than may be achieved by exercise alone. In another example, the expression of one or more genes and/or proteins that are uniquely regulated by the combination of exercise and PPARδ agonist administration can be used to identify subjects using drugs to enhance exercise performance. In still other examples, the newly identified protein complexes, including PPARδ and exercise-induced kinases (such as AMPK α1 and/or AMPK α2), can be used to identify agents that have potential to affect PPARδ-regulated gene networks and the corresponding downstream biochemical and/or physiological effects.
  • The foregoing and other features will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1A is a series of bar graphs showing the effects of orally administered PPARδ agonist (GW1516) on mRNA expression levels of three biomarkers of fatty acid oxidation, uncoupling protein 3 (UCP3), carnitine palmitoyl-transferase I (mCPT I), and pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4), in quadriceps muscle isolated from sedentary vehicle-treated (V), sedentary GW1516-treated (GW), sedentary VP16-PPARδ transgenic (TG), and sedentary wild-type littermates of VP16-PPARδ transgenic mice (WT). Data are presented as mean ±SEM of N=4-9 mice each analyzed in triplicate. * Represents a statistically significant difference between V and GW1516 groups (p<0.05, unpaired student's t-test), or TG and WT groups (p<0.05, unpaired student's t-test).
  • FIG. 1B-D are a series of bar graphs showing the regulation of oxidative genes UCP3, mCPT I, and PDK4 by GW1516 (GW) in wild-type (WT) and PPARδ null (KO) primary muscle cells. * represents statistical significance between V and indicated groups (p<0.05, One Way ANOVA; post hoc: Dunnett's Multiple Comparison Test)
  • FIG. 1E is a series of bar graphs showing running endurance of vehicle-treated sedentary (V; open bars) and GW1516-treated sedentary (GW; black bars) mice before (Week 0) and after (Week 5) treatment. Running endurance is quantified by the amount of time for which (left panel) or the distance (right panel) animals in each group ran on the treadmill. Data is represented as mean ±SD values from N=6 mice.
  • FIGS. 2A-C show the effects of administration of a PPARδ agonist, GW1516, on the gastrocnemius muscle of sedentary (V or GW) or trained (Tr or Tr+GW) mice. FIG. 2A shows digital images of representative meta-chromatically stained frozen cross-sections of gastrocnemius muscle from vehicle-treated, sedentary (V), GW1516-treated, sedentary (GW), vehicle-treated, exercised (Tr) and GW1516-treated, exercised (Tr+GW) mice. Type I (slow oxidative) fibers are darkly stained. FIG. 2B is a bar graph showing the percentage of type I fibers (as a percentage of the total fibers) in V, GW, Tr, and Tr+GW gastrocnemius (N=3).
  • FIG. 2C is a bar graph showing the fold change in mitochondrial DNA to nuclear DNA ratio in V (left bar), GW (left center bar), Tr (right center bar), and Tr+GW (right bar) groups of mice (N=9). Data in (B) and (C) are presented as mean ±SEM. In each bar graph, * represents a statistical difference between V and the group(s) indicated by asterisk (p<0.05, One-Way ANOVA; post hoc: Dunnett's Multiple Comparison Test).
  • FIGS. 3A-C are a series of bar graphs showing gene expression in quadriceps muscle isolated from V, GW, Tr and Tr+GW groups. FIG. 3A shows the relative gene expression levels of biomarkers for fatty acid oxidation (UCP3, mCPT I, PDK4; from left to right). FIG. 3B shows the relative gene expression levels of biomarkers for fatty acid storage (SCD1, FAS, SREBP1c). FIG. 3C shows the relative gene expression levels of biomarkers for fatty acid uptake (FAT/CD36, LPL). Data is presented as mean ±SEM of N=9 mice, each analyzed in triplicate. * represents statistically significant difference between V and the group(s) indicated by asterisk (p<0.05, One Way ANOVA; post hoc: Dunnett's Multiple Comparison Test).
  • FIG. 3D shows images of Western blots illustrating protein expression levels of oxidative biomarkers (myoglobin, UCP3, CYCS, SCD1) and loading control (tubulin) in protein lysates prepared from quadriceps (N=3).
  • FIG. 4 shows a graph of muscle triglyceride levels in gastrocnemius muscle of V, GW, Tr and Tr+GW mice. Data is presented as mean ±SEM of N=9 mice, each analyzed in triplicate. * represents statistical significance between V and group(s) indicated by asterisk (*p<0.05, One Way ANOVA; post hoc:Dunnett's Multiple Comparison Test).
  • FIGS. 5A and B are bar graphs showing the effects of GW1516 treatment on running endurance in exercise-trained mice. Bar graphs of the (A) time and (B) distance that vehicle-(V; open bars) and GW1516-treated (GW; black bars) mice ran on a treadmill before (Week 0) and after (Week 5) exercise training. Data is represented as mean ±SD of N=6 mice. *** represents statistically significant difference between V and GW groups (p<0.001; One Way ANOVA; post hoc:Tukey's Multiple Comparison Test).
  • FIG. 5C is a bar graph showing epididymal white adipose to body weight ratio in V, GW, Tr and Tr+GW mice. Data is presented as mean ±SEM of N=9 mice, each analyzed in triplicate. * represents statistical significance between V and group(s) indicated by asterisk (*p<0.05, One Way ANOVA; post hoc:Dunnett's Multiple Comparison Test).
  • FIG. 5D shows digital images of H&E-stained cross-sections of epididymal white adipose from V, GW, Tr and Tr+GW mice. Similar results were obtained from N=3 mice. * represents statistical significance between V and group(s) indicated by asterisk (*p<0.05, One Way ANOVA; post hoc:Dunnett's Multiple Comparison Test).
  • FIG. 6 shows a Venn diagram comparing GW, Tr and Tr+GW target genes identified in microarray analysis of quadriceps. Data is an average of N=3 samples in each group. The selection criteria used a p<0.05 on Bonferroni's multiple comparison test and a fold change greater than 1.5.
  • FIG. 7A is a series of Western blot images showing AMPK activation by exercise. The levels of phospho-AMPK (phospho-AMPK) and total-AMPK in quadriceps muscle of sedentary (Sed/C57B1) and exercise-trained (Tr/C57B1) mice (N=5-7) are shown.
  • FIG. 7B is a series of Western blot images showing AMPK activation by VP16-PPARd over-expression. The levels of phospho-AMPK (phospho-AMPK) and total-AMPK in quadriceps muscle of sedentary wild-type or transgenic mice (Sed/WT or Sed/TG) are shown.
  • FIGS. 8A-B show the synergistic regulation of muscle gene expression by PPARδ and AMPK. (A) Venn diagram comparing GW, AI, and AI+GW target genes identified in microarray analysis of quadriceps. Data is an average of N=3 samples in each group. The selection criteria used a p<0.05 on Bonferroni's multiple comparison test and fold change greater than 1.5. (B) Comparison of Tr+GW and AI+GW dependent gene signatures identified in quadriceps. Data is an average of N=3 samples in each group. The selection criteria used is similar to one used in FIG. 8A.
  • FIGS. 9A-H show the expression of (A) UCP3, (B) mCPT I, (C) PDK4, (D) SCD1, (E) ATP citrate lyase, (F) HSL, (G) mFABP, and (H) LPL transcripts in quadriceps of mice treated with vehicle (V), GW1516 (GW), AICAR (AI) and the combination of the two drugs (GW+AI) for 6 days. Data is presented as mean ±SEM of N=6 mice in each group, analyzed in triplicate. * Indicates statistically significant difference between V and indicated groups (p<0.05, One Way ANOVA; post hoc: Dunnett's Multiple Comparison Test).
  • FIGS. 10A-L demonstrate the AMPK-PPARδ interaction. (A-D) show the expression of metabolic genes in wild type and PPARδ null (KO) primary muscle cells treated with V, GW, AI and GW+AI (bars from left to right) for 24 hours. In (E-F, J), AD293 cells were transfected with PPARδ+RXRα+Tk−PPRE along with control vector, AMPK α1, α2 and/or PGC1α as indicated above. (E) Induction of basal PPARδ transcriptional activity by AMPK α1 or α2. (F) Dose-dependent induction of PPARδ transcriptional activity is enhanced by AMPK α1 (closed circle) or AMPK α2 (closed square) compared to control (open triangle). In (G-I, K), AD293 cells were transfected and processed as indicated. (G-H) Representative blot showing co-immunoprecipitation of transfected (G) or endogenous (H) AMPK with Flag-PPARδ. (I) Metabolic p32 labeling of PPARδ in AD293 cells transfected as described. (J) Synergistic regulation of basal (V) and ligand (GW) dependent PPARδ transcriptional activity by AMPK α2 subunit and PGC1α (K) Co-immunoprecipitation of PPARδ but not AMPK α2 subunit with Flag-PGC1α (L) Model depicting exercise-PPARδ interaction in re-programming muscle genome.
    •  SEQUENCE INFORMATION
  • Nucleic acid and amino acid sequences may be referred to herein by GenBank accession number. It is understood that the sequences given such GenBank accession numbers are incorporated by reference as they existed and were known as of Dec. 29, 2006.
    • DETAILED DESCRIPTION I. Introduction
  • Disclosed herein are methods for enhancing an exercise effect in a subject including the steps of performing by a subject physical activity (such as aerobic exercise (e.g., running)) sufficient to produce an exercise effect; and administering to the subject an effective amount of a PPARδ agonist (e.g., GW1516). The exercise effect that is enhanced can be, for example, improved running endurance (such as, improved running distance or improved running time or a combination thereof, increased fatty acid oxidation in at least one skeletal muscle of the subject, and/or body fat (e.g., white adipose tissue) reduction). In some method embodiments, a subject is a mammal (such as a racing mammal, like a horse, a dog, or a human), and/or an adult, and/or an exercise-trained subject. In other exemplary methods, the PPARδ agonist is administered on the same day(s) on which the physical activity is performed. In some methods, administration of the PPARδ agonist is by oral administration, intravenous injection, intramuscular injection, and/or subcutaneous injection. In other method embodiments, the effective amount of the PPARδ agonist is from about 1 mg per day to about 20 mg per day in a single dose or in divided doses.
  • Also disclosed herein are methods for identifying the use of performance-enhancing substances in an exercise-trained subject, which include determining in a biological sample taken from an exercise-trained subject (e.g. a skeletal muscle biopsy) the expression of the molecules listed in Table 2 or listed in Table 4, or a subset thereof, such as expression of at least 1, at least 5, at least 10, at least 20, at least 40 of the molecules listed in Table 2 or in Table 4.
  • In some methods for identifying the use of performance-enhancing substances in an exercise-trained subject, (i) expression is upregulated in one or more of (such as at least 5, at least 10, at least 20, at least 35, or all of) adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; protein tyrosine phosphatase-like (proline instead of catalytic arginine); member b; CCAAT/enhancer binding protein (C/EBP), alpha; nuclear receptor subfamily 1, group D, member 2(Reverb-b); transferring; archain 1; solute carrier family 1 (neutral amino acid transporter), member 5; RIKEN cDNA 1810073N04 gene; haptoglobin; retinol binding protein 4, plasma; phosphoenolpyruvate carboxykinase 1, cytosolic; cell death-inducing DFFA-like effector c; interferon, alpha-inducible protein 27; carbonic anhydrase 3; cysteine dioxygenase 1, cytosolic; DNA segment, Chr 4, Wayne State University 53, expressed; dynein cytoplasmic 1 intermediate chain 2; Kruppel-like factor 3 (basic); thyroid hormone responsive SPOT14 homolog (Rattus); cytochrome P450, family 2, subfamily e, polypeptide 1; complement factor D (adipsin); and/or transketolase; and/or (ii) expression is downregulated in one or more of gamma-glutamyl carboxylase; 3-oxoacid CoA transferase 1; solute carrier family 38, member 4; annexin A7; CD55 antigen; RIKEN cDNA 1190002H23 gene; fusion, derived from t(12;16) malignant liposarcoma (human); lysosomal membrane glycoprotein 2; and/or neighbor of Punc E11, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9 of these molecules.
  • Exemplary methods for identifying the use of performance-enhancing substances in an exercise-trained subject involve determining protein expression and/or determining expression of a gene encoding the protein. Such methods are routine in the art. In some examples, the level of protein or nucleic acid expression is quantified.
  • Methods of identifying an agent having potential to enhance exercise performance in a subject also are disclosed herein. Such methods can include (i) providing a first component comprising a PPARδ receptor or an AMPK-binding fragment thereof; (ii) providing a second component comprising an AMP-activated protein kinase (AMPK), AMPKα1, AMPKα2, or a PPARδ-binding fragment of any thereof; (iii) contacting the first component and the second component with at least one test agent under conditions that would permit the first component and the second component to specifically bind to each other in the absence of the at least one test agent; and (iv) determining whether the at least one test agent affects the specific binding of the first component and the second component to each other. An effect on specific binding of the first component and the second component to each other identifies the at least one test agent as an agent having potential to enhance exercise performance in a subject.
  • In some methods of identifying an agent having potential to enhance exercise performance a third component, i.e., a PPARδ agonist (e.g., GW1516), is involved and the first component, second component, and third component are contacted as described above.
    • II. Abbreviations and Terms
  • AMPK AMP-activated protein kinase
  • bps Beats per second
  • MAPK Mitogen-activated protein kinase
  • mCPT I Muscle carnitine palmitoyl transferase I
  • QPCR or qPCR Quantitative PCR
  • PDK4 Pyruvate dehydrogenase kinase 4
  • PES Performance-enhancing substance(s)
  • PPAR Peroxisome proliferator-activated receptors
  • UCP3 Uncoupling protein 3
  • Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed subject matter belongs. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and/or Robert A. Meyers (ed.), Molecular Biology and Biotechnology: A Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8). In order to facilitate review of various embodiments of the disclosure, the following explanations of specific terms are provided:
  • Expression: The process by which the coded information of a nucleic acid transcriptional unit (including, for example, genomic DNA or cDNA) is converted into an operational, non-operational, or structural part of a cell, often including the synthesis of a polypeptide. Gene expression can be influenced by external signals; for instance, exposure of a cell, tissue or subject to an agent that enhances gene expression. Expression of a gene also may be regulated anywhere in the pathway from DNA to RNA to polypeptide. Regulation of gene expression occurs, for instance, through controls acting on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization or degradation of specific protein molecules after they have been made, or by combinations thereof. Gene expression (for example expression of one or more of the genes listed in Tables 2 and 4) can be measured at the RNA level or the protein level and by any method known in the art, including, without limitation, Northern blot, RT-PCR, Western blot, or in vitro, in situ, or in vivo protein activity assay(s).
  • The expression of a nucleic acid may be modulated compared to a control state, such as at a control time (for example, prior to administration of a substance or agent that affects regulation of the nucleic acid under observation) or in a control cell or subject, or as compared to another nucleic acid. Such modulation includes but is not necessarily limited to overexpression, underexpression, or suppression of expression. In addition, it is understood that modulation of nucleic acid expression may be associated with, and in fact may result in, a modulation in the expression of an encoded polypeptide or even a polypeptide that is not encoded by that nucleic acid (such as downstream regulated polypeptide(s)).
  • The expression of a polypeptide also may be modulated compared to a control state, such as at a control time (for example, prior to administration of a substance or agent that affects expression of a nucleic acid encoding or regulating the polypeptide) or in a control cell or subject, or as compared to another polypeptide. Modulation of polypeptide expression includes, but is not limited to, overexpression or decreased expression of the polypeptide, alteration of the subcellular localization or targeting of the polypeptide, alteration of the temporally regulated expression of the polypeptide (such that the polypeptide is expressed when it normally would not be, or alternatively is not expressed when it normally would be), alteration in the stability of the polypeptide, alteration in the spatial localization of the protein (such that the polypeptide is not expressed where it would normally be expressed or is expressed where it normally would not be expressed).
  • Isolated: An “isolated” biological component (such as a polynucleotide, polypeptide, or cell) has been purified away from other biological components in a mixed sample (such as a cell or tissue extract). For example, an “isolated” polypeptide or polynucleotide is a polypeptide or polynucleotide that has been separated from the other components of a cell in which the polypeptide or polynucleotide was present (such as an expression host cell for a recombinant polypeptide or polynucleotide).
  • The term “purified” refers to the removal of one or more extraneous components from a sample. For example, where recombinant polypeptides are expressed in host cells, the polypeptides are purified by, for example, the removal of host cell proteins thereby increasing the percent of recombinant polypeptides in the sample. Similarly, where a recombinant polynucleotide is present in host cells, the polynucleotide is purified by, for example, the removal of host cell polynucleotides thereby increasing the percent of recombinant polynucleotide in the sample. Isolated polypeptides or nucleic acid molecules, typically, comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or even over 99% (w/w or w/v) of a sample.
  • Polypeptides and nucleic acid molecules are isolated by methods commonly known in the art and as described herein. Purity of polypeptides or nucleic acid molecules may be determined by a number of well-known methods, such as polyacrylamide gel electrophoresis for polypeptides, or agarose gel electrophoresis for nucleic acid molecules.
  • Sequence identity: The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences.
  • Methods for aligning sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins and Sharp, Gene 73:237-244, 1988; Higgins and Sharp, CABIOS 5:151-153, 1989; Corpet et al., Nucleic Acids Research 16:10881-10890, 1988; Huang, et al., Computer Applications in the Biosciences 8:155-165, 1992; Pearson et al., Methods in Molecular Biology 24:307-331, 1994; Tatiana et al., (1999), FEMS Microbiol. Lett., 174:247-250, 1999. Altschul et al. present a detailed consideration of sequence alignment methods and homology calculations (J. Mol. Biol. 215:403-410, 1990).
  • The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™, Altschul et al., J. Mol. Biol. 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and on the Internet, for use in connection with the sequence-analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the internet under the help section for BLAST™.
  • For comparisons of amino acid sequences of greater than about 30 amino acids, the “Blast 2 sequences” function of the BLAST™ (Blastp) program is employed using the default BLOSUM62 matrix set to default parameters (cost to open a gap [default=5]; cost to extend a gap [default=2]; penalty for a mismatch [default=−3]; reward for a match [default=1]; expectation value (E) [default=10.0]; word size [default=3]; number of one-line descriptions (V) [default=100]; number of alignments to show (B) [default=100]). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method.
  • For comparisons of nucleic acid sequences, the “Blast 2 sequences” function of the BLAST™ (Blastn) program is employed using the default BLOSUM62 matrix set to default parameters (cost to open a gap [default=11]; cost to extend a gap [default=1]; expectation value (E) [default=10.0]; word size [default=11]; number of one-line descriptions (V) [default=100]; number of alignments to show (B) [default=100]). Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method.
  • Specific binding: Specific binding refers to the particular interaction between one binding partner (such as a binding agent) and another binding partner (such as a target). Such interaction is mediated by one or, typically, more noncovalent bonds between the binding partners (or, often, between a specific region or portion of each binding partner). In contrast to non-specific binding sites, specific binding sites are saturable. Accordingly, one exemplary way to characterize specific binding is by a specific binding curve. A specific binding curve shows, for example, the amount of one binding partner (the first binding partner) bound to a fixed amount of the other binding partner as a function of the first binding partner concentration. As the first binding partner concentration increases under these conditions, the amount of the first binding partner bound will saturate. In another contrast to non-specific binding sites, specific binding partners involved in a direct association with each other (e.g., a protein-protein interaction) can be competitively removed (or displaced) from such association (e.g., protein complex) by excess amounts of either specific binding partner. Such competition assays (or displacement assays) are very well known in the art.
  • The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. “Comprising” means “including.” Hence “comprising A or B” means “including A or B”, or “including A and B.”
  • Materials, methods, and examples are illustrative only and not intended to be limiting. Methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Sambrook et al., Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press, 2001; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates, 1992 (and Supplements to 2000); Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, 4th ed., Wiley & Sons, 1999; Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1990; and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999).
    • III. Methods of Enhancing an Exercise Effect
  • Exercise is known to have many effects on subjects that perform it. Exercise effects at the molecular, biochemical, and/or cellular levels (e.g., modified regulation of genes and/or gene networks and corresponding proteins involved in energy substrate utilization and contractile properties of muscle) form the basis of physiological effects that are observed at the tissue, organ, and/or whole body levels (e.g., increased cardiorespiratory endurance, muscular strength, muscular endurance, and/or flexibility, and/or improvements in body appearance). Disclosed herein are methods for enhancing one or more exercise effects by combining, at least, physical activity with administration of one or more PPARδ agonists. In some examples, physical activity is replaced with administration of an AMPK activator (e.g., AICAR).
  • In general terms, exercise is the performance of some physical activity. A single episode (also referred to as a bout) of physical activity is performed for a particular duration and at a particular intensity. If more than one bout of exercise is performed, separate bouts of exercise may have the same or different durations and/or the same or different intensities.
  • In some method embodiments, a single bout of exercise may last for up to 30 minutes, up to 45 minutes, up to 60 minutes, up to 90 minutes, up to 2 hours, up to 2.5 hours, up to 3 hours, or even longer. Typically, in the absence of a prior exercise history, repeated episodes of physical activity are needed to achieve an exercise-induced effect (such as, increased aerobic capacity or increase running endurance). Thus, in some disclosed methods, bouts of physical activity may be repeated within a single day; for instance, up to 2 bouts of exercise per day, up to 3 bouts of exercise per day, up to 4 bouts of exercise per day, up to 5 bouts of exercise per day, or even more bouts per day. Some professional athletes or racing mammals may exercise in repeated bouts for a total of 8 hours or more a day. In other method embodiments, bouts (or repeated bouts) of exercise are performed on a daily basis, 6 times per week, 5 times per week, 4 times per week or 3 times per week. In at least some of the disclosed methods, exercise may continue for at least 2 weeks, for at least 4 weeks, for at least 6 weeks, for at least 3 months, for at least 6 months, for at least 1 year, for at least 3 years, or indefinitely (for the lifetime of the subject).
  • Exercise generally is performed at an intensity that is more than the usual (e.g., average, median, normal standard, or normoactive) activity for a subject, and/or at or less than the maximum activity achievable by a subject performing a particular exercise. Any known indicator of physical performance can be used to determine whether a subject is performing more than a usual amount of activity, including, for instance, measuring heart rate, repetition rate (e.g., revolutions per second, minutes per mile, lifts per minute, and many others), and/or force output. In some methods, a bout of exercise is performed at sub-maximal intensity; for instance, at about 10% maximal intensity, 25% maximal intensity, 50% maximal intensity, or 75% maximal intensity. In other methods, a bout of exercise is performed at 40%-50% maximal heart rate, 50%-60% maximal heart rate, 60%-70% maximal heart rate, or 75%-80% maximal heart rate, where maximum heart rate for a human subject is calculated as: 220 bps−(age of the subject).
  • Exercise is generally grouped into three types: (i) flexibility exercise (such as, stretching), which is believed to, at least, improve the range of motion of muscles and joints; (ii) aerobic exercise; and (iii) anaerobic exercise (such as, weight training, functional training or sprinting) which is believed to, at least, increase muscle strength and mass.
  • Aerobic exercise refers to a physical activity in which oxidative or aerobic metabolism (as compared to glycolytic or anaerobic metabolism) substantially predominates in exercised skeletal muscles. In particular method embodiments, a subject performs one or more aerobic exercises. Exemplary aerobic exercises include, without limitation, aerobics, calisthenics, cycling, dancing, exercise machines (rowing machine, cycling machine (e.g., inclined or upright), climbing machine, elliptical trainers, and/or skiing machines), basketball, football, baseball, soccer, footbag, housework, jogging, martial arts, massage, pilates, rowing, running, skipping, swimming, walking, yoga, boxing, gymnastics, badminton, cricket, track and field, golf, ice hockey, lacrosse, rugby, tennis, or combinations thereof.
  • The disclosed methods contemplate enhancing any known or observable effect of exercise (such as an aerobic exercise, like walking or running). In particular methods, running endurance (e.g., running distance and/or running time) is enhanced.
  • Enhancing an exercise effect (such as running endurance) means that such effect is improved in a subject more than would have occurred by exercise alone. In some method embodiments, an enhanced exercise effect is determined by discontinuing administration of a PPARδ agonist in the subject and observing (e.g., qualitatively or quantitatively) a reduction in the exercise effect of interest (e.g., aerobic endurance, such as running endurance). In some instances, an exercise effect of interest, the PPARδ-enhanced portion of which is lost upon discontinuance of PPARδ administration, will be reduced by at least about 5%, by at least about 10%, by at least about 20%, by at least about 30%, or by at least about 50% as compared to the magnitude of the effect with exercise alone.
  • A. PPARδ Agonists
  • The disclosed methods envision the use of any PPARδ agonist. Preferably such agonist would be non-toxic in the subject to which it is administered. Exemplary PPARδ agonists include GW1516, L-165041 (as described by, e.g., Leibowitz et al., FEBS Lett., 473(3):333-336, 2000), any one or more compounds described in PCT Publication Nos. WO/2006/018174, WO/2005/113506, WO/2005/105754, WO/2006/041197, WO/2006/032023, WO/01/00603, WO/02/092590, WO/97/28115, WO/97/28149, WO/97/27857, WO/97/28137, WO/97/27847, and/or WO/98/27974, and/or a published U.S. national phase application or issued U.S. patent corresponding to any of the foregoing (each of which is expressly incorporated herein by reference). Moreover, other PPARδ agonists can be identified using the methods described, for example, in PCT Publication No. WO/1998/049555 or any corresponding published U.S. national phase application or issued U.S. patent (each of which is expressly incorporated herein by reference).
  • In a specific example, the PPARδ agonist is GW1516 (also referred to in the art as GW501516). GW1516 is (2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfanyl)phenoxy)acetic acid as has been shown to be is bioactive in humans (Sprecher et al., Arterioscler. Thromb. Vasc. Biol. 27(2): 359-65, 2007). In specific examples, GW1516 is administered orally, for example 1 mg-20 mg/day, such as 2.5 mg or 10 mg per day.
  • B. Subjects
  • The disclosed methods can be performed in any subject capable of performing physical activity (e.g., aerobic exercise). In some method embodiments, a subject is a living multi-cellular vertebrate organism (e.g., human and/or non-human animals). In other exemplary methods, a subject is a mammal (including humans and/or non-human mammals such as veterinary or laboratory mammals) or, in more particular examples, a racing mammal (such as a horse, a dog, or a human). In still other methods, a subject is an adult, an exercise-trained subject, or a healthy subject. Some representative adult, human subjects are 16 years old or old, 18 years old or older, or 21 years old or older. Some representative exercised-trained subjects have performed physical activity (such described in detail above) for at least 4 weeks, for at least 6 weeks, for at least 3 months, or for at least 6 months. In some examples the subject is healthy, for example, is a subject in which no known disease or disorder has been diagnosed or would be apparent after reasonable inquiry to an ordinarily skilled physician in the field to which the disease or disorder pertains.
  • C. Methods of Administration, Formulations and Dosage
  • The disclosed methods envision the use of any method of administration, dosage, and/or formulation of PPARδ agonist that has the desired outcome of enhancing an exercise effect in a subject receiving the formulation, including, without limitation, methods of administration, dosages, and formulations well known to those of ordinary skill in the pharmaceutical arts.
  • Modes of administering a PPARδ agonist (or a formulation including a PPARδ agonist) in a disclosed method include, but are not limited to, intrathecal, intradermal, intramuscular, intraperitoneal (ip), intravenous (iv), subcutaneous, intranasal, epidural, intradural, intracranial, intraventricular, and oral routes. In a specific example the PPARδ agonist is administered orally. Other convenient routes for administration of a PPARδ agonist (or a formulation including a PPARδ agonist) include for example, infusion or bolus injection, topical, absorption through epithelial or mucocutaneous linings (for example, oral mucosa, rectal and intestinal mucosa, and the like) ophthalmic, nasal, and transdermal. Administration can be systemic or local. Pulmonary administration also can be employed (for example, by an inhaler or nebulizer), for instance using a formulation containing an aerosolizing agent.
  • In specific method embodiments, it may be desirable to administer a PPARδ agonist locally. This may be achieved by, for example, local or regional infusion or perfusion, topical application (for example, wound dressing), injection, catheter, suppository, or implant (for example, implants formed from porous, non-porous, or gelatinous materials, including membranes, such as sialastic membranes or fibers), and the like.
  • In other method embodiments, a pump (such as a transplanted minipump) may be used to deliver a PPARδ agonist (or a formulation including a PPARδ agonist) (see, e.g. Langer Science 249, 1527, 1990; Sefton Crit. Rev. Biomed. Eng 14, 201, 1987; Buchwald et al., Surgery 88, 507, 1980; Saudek et al., N. Engl. J. Med. 321, 574, 1989). In another embodiment, a PPARδ agonist (or a formulation including a PPARδ agonist) is delivered in a vesicle, in particular liposomes (see, e.g. Langer, Science 249, 1527, 1990; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, N.Y., pp. 353-365, 1989).
  • In yet another method embodiment, a PPARδ agonist can be delivered in a controlled-release formulation. Controlled-release systems, such as those discussed in the review by Langer (Science 249, 1527 1990), are known. Similarly, polymeric materials useful in controlled-released formulations are known (see, e.g. Ranger et al., Macromol. Sci. Rev. Macromol. Chem. 23, 61, 1983; Levy et al., Science 228, 190, 1985; During et al., Ann. Neurol. 25, 351, 1989; Howard et al., J. Neurosurg. 71, 105, 1989). For example, a PPARδ agonists may be coupled to a class of biodegradable polymers useful in achieving controlled release of a compound, including polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • The disclosed methods contemplate the use of any dosage form of PPARδ agonist (or formulation containing the same) that delivers the PPARδ agonist and achieves a desired result. Dosage forms are commonly known and are taught in a variety of textbooks, including for example, Allen et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Eighth Edition, Philadelphia, Pa.: Lippincott Williams & Wilkins, 2005, 738 pages. Dosage forms for use in a disclosed method include, without limitation, solid dosage forms and solid modified-release drug delivery systems (e.g., powders and granules, capsules, and/or tablets); semi-solid dosage forms and transdermal systems (e.g., ointments, creams, and/or gels); transdermal drug delivery systems; pharmaceutical inserts (e.g., suppositories and/or inserts); liquid dosage forms (e.g., solutions and disperse systems); and/or sterile dosage forms and delivery systems (e.g., parenterals, and/or biologics). Particular exemplary dosage forms include aerosol (including metered dose, powder, solution, and/or without propellants); beads; capsule (including conventional, controlled delivery, controlled release, enteric coated, and/or sustained release); caplet; concentrate; cream; crystals; disc (including sustained release); drops; elixir; emulsion; foam; gel (including jelly and/or controlled release); globules; granules; gum; implant; inhalation; injection; insert (including extended release); liposomal; liquid (including controlled release); lotion; lozenge; metered dose (e.g., pump); mist; mouthwash; nebulization solution; ocular system; oil; ointment; ovules; powder (including packet, effervescent, powder for suspension, powder for suspension sustained release, and/or powder for solution); pellet; paste; solution (including long acting and/or reconstituted); strip; suppository (including sustained release); suspension (including lente, ultre lente, reconstituted); syrup (including sustained release); tablet (including chewable, sublingual, sustained release, controlled release, delayed action, delayed release, enteric coated, effervescent, film coated, rapid dissolving, slow release); transdermal system; tincture; and/or wafer.
  • Typically, a dosage form is a formulation of an effective amount (such as a therapeutically effective amount) of at least one active pharmaceutical ingredient (such as a PPARδ agonist) with pharmaceutically acceptable excipients and/or other components (such as one or more other active ingredients). The preferred aim of a drug formulation is to provide proper administration of an active ingredient (such as a PPARδ agonist) to a subject. A formulation should suit the mode of administration. The term “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and, more particularly, in humans.
  • Excipients for use in exemplary formulations include, for instance, one or more of the following: binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, colorings, preservatives, diluents, adjuvants, and/or vehicles. In some instances, excipients collectively may constitute about 5%-95% of the total weight (and/or volume) of a particular dosage form.
  • Pharmaceutical excipients can be, for instance, sterile liquids, such as water and/or oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is an exemplary carrier when a formulation is administered intravenously. Saline solutions, blood plasma medium, aqueous dextrose, and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Oral formulations can include, without limitation, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. A more complete explanation of parenteral pharmaceutical excipients can be found in Remington, The Science and Practice of Pharmacy, 19th Edition, Philadelphia, Pa.: Lippincott Williams & Wilkins, 1995, Chapter 95. Excipients may also include, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like. Other examples of pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. A formulation, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • A dosage regimen utilizing a PPARδ agonist is selected in accordance with a variety of factors including type, species, age, weight, sex and physical condition of the subject; the route of administration; and/or the particular PPARδ agonist formulation employed. An ordinarily skilled physician or veterinarian can readily determine an effective amount of a PPARδ agonist (or formulation thereof) useful for enhancing an exercise effect in a subject.
  • In some method embodiments involving oral administration, oral dosages of a PPARδ agonist will generally range between about 0.001 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, and such as about 0.01-10 mg/kg/day (unless specified otherwise, amounts of active ingredients are on the basis of a neutral molecule, which may be a free acid or free base). For example, an 80 kg subject would receive between about 0.08 mg/day and 8 g/day, such as between about 0.8 mg/day and 800 mg/day. A suitably prepared medicament for once a day administration would thus contain between 0.08 mg and 8 g, such as between 0.8 mg and 800 mg. In some instance, formulation including a PPARδ agonist may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared medicament as described above would contain between 0.04 mg and 4 g, such as between 0.4 mg and 400 mg. Dosages outside of the aforementioned ranges may be necessary in some cases. Examples of daily dosages that may be given in the range of 0.08 mg to 8 g per day include 0.1 mg, 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1 g, 2 g, 4 g and 8 g. These amounts can be divided into smaller doses if administered more than once per day (e.g., one-half the amount in each administration if the drug is taken twice daily).
  • For some method embodiments involving administration by injection (e.g., intravenously or subcutaneous injection), a subject would receive an injected amount that would deliver the active ingredient in approximately the quantities described above. The quantities may be adjusted to account for differences in delivery efficiency that result from injected drug forms bypassing the digestive system. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, such as for example 0.1 mg/ml, 0.3 mg/ml, or 0.6 mg/ml, and administered in amounts per day equivalent to the amounts per day stated above. For example, an 80 kg subject, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day.
  • In other method embodiments, a PPARδ agonist (or a formulation thereof) can be administered at about the same dose throughout a treatment period, in an escalating dose regimen, or in a loading-dose regime (for example, in which the loading dose is about two to five times a maintenance dose). In some embodiments, the dose is varied during the course of PPARδ agonist usage based on the condition of the subject receiving the composition, the apparent response to the composition, and/or other factors as judged by one of ordinary skill in the art. In some embodiments long-term administration of a PPARδ agonist (or formulation thereof) is contemplated, for instance in order to effect sustained enhancement of an exercise effect (such as aerobic endurance, e.g., running endurance).
    • IV. Methods for Determining Drug-Induced Enhancement of Exercise Performance
  • The use of performance-enhancing substances (PES), particularly by children and professional athletes, has been in the news because of potential adverse health consequences and the arguable effects that such practices have on moral development of the individual and on fair athletic competition for all (Committee on Sports Medicine and Fitness, Reginald L. Washington, Md., Chairperson, Pediatrics, 115(4):1103-1106, 2005). One of the discoveries provided herein is that certain genes (and/or the proteins encoded thereby) are uniquely regulated by a combination of exercise and a pharmaceutical agent (a PPARδ agonist) that results in enhanced physical performance (see Table 2). In some cases, the particular genes (and/or proteins encoded thereby) were up- or down-regulated by the combined treatment but were not affected by either intervention alone. In other cases, the particular genes (and/or proteins encoded thereby) were not affected by the combined treatment but were up- or down-regulated by one or both intervention when practiced alone. The unique regulation of these genes (and/or the encoded proteins) makes them useful markers (either alone or in any combination) for identifying exercising subjects who are taking (or receiving) PES.
  • A PES is any substance taken in nonpharmacologic doses specifically for the purpose of improving sports performance (e.g., by increasing strength, power, speed, or endurance (ergogenic) or by altering body weight or body composition). Exemplary PES include the following: (i) pharmacologic agents (prescription or nonprescription) taken in doses that exceed the recommended therapeutic dose or taken when the therapeutic indication(s) are not present (e.g., using decongestants for stimulant effect, using bronchodilators when exercise-induced bronchospasm is not present, increasing baseline methylphenidate hydrochloride dose for athletic competition); (ii) agents used for weight control, including stimulants, diet pills, diuretics, and laxatives, when the user is in a sport that has weight classifications or that rewards leanness; (iii) agents used for weight gain, including over-the-counter products advertised as promoting increased muscle mass; (iv) physiologic agents or other strategies used to enhance oxygen-carrying capacity, including erythropoietin and red blood cell transfusions (blood doping); (v) any substance that is used for reasons other than to treat a documented disease state or deficiency; (vi) any substance that is known to mask adverse effects or detectability of another performance-enhancing substance, and/or (vii) nutritional supplements taken at supraphysiologic doses or at levels greater than required to replace deficits created by a disease state, training, and/or participation in sports. In one example the PES is GW1516.
  • The biomarkers of substance-induced performance enhancement identified herein and useful in a disclosed method include one or more (or any combination of) the genes (and/or proteins encoded thereby) listed in Table 2, and in some examples listed in Table 4. In particular method embodiments, at least 2, at least 3, at least 5, at least 7, at least 10, at least 15, at least 20, at least 30, or at least 40 of the genes (and/or proteins encoded thereby) listed in Table 2 (or Table 4) are detected in a disclosed method. In one example at least one gene (and/or protein encoded thereby) from each class listed in Table 2 (e.g. cytokines, fat metabolism) is analyzed.
  • In more specific method embodiments, upregulated expression is detected for one or more of the following genes (or proteins encoded thereby): adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; protein tyrosine phosphatase-like (proline instead of catalytic arginine); member b; CCAAT/enhancer binding protein (C/EBP), alpha; nuclear receptor subfamily 1, group D, member 2(Reverb-b); transferring; archain 1; solute carrier family 1 (neutral amino acid transporter), member 5; RIKEN cDNA 1810073N04 gene; haptoglobin; retinol binding protein 4, plasma; phosphoenolpyruvate carboxykinase 1, cytosolic; cell death-inducing DFFA-like effector c; interferon, alpha-inducible protein 27; carbonic anhydrase 3; cysteine dioxygenase 1, cytosolic; DNA segment, Chr 4, Wayne State University 53, expressed; dynein cytoplasmic 1 intermediate chain 2; Kruppel-like factor 3 (basic); thyroid hormone responsive SPOT14 homolog (Rattus); cytochrome P450, family 2, subfamily e, polypeptide 1; complement factor D (adipsin); and/or transketolase. In particular method embodiments, upregulation of at least 2, at least 3, at least 5, at least 7, at least 10, at least 15, at least 20, at least 30, or at least 38 of the foregoing genes (and/or proteins encoded thereby) are detected in a disclosed method.
  • In other method embodiments, downregulated expression is detected in one or more of the following genes (and/or proteins encoded thereby): gamma-glutamyl carboxylase; 3-oxoacid CoA transferase 1; solute carrier family 38, member 4; annexin A7; CD55 antigen; RIKEN cDNA 1190002H23 gene; fusion, derived from t(12;16) malignant liposarcoma (human); lysosomal membrane glycoprotein 2; and/or neighbor of Punc E11. In particular method embodiments, downregulation of at least 2, at least 3, at least 5, or at least 7 of the foregoing genes (and/or proteins encoded thereby) are detected in a disclosed method.
  • In still other method embodiments, a combination of upregulated genes (and/or proteins encoded thereby) and downregulated genes (and/or proteins encoded thereby) as described above is detected in a sample from a subject (such as, an exercised or exercise-trained subject).
  • Yet other method embodiments involve the detection in a sample of a combination of the above-described upregulated genes (and/or proteins encoded thereby) and/or the above-described downregulated genes (and/or proteins encoded thereby), and/or the above-described exercise-regulated genes that are not affected by exercise combined with PPARδ administration.
  • Disclosed methods may be used for detecting PES use in any subject capable of taking or receiving one or more such PES. In some method embodiments, a subject is a living multi-cellular vertebrate organism (e.g., human and/or non-human animals). In other exemplary methods, a subject is a mammal (including humans and/or non-human mammals) or, in more particular examples, a racing mammal (such as a horse, a dog, or a human). In still other methods, a subject is an exercise-trained subject. Some representative exercised-trained subjects have performed physical activity (such described in detail above) for at least 4 weeks, for at least 6 weeks, for at least 3 months, or for at least 6 months. Other exercise-trained subjects may be student athletes and/or professional athletes (including, in some examples, non-human professional athletes, such as race horses and/or racing dogs).
  • Any sample from a subject (e.g., a biological sample) in which can be detected one or more genes and/or proteins uniquely regulated by exercise in combination with PPARδ agonist intake (as described in detail throughout this specification) is contemplated for use in a disclosed method. Exemplary samples for use in a disclosed method include blood, saliva, urine, muscle biopsy (e.g., skeletal muscle biopsy), cheek swab, fecal sample, sweat, and/or sperm.
  • Methods of detecting the expression of genes and/or proteins in a sample (e.g, biological sample) are very well known (see, e.g., U.S. Pat. Nos. 6,911,307; 6,893,824; 5,972,692; 5,972,602; 5,776,672; 7,031,847; 6,816,790; 6,811,977; 6,806,049; 6,203,988; and/or 6,090,556).
  • In particular method embodiments, expression of one or more genes identified herein can be detected by any method of nucleic acid amplification (such as, polymerase chain reaction (PCR) or any adaptation thereof, ligase chain reaction, transcription-based amplification systems, cycling probe reaction, Qβ replicase amplification, strand displacement amplification, and/or rolling circle amplification), solid-surface hybridization assays (such as Northern blot, dot blot, gene chips, and/or reversible target capture), solution hybridization assays (such as MAP technology (which uses a liquid suspension array of 100 sets of 5.5 micron probe-conjugated beads, each internally dyed with different ratios of two spectrally distinct fluorophores to assign it a unique spectral address)), and/or in situ hybridization. Various of the foregoing nucleic acid detection methods are described in detail in the review by Wolcott (Clin. Microbiol. Rev., 5(4):370-386, 1992). Other detailed and long-established protocols for practicing some such nucleic acid detection methods are found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989; Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, 2001; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates, 1992 (and Supplements to 2000); and/or Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, 4th edition, Wiley & Sons, 1999.
  • In other method embodiments, expression of one or more proteins encoded by corresponding genes identified herein can be detected by Western blot, immunohistochemistry, immunoprecipitation, antibody microarrays, ELISA, and/or by functional assay (e.g., kinase assay, ATPase assay, substrate (or ligand) binding assay, protein-protein binding assay, or other assay suitable for measuring a particular protein function).
  • If the pattern of expression identified in the test subject is similar to that shown in Table 2 (e.g. the genes shown as upregulated and downregulated in Table 2 are observed in the subject to be upregulated and downregulated, respectively), this indicates that the subject is taking a PES, such as a PPARδ agonist (e.g. GW1516). In contrast, If the pattern of expression identified in the test subject is different to that shown in Table 2 (e.g. the genes shown as upregulated and downregulated in Table 2 are observed in the subject to be not differentially expressed or show a different pattern of regulation), this indicates that the subject is not taking a PES, such as a PPARδ agonist (e.g. GW1516).
    • V. Methods for Identifying Agents of Potential Interest
  • This disclosure identifies a previously unknown protein-protein interaction between PPARδ and particular exercise-induced kinases (e.g., AMPK, such as the AMPKα1 and/or AMPKα2 subunit(s) of AMPK). The interaction between PPARδ and AMPK may have important functional outcomes, such as enhancing exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject.
  • The foregoing discoveries enable methods for identify agents, e.g., having potential to enhance exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject. In some such methods, agents that affect (e.g., enhance, weaken, or substantially disrupt) the protein-protein interaction are identified. In other such methods, agents that affect (e.g., increase, decrease, or substantially eliminate) AMPK-dependent phosphorylation of a PPARδ complex are identified.
  • A. Exemplary Agents
  • An “agent” is any substance or any combination of substances that is useful for achieving an end or result; for example, a substance or combination of substances useful for modulating a protein activity (e.g., AMPK-dependent phosphorylation of a PPARδ complex), or useful for modifying or affecting a protein-protein interaction (e.g., PPARδ-AMPK interaction). Any agent that has potential (whether or not ultimately realized) to modulate any aspect of the PPARδ-AMPK interaction disclosed herein is contemplated for use in the screening methods of this disclosure.
  • Exemplary agents include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries (see, e.g. Lam et al., Nature, 354:82-84, 1991; Houghten et al., Nature, 354:84-86, 1991), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g. Songyang et al., Cell, 72:767-778, 1993), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab′)2 and Fab expression library fragments, epitope-binding fragments thereof), small organic or inorganic molecules (such as, so-called natural products or members of chemical combinatorial libraries), molecular complexes (such as protein complexes), or nucleic acids.
  • Libraries (such as combinatorial chemical libraries) useful in the disclosed methods include, but are not limited to, peptide libraries (see, e.g. U.S. Pat. No. 5,010,175; Furka, Int. J. Pept. Prot. Res., 37:487-493, 1991; Houghton et al., Nature, 354:84-88, 1991; PCT Publication No. WO 91/19735), encoded peptides (e.g. PCT Publication WO 93/20242), random bio-oligomers (e.g. PCT Publication No. WO 92/00091), benzodiazepines (e.g. U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Natl. Acad. Sci. USA, 90:6909-6913, 1993), vinylogous polypeptides (Hagihara et al., J. Am. Chem. Soc., 114:6568, 1992), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., J. Am. Chem. Soc., 114:9217-9218, 1992), analogous organic syntheses of small compound libraries (Chen et al., J. Am. Chem. Soc., 116:2661, 1994), oligocarbamates (Cho et al., Science, 261: 1303, 1003), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem., 59:658, 1994), nucleic acid libraries (see Sambrook et al. Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y., 1989; Ausubel et al., Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., 1989), peptide nucleic acid libraries (see, e.g. U.S. Pat. No. 5,539,083), antibody libraries (see, e.g. Vaughn et al., Nat. Biotechnol., 14:309-314, 1996; PCT App. No. PCT/US96/10287), carbohydrate libraries (see, e.g. Liang et al., Science, 274:1520-1522, 1996; U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g. benzodiazepines, Baum, C&EN, January 18, page 33, 1993; isoprenoids, U.S. Pat. No. 5,569,588; thiazolidionones and methathiazones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514) and the like.
  • Libraries useful for the disclosed screening methods can be produce in a variety of manners including, but not limited to, spatially arrayed multipin peptide synthesis (Geysen, et al., Proc. Natl. Acad. Sci., 81(13):3998-4002, 1984), “tea bag” peptide synthesis (Houghten, Proc. Natl. Acad. Sci., 82(15):5131-5135, 1985), phage display (Scott and Smith, Science, 249:386-390, 1990), spot or disc synthesis (Dittrich et al., Bioorg. Med. Chem. Lett., 8(17):2351-2356, 1998), or split and mix solid phase synthesis on beads (Furka et al., Int. J. Pept. Protein Res., 37(6):487-493, 1991; Lam et al., Chem. Rev., 97(2):411-448, 1997).
  • Libraries may include a varying number of compositions (members), such as up to about 100 members, such as up to about 1000 members, such as up to about 5000 members, such as up to about 10,000 members, such as up to about 100,000 members, such as up to about 500,000 members, or even more than 500,000 members.
  • In one convenient embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (e.g., affectors of AMPK-PPARδ protein-protein interactions). Such combinatorial libraries are then screened in one or more assays as described herein to identify those library members (particularly chemical species or subclasses) that display a desired characteristic activity (such as increasing or decreasing an AMPK-PPARδ protein-protein interaction). The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics. In some instances, pools of candidate agents may be identify and further screened to determine which individual or subpools of agents in the collective have a desired activity.
  • B. Exemplary Assays
  • As disclosed herein, PPARδ forms a protein-protein interaction with AMPK or one or more of its subunits (such as AMPKα1 and/or AMPKα2). Agents that affect (e.g., increase or decrease) an AMPK-PPARδ interaction or AMP-dependent phosphorylation of a PPARδ complex may have the effect of enhancing exercise performance (e.g., aerobic exercise performance, such as running endurance) in a subject and, therefore, are desirable to identify.
  • In screening methods described here, tissue samples, isolated cells, isolated polypeptides, and/or test agents can be presented in a manner suitable for high-throughput screening; for example, one or a plurality of isolated tissue samples, isolated cells, or isolated polypeptides can be inserted into wells of a microtitre plate, and one or a plurality of test agents can be added to the wells of the microtitre plate. Alternatively, one or a plurality of test agents can be presented in a high-throughput format, such as in wells of microtitre plate (either in solution or adhered to the surface of the plate), and contacted with one or a plurality of isolated tissue samples, isolated cells, and/or isolated polypeptides under conditions that, at least, sustain the tissue sample or isolated cells or a desired polypeptide function and/or structure. Test agents can be added to tissue samples, isolated cells, or isolated polypeptides at any concentration that is not lethal to tissues or cells, or does not have an adverse effect on polypeptide structure and/or function. It is expected that different test agents will have different effective concentrations. Thus, in some methods, it is advantageous to test a range of test agent concentrations.
  • Disclosed methods envision, as appropriate, the use of PPARδ or AMPK (such as AMPKα1 or AMPKα2) or functional fragments of any thereof as contained, independently, in a subject, one or a plurality of cells or cellular extracts, one or a plurality of tissue or tissue extracts, or as an isolated polypeptide. PPARδ ligand optionally is included (or is omitted) in disclosed methods.
  • 1. Agents that Affect a Protein-Protein Interaction
  • A “direct association” between two or more polypeptides (such as, PPARδ and AMPK (such as AMPKα1 or AMPKα2) is characterized by physical contact between at least a portion of the interacting polypeptides that is of sufficient affinity and specificity that, for example, immunoprecipitation of one of the polypeptides also will specifically precipitate the other polypeptide; provided that the immunoprecipitating antibody does not also affect the site(s) involved in the interaction. A direct association between polypeptides also may be referred to as a “protein-protein interaction.” The binding of one polypeptide to another in a protein-protein interaction (e.g., PPARδ to AMPK (or AMPKα1 and/or AMPKα2) and vice versa) is considered “specific binding”.
  • Agents that affect an AMPK-PPARδ interaction can be identified by a variety of assays, including solid-phase or solution-based assays. In an exemplary solid-phase assay, PPARδ or an AMPK-binding fragment thereof and AMPK or a subunit thereof (such as AMPKα1 and/or AMPKα2) or a PPARδ-binding fragment thereof are mixed under conditions in which PPARδ and AMPK (or its subunit(s) or functional fragments) normally interact (e.g., co-immunoprecipitate). One of the binding partners is labeled with a marker such as biotin, fluoroscein, EGFP, or enzymes to allow easy detection of the labeled component. The unlabeled binding partner is adsorbed to a support, such as a microtiter well or beads. Then, the labeled binding partner is added to the environment where the unlabeled binding partner is immobilized under conditions suitable for interaction between the two binding partners. One or more test compounds, such as compounds in one or more of the above-described libraries, are separately added to individual microenvironments containing the interacting binding partners. Agents capable of affecting the interaction between the binding partners are identified, for instance, as those that increase or decrease (e.g., increase) retention or binding of the signal (i.e., labeled binding partner) in the reaction microenvironment, for example, in a microtiter well or on a bead for example. As discussed previously, combinations of agents can be evaluated in an initial screen to identify pools of agents to be tested individually, and this process is easily automated with currently available technology.
  • In other method embodiments, solution phase selection can be used to screen large complex libraries for agents that specifically affect protein-protein interactions (see, e.g., Boger et al., Bioorg. Med. Chem. Lett., 8(17):2339-2344, 1998); Berg et al., Proc. Natl. Acad. Sci., 99(6):3830-3835, 2002). In one such example, each of two proteins that are capable of physical interaction (for example, PPARδ (or AMPK-binding fragments thereof) and AMPK or AMPKα1 or AMPKα2 (or PPARδ-binding fragments of any thereof) are labeled with fluorescent dye molecule tags with different emission spectra and overlapping adsorption spectra. When these protein components are separate, the emission spectrum for each component is distinct and can be measured. When the protein components interact, fluorescence resonance energy transfer (FRET) occurs resulting in the transfer of energy from a donor dye molecule to an acceptor dye molecule without emission of a photon. The acceptor dye molecule alone emits photons (light) of a characteristic wavelength. Therefore, FRET allows one to determine the kinetics of two interacting molecules based on the emission spectra of the sample. Using this system, two labeled protein components are added under conditions where their interaction resulting in FRET emission spectra. Then, one or more test compounds, such as compounds in one or more of the above-described libraries, are added to the environment of the two labeled protein component mixture and emission spectra are measured. An increase in the FRET emission, with a concurrent decrease in the emission spectra of the separated components indicates that an agent (or pool of candidate agents) has affected (e.g., enhanced) the interaction between the protein components.
  • Interactions between PPARδ (or AMPK-binding fragments thereof) and AMPK or AMPKα1 or AMPKα2 (or PPARδ-binding fragments of any thereof) also can be determined (e.g., quantified) by co-immunoprecipitation of the relevant component polypeptides (e.g. from cellular extracts), by GST-pull down assay (e.g., using purified GST-tagged bacterial proteins), and/or by yeast two-hybrid assay, each of which methods is standard in the art. Conducting any one or more such assays in the presence and, optionally, absence of a test compound can be used to identify agents that improve or enhance (or, in other embodiments, decrease or inhibit) the interaction between PPARδ (or AMPK-binding fragments thereof) and AMPK or AMPKα1 or AMPKα2 (or PPARδ-binding fragments of any thereof) in the presence of a test compound as compared to in the absence of the test compound or as compared to some other standard or control.
  • In certain method embodiments, one or more AMPK (such as AMPKα1 and/or AMPKα2)-binding fragments of PPARδ and/or one or more PPARδ-binding fragments of AMPK (such as AMPKα1 and/or AMPKα2) are used. Polypeptide fragments having the desired binding activities can be identified by making a series of defined PPARδ fragments and/or AMPK (such as AMPKα1 or AMPKα2) fragments using methods standard in the art. For example, cDNA encoding the protein(s) of interest (e.g., PPARδ or AMPK) can be serially truncated from the 3′ or 5′ end (provided that a start codon is engineered into 5′ truncations) using conveniently located restriction enzyme sites (or other methods) and leaving intact (or otherwise correcting) the proper reading frame. Conveniently, a nucleic acid sequence encoding an epitope tag (such as a FLAG tag) is placed in frame with (and substantially adjacent to) the truncated protein-encoding sequence to produce a nucleic acid sequence encoding an epitope-tagged protein fragment. The epitope-tagged protein fragment can be expressed in any convenient expression system (such as a bacterial expression system), isolated or not, and mixed with a sample containing a protein or other protein fragment to which the epitope-tagged protein fragment may bind. An antibody specific for the tag (or other region of the protein fragment) can be used to immunoprecipitate the fragment of interest together with any protein(s) or protein fragment(s) that bind to it. Protein(s) or protein fragment(s) that bind to the epitope-tagged protein fragment of interest can be particular identified, e.g., by Western blot.
  • In particular methods, the formation of a PPARδ-AMPK (such as AMPKα1 and/or AMPKα2) complex (including complexes including one or both of PPARδ-binding AMPK fragments and/or AMPK-binding PPARδ fragments) or the affinity of PPARδ (or AMPK-binding fragments thereof) and AMPK (or PPARδ-binding fragments thereof) for each other is increased when the amount of such complex or the binding affinity is at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 100% or at least 250% higher than a control measurement (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent).
  • In other particular methods, the formation of a PPARδ-AMPK (such as AMPKα1 and/or AMPKα2) complex (including complexes including one or both of PPARδ-binding AMPK fragments and/or AMPK-binding PPARδ fragments) or the affinity of PPARδ (or AMPK-binding fragments thereof) and AMPK (or PPARδ-binding fragments thereof) for each other is decreased when the amount of such complex or the binding affinity is at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 100% or at least 250% lower than a control measurement (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent).
  • 2. Agents that Affect AMPK-Dependent Phosyphorylation
  • Disclosed are methods of screening test agents for those that affect (e.g., increase or decrease) AMPK (e.g., AMPKα1 and/or AMPKα2)-dependent phosphorylation of the PPARδ complex. Agents that affect AMPK-dependent phosphorylation of the PPARδ complex can be identified by a variety of assays, such adaptations of solid-phase- or solution-based assays described above, where the end point to be detected is phosphorylation of one or more components of the PPARδ complex.
  • Methods for detecting protein phosphorylation are conventional (see, e.g., Gloffke, The Scientist, 16(19):52, 2002; Screaton et al., Cell, 119:61-74, 2004) and detection kits are available from a variety of commercial sources (see, e.g., Upstate (Charlottesville, Va., USA), Bio-Rad (Hercules, Calif., USA), Marligen Biosciences, Inc. (Ijamsville, Md., USA), Calbiochem (San Diego, Calif., USA). Briefly, phosphorylated protein (e.g., phosphorylation of one or more components of the PPARδ complex) can be detected using stains specific for phosphorylated proteins in gels. Alternatively, antibodies specific phosphorylated proteins can be made or commercially obtained. Antibodies specific for phosphorylated proteins can be, among other things, tethered to the beads (including beads having a particular color signature) or used in ELISA or Western blot assays.
  • In one example, a PPARδ complex (or a fragment thereof containing an AMPK phosphorylation site) and AMPK or one or more of it subunits (such as AMPKα1 and/or AMPKα2) or functional fragments thereof that are capable of phosphorylation are mixed under conditions whereby a PPARδ complex is phosphorylated by AMPK. A PPARδ complex is adsorbed to a support, such as a microtiter well or beads. Then, AMPK (or its one or more subunits (such as AMPKα1 and/or AMPKα2) or phosphorylation-capable fragments thereof) is added to the environment where the complex is immobilized. A phosphate donor typically is also included in the environment. The phosphate to be donated, optionally, can be labeled. One or more test compounds, such as compounds in one or more of the above-described libraries, are separately added to the individual microenvironments. Agents capable of affecting AMPK-dependent phosphorylation are identified, for instance, as those that enhance (or inhibit) phosphorylation of immobilized PPARδ complex. In embodiments involving a labeled phosphate donor, phosphorylation of immobilized PPARδ complex can be determined by retention or binding of a labeled phosphate in the reaction microenvironment, for example, in a microtiter well or on a bead for example. In other embodiments, such reactions can take place in solution (i.e., with no immobilized components), PPARδ complex can be isolated from the solution (e.g., by immunoprecipitation with PPARδ-specific or phosphate-specific antibodies), and its level of phosphorylation in the presence (and, optionally, absence) of one of more test agents determined as previously discussed.
  • In particular methods, the phosphorylation of a PPARδ complex is increased when such posttranslational modification is detectably measured or when such posttranslational modification is at least 20%, at least 30%, at least 50%, at least 100% or at least 250% higher than control measurements (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent, or in a comparable test system in the absence of AMPK).
  • In particular methods, the phosphorylation of PPARδ complex is decreased when such posttranslational modification is detectably reduced or when such posttranslational modification is at least 20%, at least 30%, at least 50%, at least 100% or at least 250% lower than control measurements (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent, or in a comparable test system in the absence of AMPK).
  • C. Screening Assay Target(s)
  • 1. PPARδ
  • A PPARδ polypeptide useful in a disclosed screening method is any known PPARδ receptor. Also useful in the disclosed screening methods are homologs, functional fragments, or functional variants of a PPARδ that retains at least AMPK-binding activity as described herein for a prototypical PPARδ polypeptide (see Example 6).
  • The amino acid sequences of prototypical PPARδ polypeptides (and PPARδ-encoding nucleic acid sequences) are well known. Exemplary PPARδ amino acid sequences and PPARδ-encoding nucleic acid sequences are described, for instance, in U.S. Pat. No. 5,861,274, and U.S. Pat. Appl. Pub. No. 20060154335 (each of which is expressly incorporated herein by reference), and in GenBank Accession Nos. NP—035275 (GI:33859590)(Mus musculus amino acid sequence); NM—011145.3 (GI:89001112)(Mus musculus nucleic acid sequence); NP—006229 (GI:5453940)(Homo sapiens amino acid sequence); NM 006238.3 (GI:89886454)(Homo sapiens nucleic acid sequence); NP—037273 (GI:6981384)(Rattus norvegicus amino acid sequence); NM—013141.1 (GI:6981383)(Rattus norvegicus nucleic acid sequence); NP—990059 (gi45382025)(Gallus gallus amino acid sequence) or NM—204728.1 (GI:45382024)(Gallus gallus nucleic acid sequence). In some method embodiments, a PPARδ homolog or functional variant shares at least 60% amino acid sequence identity with a prototypical PPARδ polypeptide; for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity with an amino acid sequence as set forth in U.S. Pat. No. 5,861,274, U.S. Pat. Appl. Pub. No. 20060154335, or GenBank Accession No. NP—035275 (GI:33859590)(Mus musculus amino acid sequence); NP—006229 (GI:5453940)(Homo sapiens amino acid sequence); NP—037273 (GI:6981384)(Rattus norvegicus amino acid sequence); or NP—990059 (gi45382025) (Gallus gallus amino acid sequence). In other method embodiments, a PPARδ homolog or functional variant has one or more conservative amino acid substitutions as compared to with a prototypical PPARδ polypeptide; for example, no more than 3, 5, 10, 15, 20, 25, 30, 40, or 50 conservative amino acid changes compared to an amino acid sequence as set forth in U.S. Pat. No. 5,861,274, U.S. Pat. Appl. Pub. No. 20060154335, or GenBank Accession No. NP—035275 (GI:33859590)(Mus musculus amino acid sequence); NP—006229 (GI:5453940)(Homo sapiens amino acid sequence); NP—037273 (GI:6981384)(Rattus norvegicus amino acid sequence); or NP—990059 (gi45382025)(Gallus gallus amino acid sequence). The following table shows exemplary conservative amino acid substitutions:
  • Conservative
    Original Residue Substitutions
    Ala Ser
    Arg Lys
    Asn Gln; His
    Asp Glu
    Cys Ser
    Gln Asn
    Glu Asp
    Gly Pro
    His Asn; Gln
    Ile Leu; Val
    Leu Ile; Val
    Lys Arg; Gln; Glu
    Met Leu; Ile
    Phe Met; Leu; Tyr
    Ser Thr
    Thr Ser
    Trp Tyr
    Tyr Trp; Phe
    Val Ile; Leu
  • Some method embodiments involve a PPARδ functional fragment (such as an AMPK-binding fragment), which can be any portion of a full-length known PPARδ polypeptide, including, e.g., about 20, about 30, about 40, about 50, about 75, about 100, about 150 or about 200 contiguous amino acid residues of same; provided that the fragment retains a PPARδ function of interest (e.g., AMPK binding). PPARδ encompasses known functional motifs (such as ligand-binding domain, a DNA-binding domain, and a transactivation domain).
  • 2. AMPK
  • Mammalian AMP-activated kinase (AMPK) is a heterotrimeric protein composed of 1 alpha subunit, 1 beta subunit, and 1 gamma subunit. There are, at least, two known isoforms of the alpha subunit (α1 and a2). AMPKα1 and AMPKα2 have 90% amino acid sequence identity within their catalytic cores but only 61% in their C-terminal tails (see Online Mendelian Inheritance in Man (OMIM) Database Accession No. 602739; publicly available at the following website: ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602739).
  • An AMPK (such as AMPKα1 and/or AMPKα2) polypeptide useful in a disclosed screening method is any known AMPK protein or subunit thereof (such as AMPKα1 and/or AMPKα2). Also useful in the disclosed screening methods are homologs, functional fragments, or functional variants of an AMPK protein or subunit thereof (such as AMPKα1 and/or AMPKα2) that retains at least PPARδ-binding activity as described herein (see Example 6).
  • The amino acid sequences of prototypical AMPK subunits (such as AMPKα1 and/or AMPKα2) (and nucleic acids sequences encoding prototypical AMPK subunits (such as AMPKα1 and/or AMPKα2)) are well known. Exemplary AMPKα1 amino acid sequences and the corresponding nucleic acid sequences are described, for instance, in GenBank Accession Nos. NM—206907.3 (GI:94557298)(Homo sapiens transcript variant 2 REFSEQ including amino acid and nucleic acid sequences); NM—006251.5 (GI:94557300)(Homo sapiens transcript variant 1 REFSEQ including amino acid and nucleic acid sequences); NM—001013367.3 (GI:94681060)(Mus musculus REFSEQ including amino acid and nucleic acid sequences); NM—001039603.1 (GI:88853844)(Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM 019142.1 (GI: 11862979)(Rattus norvegicus REFSEQ including amino acid and nucleic acid sequences). Exemplary AMPKα2 amino acid sequences and the corresponding nucleic acid sequences are described, for instance, in GenBank Accession Nos. NM—006252.2 (GI:46877067)(Homo sapiens REFSEQ including amino acid and nucleic acid sequences); NM—178143.1 (GI:54792085)(Mus musculus REFSEQ including amino acid and nucleic acid sequences); NM—001039605.1 (GI:88853850) (Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM—214266.1 (GI:47523597)(Sus scrofa REFSEQ including amino acid and nucleic acid sequences).
  • In some method embodiments, a homolog or functional variant of an AMPK subunit shares at least 60% amino acid sequence identity with a prototypical AMPKα1 and/or AMPKα2 polypeptide; for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity with an amino acid sequence as set forth in the GenBank Accession Nos. NM 206907.3; NM—006251.5; NM—001013367.3; NM—001039603.1; NM—019142.1; NM—006252.2; NM—178143.1; NM—001039605.1; or NM—214266.1. In other method embodiments, a homolog or functional variant of an AMPK subunit has one or more conservative amino acid substitutions as compared to a prototypical AMPKα1 and/or AMPKα2 polypeptide; for example, no more than 3, 5, 10, 15, 20, 25, 30, 40, or 50 conservative amino acid changes compared to an amino acid sequence as set forth in as set forth in GenBank Accession Nos. NM 206907.3; NM—006251.5; NM—001013367.3; NM—001039603.1; NM—019142.1; NM—006252.2; NM—178143.1; NM—001039605.1; or NM—214266.1. Exemplary conservative amino acid substitutions have been previously described herein.
  • Some method embodiments involve a functional fragment of AMPK or a subunit thereof (such as AMPKα1 and/or AMPKα2), including a PPARδ-binding fragment or a fragment with PPARδ phosphorylation activity. Functional fragments of AMPK or a subunit thereof (such as AMPKα1 and/or AMPKα2) can be any portion of a full-length or intact AMPK polypeptide complex or subunit thereof (such as AMPKα1 and/or AMPKα2), including, e.g., about 20, about 30, about 40, about 50, about 75, about 100, about 150 or about 200 contiguous amino acid residues of same; provided that the fragment retains at least one AMPK (or AMPKα1 and/or AMPKα2) function of interest (e.g., PPARδ binding and/or PPARδ phosphorylation activity). Protein-protein interactions between PPARδ and AMPK are believed to involve, at least, an AMPKA subunit (such as AMPKα1 and/or AMPKα2). Moreover, because PPARδ specifically binds both AMPKα1 and AMPKα2 (see Example 6), such interaction likely is mediated by the portions of these AMPKA isoforms that share the most sequence homology (as discussed above). Accordingly, in some method embodiments, an AMPK PPARδ-binding fragment includes a functional fragment encompassing (or consisting of) the catalytic core domain of an alpha subunit of AMPK (such as AMPKα1 and/or AMPKα2).
    • EXAMPLES
  • The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the invention to the particular features or embodiments described.
    • Example 1 Administration of PPARδ Agonist Surprisingly does not Enhance Physical Performance in Non-Exercised Subjects
  • Wang et al. previously demonstrated that skeletal muscle-specific expression of a constitutively active form of PPARδ receptor resulted in transgenic mice with skeletal muscles that had an increased number of slow, oxidative (type I) muscle fibers and markedly increased running endurance (Wang et al., PLoS Biol., 2:e294, 2004). This Example demonstrates that administration of a PPARδ agonist (GW1516) to non-transgenic mice also results in the expression in skeletal muscle of some biomarkers of oxidative metabolism. However, in unexpected contrast to the results obtained by genetic activation of the PPARδ pathway, PPARδ activation by pharmacological treatment did not modify fiber-type composition of skeletal muscle, nor improve running endurance in non-transgenic, sedentary (also referred to as “non-exercised” or “untrained”) mice.
  • Male C57B/6J mice (8 wks old) were obtained from Jackson Laboratory and housed in the Salk Institute animal care facility. The animals were acclimated to their surroundings for one week prior to experimentation, and had access at all times to standard mouse chow and water ad libitum.
  • Mice were acclimated to moderate treadmill running (10 m/min for 15 min) every other day for 1 week. After acclimation, basal running endurance was determined by placing each mouse on a treadmill, gradually increasing the speed from 0 to 15 m/min, and maintaining 15 m/min until the mouse was exhausted. The time and distance run until exhaustion were recorded as the basal endurance values (Week 0).
  • Mice then were treated once per day for 4 weeks with vehicle or the PPARδ agonist, GW1516 (5 mg/kg). Treatments were administered orally. During the treatment period, mice were housed in standard laboratory cages and received only the amount of physical activity that could be had by normal movements about such cage.
  • Animals were euthanized by carbon dioxide asphyxiation 72 hours after the final treatment. Gastrocnemius and quadriceps muscles were isolated, frozen and stored at −80° C. for future analysis. Total RNA was prepared from quadriceps muscle using TRIZOL™ reagent (Invitrogen, Calsbad, Calif., USA) in conformance with manufacturer's instructions. Real time quantitative PCR (QPCR) was used to determine expression levels of uncoupling protein 3 (UCP3), muscle carnitine palmitoyl transferase I (mCPT I) and pyruvate dehydrogenase kinase 4 (PDK4) using primers known to those of ordinary skill in the art.
  • As shown in FIG. 1A, four weeks of GW1516 treatment induced the expression of UCP3, mCPT I, and PDK4, in quadriceps muscle of treated mice (compare V to GW). These changes in gene expression were detected as early as 4 days after treatment and with drug concentrations ranging from 2-5 mg/kg/day. Moreover, in the gene expression studies, maximal effects of PPARδ activation were detected in pre-dominantly fast-twitch (quadricep and gastrocnemius) but not slow-twitch (soleus) muscles.
  • Using primary muscle cells cultured from wild type and PPARδ null mice (Chawla et al., Proc. Natl. Acad. Sci. USA. 100(3): 1268-73, 2003; Man et al., J. Invest. Dermatol. 2007; Rando and Blau, J. Cell. Biol. 125(6): 1275-87, 1994), it was confirmed that the induction of oxidative genes by GW1516 is mediated via activation of PPARδ in skeletal muscles (FIGS. 1B-D). Moreover, this is similar to the expression changes found in the same gene set in muscles from mice expressing the constitutively active VP16-PPARδ transgene (Wang et al., PLoS Biol., 2:e294, 2004) (FIG. 1A, see TG). Collectively, these results indicate that pharmacological activation of PPARδ can initiate an oxidative response in adult skeletal muscle.
  • Expression of biomarkers characteristic of an oxidative phenotype in skeletal muscle, typically, has been correlated with increased oxidative performance (e.g., increased running endurance) of such skeletal muscle. This correlation was observed, for instance, in the VP16-PPARδ transgenic mouse (Wang et al., PLoS Biol., 2:e294, 2004). For this and other reasons, it was expected that GW1516 treatment similarly would increase running performance. Accordingly, to determine the functional effects of ligand, age and weight matched cohorts of treated and control mice were subjected to an endurance treadmill performance test before (week 0) and after (week 5) treatment.
  • Following four weeks of treatment and housing in standard laboratory cages without additional exercise, the running endurance of GW1516-treated and control mice again was determined as described above. Remarkably, and despite expectations for improvement, GW1516-treated mice did not significantly differ from controls in either the time spent or distance run on the treadmill prior to exhaustion (FIG. 1E). Furthermore, long-term drug treatment of up to 5 months also did not change running endurance.
  • These results indicate that although in non-trained adult muscle pharmacological activation of PPARδ induces some transcriptional changes, it fails to alter either fiber type composition or endurance. In summary, pharmacologic activation of the PPARδ genetic program in adult C57B1/6J mice is insufficient to promote a measurable enhancement of treadmill endurance.
    • Example 2 Administration of PPARδ Agonist Remodels Skeletal Muscle in Exercised-Trained Subjects
  • Fiber type proportions in skeletal muscle are believed to be determined by heredity and environmental factors, such as physical activity level (Simoneau and Bouchard, FASEB J., 9(11):1091-1095, 1995; Larsson and Ansved, Muscle Nerve, 8(8):714-722, 1985). Endurance exercise training is known to remodel the skeletal muscle by increasing type I slow-twitch fibers, oxidative enzymes, and mitochondrial density, which progressively alter performance (Holloszy et al., J. Appl. Physiol. 56:831-8, 1984; Booth et al., Physiol Rev. 71:541-85, 1991; Schmitt et al., Physiol. Genomics. 15:148-57, 2003; Yoshioka et al., FASEB J. 17:1812-9, 2003; Mahoney et al., Phys. Med. Rehabil. Clin. N. Am. 16:859-73, 2005; Mahoney et al., FASEB J. 19:1498-500, 2005; Siu et al., J. Appl. Physiol. 97:277-85, 2004; Garnier et al., FASEB J. 19:43-52, 2005; Short et al., J. Appl. Physiol. 99:95-102, 2005; Timmons et al., FASEB J. 19: 750-60, 2005). This example demonstrates that PPARδ agonist treatment influences skeletal muscle on a molecular level.
  • To determine whether co-administration of GW1516 in the context of endurance exercise can enhance changes in fiber type composition and mitochondrial biogenesis, the effect of GW1516 treatment on muscle fiber-type composition was determined by meta-chromatic staining of cryo-sections of gastrocnemius as described by Wang et al. (PLoS Biol., 2:e294, 2004). Meta-chromatic staining was used, following a routine myofibrillar ATPase reaction, to demonstrate quantitative differences in phosphate deposition among different skeletal muscle fiber types and, thereby, differentiate skeletal muscle fiber types (Doriguzzi et al., Histochem., 79(3):289-294, 1983; Ogilvie and Feeback, Stain Technol., 65(5):231-241, 1990). In this assay, muscle fibers with high ATPase activity (e.g., type I (slow oxidative) muscle fibers) are darkly stained.
  • As shown in FIG. 2A, there was no significant difference in the proportion of type I (slow, oxidative) muscle fibers in the gastrocnemius muscles of vehicle- and GW1516-treated sedentary mice. In contrast, hindlimb muscles of VP16-PPARδ transgenic mice exhibited an increased number of type I muscle fibers when assayed by monochromatic staining. In trained mice, GW1516 increased the proportion of type I fibers (by 38%) compared to the vehicle-treated sedentary mice (FIGS. 2A and 2B). Therefore, administration of a PPARδ agonist (e.g., GW1516) alone to sedentary subjects does not significantly affect the number of type I (slow-twitch, oxidative) muscle fibers in hindlimb muscles, but can increase the number of type I muscle fibers in hindlimb muscles of trained subjects.
  • In addition to its effects on the fiber type, exercise training increased skeletal muscle mitochondrial biogenesis, which can be measured as a function of mitochondrial DNA expression levels using quantitative real time PCR (QPCR). Mitochondrial DNA expression levels were determined in muscles of V, GW, Tr, and GW+Tr subjects using quantitative real time PCR. As shown in FIG. 2C, similar to type I fiber changes, mitochondrial DNA expression was not changed by drug alone but was increased by approximately 50% with the combination of exercise and GW1516 treatment (FIG. 2C). Such an increase is known to contribute to enhanced endurance capacity (e.g., Holloszy, Med. Sci. Sports 7: 155-64, 1975).
  • Slow-twitch and fast-twitch muscle fiber types also can be distinguished by myosin isoform expression (Gauthier and Lowey, J. Cell Biol. 81:10-25, 1979; Fitzsimons and Hoh, Biochem. J. 193:229-33, 1981). Myosin isoform expression in skeletal muscle adapts to various conditions, such as changes in muscle mechanics, muscle innervation, or exercise paradigm (for review, see, e.g., Baldwin and Haddad, J. Appl. Physiol., 90(1):345-57, 2001; Baldwin and Haddad, Am. J. Phys. Med. Rehabil., 81(11 Suppl):S40-51, 2002; Parry, Exerc. Sport Sci. Rev., 29(4):175-179, 2001). The effect of GW1516 administration on myosin heavy chain (MHC) expression (MHC I, MHC IIa, MHC IIb) was determined by methods known to those of ordinary skill in the art.
  • GW1516 treatment in sedentary mice increased the expression of MHC I (a marker of slow-twitch, oxidative muscle fibers) and decreased the expression of MHC IIb (a marker of fast-twitch, glycolytic muscle fibers) as compared to vehicle-treated, control mice. In comparison, GW1516 treatment did not alter the expression of MHC IIa (a marker of fast-twitch oxidative/glycolytic muscle fibers) in sedentary mice. Therefore, at least at the transcriptional level, the PPARδ agonist was capable of inducing some proteins characteristic of a slow-twitch muscle fiber phenotype.
  • In summary, expression of constitutively active PPARδ in the skeletal muscles of VP16-PPARδ transgenic mice resulted in a “long-distance running phenotype” with “profound and coordinated increases in oxidative enzymes, mitochondrial biogenesis and production of specialized type I fiber contractile proteins—the three hallmarks of muscle fiber type switching” (Wang et al., PLoS Biol., 2:e294, 2004). In contrast, pharmacological activation of PPARδ in normal subjects only partially recapitulated VP16-PPARδ transgenesis by regulating some metabolic genes. Markedly, administration of a PPARδ agonist to sedentary subjects did not lead to a change in fiber type specification (as measured by monochromatic staining) or enhance exercise endurance. Transgenic over-expression of activated PPARδ at birth pre-programs the nascent myofibers to trans-differentiate into slow-twitch fibers, thus imparting a high basal endurance capacity to adult transgenic mice. In contrast, since fiber type specification is completed prior to exposure of adults to PPARδ agonist, the potential plasticity of muscle to drug treatment alone is virtually non-existent.
  • This example illustrates that the genetic or pharmacologic activation of the PPARδ regulatory program in skeletal muscles of adult, sedentary subjects does not have the same outcome. The ability to genetically manipulate skeletal muscle specification by activation of the PPARδ receptor in a transgenic mouse from early development in the absence of exercise is not necessarily predictive of the result of pharmacologically activating the PPARδ program in the sedentary, normal adult. The cellular “template” for PPARδ effects on skeletal muscle is very different in a normal subject as compared to a genetically engineered transgenic subject. For example, in a normal adult, muscle fiber specification of individual muscle groups is already determined and the connections between muscle fibers and spinal motor neurons are established prior to pharmacological activation of the PPARδ-regulated program. In the transgenic mouse, the constitutively active PPARδ transgene is active all the while muscle fiber specification is being determined and connections between muscle fibers and motor neurons are being made. In addition, the effects of activation of endogenous PPARδ receptor by a single daily dose of a PPARδ agonist, which is expect to have a transient peak exposure followed by clearance, likely are much different from the effects of the constitutive activation of a VP16-PPARδ transgene.
    • Example 3 The Combination of PPARδ Agonist Treatment and Exercise Training Significantly Affected Fatty Acid Metabolism and Markers of Fatty Acid Oxidation
  • In addition to affecting the contractile apparatus of skeletal muscle, exercise training also increases skeletal muscle mitochondrial density (e.g., Freyssenet et al., Arch. Physiol. Biochem., 104(2):129-141, 1996). This Example illustrates that PPARδ agonist treatment (e.g., GW1516) in exercise-trained subjects affected fatty acid metabolism in exercised muscle.
  • The effects of GW1516 treatment and exercise, alone or in combination, on components of the oxidative metabolism of fatty acids were determined by measuring gene expression levels of selective biomarkers for fatty acid β-oxidation (FAO). Male C57B/6J mice (8-10 wks old) were randomly divided into four groups (nine per group): (i) vehicle-treated and sedentary (V), (ii) GW1516-treated and sedentary (GW), (iii) vehicle-treated and exercise trained (Tr) and (iv) GW1516-treated and exercise trained (GW+Tr). Mice in all groups were acclimated to moderate treadmill running and basal running endurance was determined as described in Example 1. Thereafter, mice in the exercise-trained groups received four weeks (5 days/week) of exercise training on a treadmill inclined at 5 degrees. Intensity and time of training were gradually increased. At the end of four weeks, all exercise-trained mice were running for 50 min/day at 18 m/min. Vehicle or GW1516 was administered to the respective exercise-treated or sedentary groups as described in Example 1. Unless otherwise noted, V, GW, Tr and GW+Tr subjects described in this and the examples below were similarly treated. At the end of the drug treatment and/or training protocol (Week 5) 6 mice per group were subjected to the running test. These interventions do not affect body weight and food intake in mice. RNA was prepared real time quantitative PCR performed as described in Example 1.
  • Confirming the results obtained in Example 1, UCP3, mCPT I, and PDK4 were upregulated by GW1516 but showed no further induction with exercise (see FIGS. 1A and 3A). Unexpectedly, a second set of genes were identified that showed no response to exercise or GW1516 alone but were robustly induced by the combination. This intriguing response profile includes a series of genes involved in the regulation of fatty acid storage [such as steroyl-CoA-desaturase (SCD1), fatty acyl coenzyme A synthase (FAS) and serum response element binding protein 1c (SREBP1c)] and fatty acid uptake [such as the fatty acid transporter (FAT/CD36) and lipoprotein lipase (LPL)] adding a new set of target genes to exercise and drug treated mice (FIGS. 3B, 3C and 6A-C).
  • In addition to gene expression, protein expression was determined for selective oxidative biomarkers including myoglobin, UCP3, cytochrome c (CYCS) and SCD1, using Western blotting. Protein homogenates were prepared from quadriceps muscle, separated by SDS polyacrylamide gel electrophoresis, transferred to blotting membrane and probed with antibodies specific for myoglobin (Dako), UCP3 (Affinity Bioreagents), cytochrome c (Santacruz) SCD1 (Santacruz), and, as a loading control, tubulin (Sigma). A robust up regulation of myoglobin, UCP3, cytochrome c, and SCD1 protein expression was observed with combined exercise and GW1516 treatment in comparison to treatment with the PPARδ agonist or exercise alone (FIG. 3D).
  • Altered triglycerides can be used to access changes in muscle oxidative capacity. Muscle triglyceride (mTG) content was measured as previously described (Wang et al., PLoS Biol., 2:e294, 2004) using a kit from Thermo Electron Corporation. As shown in FIG. 4, mTG content was comparable between vehicle and GW1516-treated sedentary mice and was substantially increased in muscle of mice receiving only exercise training. In contrast, dramatic increase in triglycerides in exercised muscle was completely reversed in GW1516-treated exercise trained mice, indicating increased fat utilization (FIG. 4).
  • Gene and/or protein expression that is induced by a combination of exercise and drug treatment (e.g., PPARδ agonist administration) but not by either input alone is believed to be a new discovery. This type of response can be used to further characterize the intersection of pharmacologic and physiologic genetic networks. For example, one or more genes and/or proteins uniquely regulated by one or more drugs (e.g., PPARδ agonists) and exercise can be used as markers, for instance, of illicitly boosting performance in professional and/or amateur athletes.
    • Example 4 Administration of PPARδ Agonist Enhances the Physical Performance of Exercise-Trained Subjects
  • As described in Example 1, although GW1516 treatment induces wide-spread genomic changes associated with oxidative metabolism, nonetheless alone it failed to increase running endurance. This finding was unexpected because it was known that constitutive activation of the PPARδ gene network (in the VP16-PPARδ transgenic mouse) lead to a distance-running phenotype (familiarly, a “marathon mouse”). On the other hand, as surprisingly shown in Example 3, PPARδ agonist (e.g., GW1516) treatment in conjunction with exercise produced an enriched remodeling program that included a series of transcriptional and post-translational adaptations in the skeletal muscle. This indicates that exercise training serves as a trigger to unmask a set of PPARδ target genes. This Example provides methods used to demonstrate that administration of a PPARδ agonist (e.g., GW1516) surprisingly improves physical performance in exercised (trained) subjects.
  • Male C57B/6J mice (8-10 wks old) were randomly divided into four groups (nine per group): (i) vehicle-treated and sedentary (V), (ii) GW1516-treated and sedentary (GW), (iii) vehicle-treated and exercise trained (Tr) and (iv) GW1516-treated and exercise trained (GW+Tr), acclimated to moderate treadmill running as described in Example 1, and exercise-trained as described in Example 3. At the end of the drug treatment and/or training protocol (Week 5) 6 mice per group were subjected to the running test.
  • At the end of the drug treatment and/or training protocol (Week 5), running endurance of six mice per group was determined in the same manner as was basal running endurance. No follow-up endurance tests were performed on three mice in each group to confirm that changes observed in the skeletal muscle were not due to the acute run, but were related to the exercise training.
  • As shown in FIGS. 5A and 5B, the same dose and duration of GW1516 treatment that failed to alter running endurance in sedentary mice, when paired with 4 weeks of exercise training, increases running time by 68% and running distance by 70% over vehicle-treated trained mice (FIGS. 5A and 5B, compare Week 5). Comparison of running time and distance before (week 0) and after (week 5) exercise and drug treatment revealed a 100% increment in endurance capacity for individual mice, underscoring the robustness of the combination paradigm (FIGS. 5A and 5B). In contrast, the same exercise protocol without concurrent GW1516 treatment did not significantly increase running endurance in C57B1/6J mice.
  • Hematoxylin and eosin (H&E) staining of white adipose tissue paraffin sections was performed as previously described (Wang et al., PLoS Biol., 2:e294, 2004; Wang et al., Cell, 113: 159-70, 2003). As shown in FIG. 5C, GW1516 treatment in combination with exercise produced a significant (32%) reduction in the epididymal fat to body weight ratio, which was further evident in the decreased cross-sectional area of the adipocytes in the same group (FIG. 5D). Therefore, the combined effects of GW1516 and exercise are not restricted to muscle.
  • Using the methods described in Example 2, it was also demonstrated that the combination of GW1516 treatment and exercise training significantly increased the number of type I muscle fibers in exercised muscle. However, combining GW1516 treatment with exercise did not induce additional changes in MHC I and MHC IIb expression. Therefore, although orally administered PPARδ agonist (GW1516) alone is capable of inducing the expression of at least some of the contractile proteins in the PPARδ-regulated gene network (see Example 5) the transcriptional effect observed was not sufficient to induce a post-transcriptional change in fiber-type composition as was observed by meta-chromatic staining in GW1516-treated, exercised mice.
  • This Example illustrates that PPARδ agonist (e.g., GW1516) treatment unexpectedly augments the performance of aerobic exercise (e.g., running distance and endurance) in an exercised subject. Endurance exercise is known to channel extra-muscular fat to muscle triglyceride stores by inducing adipose tissue lipolysis to meet increased oxidative demands (Despres et al., Metabolism, 33:235-9, 1984; Mauriege et al., Am. J. Physiol., 273:E497-506, 1997; Mader et al., Int. J. SportsMed., 22:344-9, 2001; Schmitt et al., Physiol. Genomics, 15:148-57, 2003; Schrauwen-Hinderling et al., J. Clin. Endocrinol. Metab., 88:1610-6, 2003). In addition, the induction of FAO components and selective up-regulation of fatty acid storage and up-take components in GW1516-treated, exercised mice described in Example 3 indicate enhanced mobilization of fat as fuel in skeletal muscle. Therefore, combined exercise and GW1516 treatment dramatically increases muscle oxidative capacity in subjects, for example by increasing local fatty acid synthesis and/or mobilizing fatty acid stores from adipose tissue.
  • This is the first demonstration of how an orally active PPARδ agonist and exercise can co-operatively re-program the muscle genome and raise endurance limits.
    • Example 5 The Combination of PPARδ Agonist Treatment and Exercise Training Produced a Unique Gene Expression Signature in Exercised Muscle
  • A comprehensive study of the skeletal muscle transcriptional program in V, GW, Tr and Tr+GW mice was conducted using microarray analysis. Affymetrix™ high-density oligonucleotide array mouse genome 430A 2.0 chips were used. Preparation of in vitro transcription products, oligonucleotide array hybridization, and scanning were performed in conformance with Affymetrix™-provided protocols. To minimize discrepancies due to variables, the raw expression data were scaled by using Affymetrix™ MICROARRAY SUITE™ 5.0 software, and pairwise comparisons were performed. The trimmed mean signal of all probe sets was adjusted to a user-specified target signal value (200) for each array for global scaling. No specific exclusion criteria were applied. Additional analyses were performed using the freeware program BULLFROG 7 (available on the internet Barlow-LockhartBrainMapNIMHGrant.org) and the Java-based statistical tool VAMPIRE (Hsiao et al., Bioinformatics, 20:3108-3127, 2004).
  • Genome-wide analysis of the quadriceps muscle revealed that GW1516 treatment, exercise, and the combination regulated 96, 113 and 130 genes, respectively (FIG. 6). Approximately 50% of the target genes regulated by GW1516 or exercise alone were the same, demonstrating that PPARδ activation of the gene network partially mimics exercise effects on the same network.
  • The 130 genes regulated by the combination of GW1516 treatment and exercise training and a classification of each such gene are shown in Table 1. The 130 regulated genes included 30 fat metabolism genes, 5 oxygen carriers, 5 mitochondrial genes, 3 carbohydrate metabolism genes, 15 signal transduction genes, 16 transcription genes, 10 transport genes, 3 steroid biogenesis genes, 5 heat shock genes, 2 angiogenesis genes, 5 proliferation and apoptosis genes, 2 cytokines, and 29 others. The majority of the genes in the exercise-trained/GW1516-treated (GW+Tr) gene signature shown in Table 1 were induced (109/130). The 109 upregulated genes are shown in non-bold font in Table 1 (final column>1). Down-regulated genes are shown in bold italics in Table 1 (final column<1).
  • TABLE 1
    Genes regulated by GW1516 treatment and exercise training
    FEATURE LOCUS DESCRIPTION GW + Tr
    ANGIOGENESIS
    1417130_s_at Angptl4 angiopoietin-like 4 5.495
    Figure US20080187928A1-20080807-P00001
    Figure US20080187928A1-20080807-P00002
    Figure US20080187928A1-20080807-P00003
    Figure US20080187928A1-20080807-P00004
    CARBOHYDRATE METABOLISM
    1449088_at Fbp2 fructose bisphosphatase 2 2.808
    1423439_at Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 3.518
    1434499_a_at Ldhb lactate dehydrogenase B 2.541
    PROLIFERATION & APOPTOSIS
    1425621_at Trim35 tripartite motif-containing 35 1.856
    Figure US20080187928A1-20080807-P00005
    Figure US20080187928A1-20080807-P00006
    Figure US20080187928A1-20080807-P00007
    Figure US20080187928A1-20080807-P00008
    1448272_at Btg2 B-cell translocation gene 2, anti-proliferative 1.601
    1452260_at Cidec cell death-inducing DFFA-like effector c 4.771
    1417956_at Cidea cell death-inducing DNA fragmentation factor, alpha 49.625
    subunit-like effector A
    CYTOKINES
    1426278_at Ifi27 interferon, alpha-inducible protein 27 1.714
    1421239_at Il6st interleukin 6 signal transducer 1.972
    FAT METABOLISM
    1448318_at Adfp adipose differentiation related protein 2.009
    1424729_at BC054059 cDNA sequence BC054059 5.08
    1424937_at 2310076L09Rik RIKEN cDNA 2310076L09 gene 1.868
    1450010_at Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 2.376
    1415965_at Scd1 stearoyl-Coenzyme A desaturase 1 6.494
    1415822_at Scd2 stearoyl-Coenzyme A desaturase 2 1.849
    1423828_at Fasn fatly acid synthase 6.323
    1455061_a_at Acaa2 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3- 1.926
    oxoacyl-Coenzyme A thiolase)
    1448987_at Acadl acetyl-Coenzyme A dehydrogenase, long-chain 2.549
    1422651_at Adipoq adiponectin, C1Q and collagen domain containing 3.082
    1422820_at Lipe lipase, hormone sensitive 3.032
    1449964_a_at Mlycd malonyl-CoA decarboxylase 1.781
    1426785_s_at Mgll monoglyceride lipase 1.907
    1420658_at Ucp3 uncoupling protein 3 (mitochondrial, proton carrier) 2.943
    1425326_at Acly ATP citrate lyase 2.606
    1460409_at Cpt1a carnitine palmitoyltransferase 1a, liver 2.753
    1422677_at Dgat2 diacylglycerol O-acyltransferase 2 2.784
    Figure US20080187928A1-20080807-P00009
    Figure US20080187928A1-20080807-P00010
    Figure US20080187928A1-20080807-P00011
    Figure US20080187928A1-20080807-P00012
    1425834_a_at Gpam glycerol-3-phosphate acyltransferase, mitochondrial 2.207
    1417273_at Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 2.27
    1449182_at Retn resistin 4.114
    1435630_s_at Acat2 acetyl-Coenzyme A acetyltransferase 2 1.625
    1425829_a_at Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 10.322
    1A
    1423166_at Cd36 CD36 antigen 1.584
    1422811_at Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 3.58
    1416023_at Fabp3 fatty acid binding protein 3, muscle and heart 1.833
    1424155_at Fabp4 fatty acid binding protein 4, adipocyte 2.189
    1431056_a_at Lpl lipoprotein lipase 1.659
    1422432_at Dbi diazepam binding inhibitor 1.936
    1422811_at Slc27a1 solute carrier family 27 (fatty acid transporter), 1 3.58
    HEAT SHOCK RESPONSE
    1448881_at Hp haptoglobin 1.679
    1427126_at Hspa1b heat shock protein 1B 8.845
    1438902_a_at Hsp90aa1 heat shock protein 90 kDa alpha (cytosolic), class A 1.513
    member 1
    1431274_a_at Hspa9a heat shock protein 9A 1.61
    1416755_at Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 3.59
    MISCELLANEOUS
    1460256_at Car3 carbonic anhydrase 3 2.339
    1415841_at Dync1i2 dynein cytoplasmic 1 intermediate chain 2 1.705
    1432344_a_at Aplp2 amyloid beta (A4) precursor-like protein 2 1.937
    1416429_a_at Cat catalase 1.82
    1418306_at Crybb1 crystallin, beta B1 2.457
    1448842_at Cdo1 cysteine dioxygenase 1, cytosolic 3.266
    Figure US20080187928A1-20080807-P00013
    Figure US20080187928A1-20080807-P00014
    Figure US20080187928A1-20080807-P00015
    Figure US20080187928A1-20080807-P00016
    Figure US20080187928A1-20080807-P00017
    Figure US20080187928A1-20080807-P00018
    Figure US20080187928A1-20080807-P00019
    Figure US20080187928A1-20080807-P00020
    1453527_a_at Neurl neuralized-like homolog (Drosophila) 1.941
    1451603_at Rtbdn retbindin 2.32
    1453724_a_at Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 1 7.765
    Figure US20080187928A1-20080807-P00021
    Figure US20080187928A1-20080807-P00022
    Figure US20080187928A1-20080807-P00023
    Figure US20080187928A1-20080807-P00024
    Figure US20080187928A1-20080807-P00025
    1427285_s_at Surf4 surfeit gene 4 2.091
    1424737_at Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 2.685
    1431609_a_at Acp5 acid phosphatase 5, tartrate resistant 3.91
    1448538_a_at D4Wsu53e DNA segment, Chr 4, Wayne State University 53, 1.586
    expressed
    Figure US20080187928A1-20080807-P00026
    Figure US20080187928A1-20080807-P00027
    Figure US20080187928A1-20080807-P00028
    Figure US20080187928A1-20080807-P00029
    Figure US20080187928A1-20080807-P00030
    Figure US20080187928A1-20080807-P00031
    Figure US20080187928A1-20080807-P00032
    Figure US20080187928A1-20080807-P00033
    1425552_at Hip1r huntingtin interacting protein 1 related 1.75
    Figure US20080187928A1-20080807-P00034
    Figure US20080187928A1-20080807-P00035
    Figure US20080187928A1-20080807-P00036
    1429360_at Klf3 Kruppel-like factor 3 (basic) 1.901
    1449413_at Mpv17l Mpv17 transgene, kidney disease mutant-like 1.988
    1451667_at C530043G21Rik RIKEN cDNA C530043G21 gene 1.5
    1425865_a_at Lig3 ligase III, DNA, ATP-dependent 2.693
    1415994_at Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 2.941
    1417867_at Cfd complement factor D (adipsin) 2.828
    1451015_at Tkt transketolase 2.256
    1432344_a_at Aplp2 amyloid beta (A4) precursor-like protein 2 1.937
    1419487_at Mybph Myosin binding protein H 1.578
    MITOCHONDRIAL PROTEINS
    Figure US20080187928A1-20080807-P00037
    Figure US20080187928A1-20080807-P00038
    Figure US20080187928A1-20080807-P00039
    Figure US20080187928A1-20080807-P00040
    1415897_a_at Mgst1 microsomal glutathione S-transferase 1 1.916
    Figure US20080187928A1-20080807-P00041
    Figure US20080187928A1-20080807-P00042
    Figure US20080187928A1-20080807-P00043
    Figure US20080187928A1-20080807-P00044
    1423109_s_at Slc25a20 solute carrier family 25 (mitochondrial 1.865
    carnitine/acylcarnitine translocase), member 20
    Figure US20080187928A1-20080807-P00045
    Figure US20080187928A1-20080807-P00046
    Figure US20080187928A1-20080807-P00047
    Figure US20080187928A1-20080807-P00048
    OXYGEN CARRIERS
    1448348_at Gpiap1 GPI-anchored membrane protein 1 1.83
    1451203_at Mb myoglobin 1.578
    Figure US20080187928A1-20080807-P00049
    Figure US20080187928A1-20080807-P00050
    Figure US20080187928A1-20080807-P00051
    Figure US20080187928A1-20080807-P00052
    1428361_x_at Hba-a1 hemoglobin alpha, adult chain 1 1.632
    1417184_s_at Hbb-b2|Hbb-y hemoglobin, beta adult minor chain|hemoglobin Y, beta- 1.626
    like embryonic chain
    SIGNAL TRANSDUCTION
    Figure US20080187928A1-20080807-P00053
    Figure US20080187928A1-20080807-P00054
    Figure US20080187928A1-20080807-P00055
    Figure US20080187928A1-20080807-P00056
    1455918_at Adrb3 adrenergic receptor, beta 3 3.83
    Figure US20080187928A1-20080807-P00057
    Figure US20080187928A1-20080807-P00058
    Figure US20080187928A1-20080807-P00059
    Figure US20080187928A1-20080807-P00060
    1452097_a_at Dusp7 dual specificity phosphatase 7 1.661
    1419191_at Hipk3 homeodomain interacting protein kinase 3 1.694
    1448152_at Igf2 insulin-like growth factor 2 1.635
    1422313_a_at Igfbp5 insulin-like growth factor binding protein 5 1.772
    1428265_at Ppp2r1b protein phosphatase 2 (formerly 2A), regulatory subunit A 2.509
    (PR 65), beta isoform
    Figure US20080187928A1-20080807-P00061
    Figure US20080187928A1-20080807-P00062
    Figure US20080187928A1-20080807-P00063
    Figure US20080187928A1-20080807-P00064
    1449342_at Ptplb protein tyrosine phosphatase-like (proline instead of 2.38
    catalytic arginine), member b
    1422119_at Rab5b RAB5B, member RAS oncogene family 1.603
    Figure US20080187928A1-20080807-P00065
    Figure US20080187928A1-20080807-P00066
    Figure US20080187928A1-20080807-P00067
    Figure US20080187928A1-20080807-P00068
    1425444_a_at Tgfbr2 transforming growth factor, beta receptor II 2.13
    1431164_at Rragd Ras-related GTP binding D 2.101
    1420816_at Ywhag 3-monooxygenase/tryptophan 5-monooxygenase activation 1.87
    protein, gamma polypeptide
    STEROID BIOGENESIS
    1418601_at Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 3.862
    1426225_at Rbp4 retinol binding protein 4, plasma 2.065
    Figure US20080187928A1-20080807-P00069
    Figure US20080187928A1-20080807-P00070
    Figure US20080187928A1-20080807-P00071
    Figure US20080187928A1-20080807-P00072
    TRANSCRIPTION
    1417794_at Zfp261 zinc finger protein 261 1.847
    1424731_at Nle1 notchless homolog 1 (Drosophila) 1.831
    1454791_a_at Rbbp4 retinoblastoma binding protein 4 2.865
    1460281_at Asb15 ankyrin repeat and SOCS box-containing protein 15 1.78
    1449363_at Atf3 activating transcription factor 3 1.802
    1418982_at Cebpa CCAAT/enhancer binding protein (C/EBP), alpha 2.168
    1417065_at Egr1 early growth response 1 2.577
    Figure US20080187928A1-20080807-P00073
    Figure US20080187928A1-20080807-P00074
    Figure US20080187928A1-20080807-P00075
    Figure US20080187928A1-20080807-P00076
    1415899_at Junb Jun-B oncogene 1.792
    1421554_at Lmx1a LIM homeobox transcription factor 1 alpha 4.106
    1416959_at Nr1d2 nuclear receptor subfamily 1, group D, member 2(Reverb-b) 1.794
    1450749_a_at Nr4a2 nuclear receptor subfamily 4, group A, member 2 (NURR1) 1.776
    1460215_at Rpo1-4 RNA polymerase 1-4 2.498
    Figure US20080187928A1-20080807-P00077
    Figure US20080187928A1-20080807-P00078
    Figure US20080187928A1-20080807-P00079
    Figure US20080187928A1-20080807-P00080
    1420892_at Wnt7b wingless-related MMTV integration site 7B 4.449
    1423100_at Fos FBJ osteosarcoma oncogene 3.9
    TRANSPORT PROTEINS
    Figure US20080187928A1-20080807-P00081
    Figure US20080187928A1-20080807-P00082
    Figure US20080187928A1-20080807-P00083
    Figure US20080187928A1-20080807-P00084
    Figure US20080187928A1-20080807-P00085
    Figure US20080187928A1-20080807-P00086
    Figure US20080187928A1-20080807-P00087
    Figure US20080187928A1-20080807-P00088
    1425546_a_at Trf transferrin 1.907
    1423743_at Arcn1 archain 1 1.617
    1451771_at Tpcn1 two pore channel 1 2.842
    1416629_at Slc1a5 solute carrier family 1 (neutral amino acid transporter), 1.939
    member 5
    1420295_x_at Clcn5 chloride channel 5 2.333
    1417839_at Cldn5 claudin 5 1.545
    Figure US20080187928A1-20080807-P00089
    Figure US20080187928A1-20080807-P00090
    Figure US20080187928A1-20080807-P00091
    Figure US20080187928A1-20080807-P00092
    1434617_x_at 1810073N04Rik RIKEN cDNA 1810073N04 gene 2.326
    Data is average of N = 3 samples in each group (p < 0.05).
  • Surprisingly, the combination of GW1516 treatment and exercise established a unique gene expression pattern that was neither an amalgamation nor a complete overlap of the two interventions (FIG. 6). This unique signature included 48 new target genes (Table 2) not regulated by GW1516 and exercise alone and excluded 74 genes regulated by GW1516 or exercise alone (a selected few of which are shown in Table 3). This signature for the combination of GW1516 treatment and exercise (Table 2) was highly enriched in genes encoding regulatory enzymes for energy homeostasis, angiogenesis, oxygen transport, signal transduction, transcription and substrate transport, which are processes that are involved in endurance adaptation. Particularly, a predominance of genes involved in oxidative metabolism, is selectively up-regulated by combined exercise and drug treatment (see unbolded genes in Tables 1 and 2). In addition, several stress-related genes activated by either intervention, including heat shock proteins, metallothioneins and other stress biomarkers (Table 3) are not changed by the combination possibly reflecting a potential lessening of exercise-based damage.
  • TABLE 2
    Gene targets unique to combined GW1516 treatment and exercise training.
    DESCRIPTION LOCUS GW + Tr
    ANGIOGENESIS
    Figure US20080187928A1-20080807-P00093
    Figure US20080187928A1-20080807-P00094
    Figure US20080187928A1-20080807-P00095
    CARBOHYDRATE METABOLISM
    phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 3.518
    CYTOKINES
    interferon, alpha-inducible protein 27 Ifi27 1.714
    FAT METABOLISM
    adipose differentiation related protein Adrp 2.009
    stearoyl-Coenzyme A desaturase 2 Scd2 1.849
    acetyl-Coenzyme A acetyltransferase 2 Acat2 1.625
    ATP citrate lyase Acly 2.606
    adiponectin, C1Q and collagen domain containing Adipoq 3.082
    diacylglycerol O-acyltransferase 2 Dgat2 2.784
    Figure US20080187928A1-20080807-P00096
    Figure US20080187928A1-20080807-P00097
    Figure US20080187928A1-20080807-P00098
    lipase, hormone sensitive Lipe 3.032
    monoglyceride lipase Mgll 1.907
    resistin Retn 4.114
    CD36 antigen Cd36 1.584
    fatty acid binding protein 4, adipocyte Fabp4 2.189
    lipoprotein lipase Lpl 1.659
    HEAT SHOCK RESPONSE
    haptoglobin Hp 1.679
    MITOCHONDRIAL PROTEINS
    Figure US20080187928A1-20080807-P00099
    Figure US20080187928A1-20080807-P00100
    Figure US20080187928A1-20080807-P00101
    microsomal glutathione S-transferase 1 Mgst1 1.916
    OTHERS
    carbonic anhydrase 3 Car3 2.339
    cysteine dioxygenase 1, cytosolic Cdo1 3.266
    DNA segment, Chr 4, Wayne State University 53, expressed D4Wsu53e 1.586
    dynein cytoplasmic 1 intermediate chain 2 Dync1i2 1.705
    Figure US20080187928A1-20080807-P00102
    Figure US20080187928A1-20080807-P00103
    Figure US20080187928A1-20080807-P00104
    Kruppel-like factor 3 (basic) Klf3 1.901
    Figure US20080187928A1-20080807-P00105
    Figure US20080187928A1-20080807-P00106
    Figure US20080187928A1-20080807-P00107
    Figure US20080187928A1-20080807-P00108
    Figure US20080187928A1-20080807-P00109
    Figure US20080187928A1-20080807-P00110
    thyroid hormone responsive SPOT14 homolog (Rattus) Thrsp 2.685
    cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 2.941
    complement factor D (adipsin) Cfd 2.828
    transketolase Tkt 2.256
    OXYGEN CARRIERS
    GPI-anchored membrane protein 1 Gpiap1 1.83 
    Figure US20080187928A1-20080807-P00111
    Figure US20080187928A1-20080807-P00112
    Figure US20080187928A1-20080807-P00113
    PROLIFERATION & APOPTOSIS
    Figure US20080187928A1-20080807-P00114
    Figure US20080187928A1-20080807-P00115
    Figure US20080187928A1-20080807-P00116
    cell death-inducing DFFA-like effector c Cidec 4.771
    SIGNAL TRANSDUCTION
    Figure US20080187928A1-20080807-P00117
    Figure US20080187928A1-20080807-P00118
    Figure US20080187928A1-20080807-P00119
    dual specificity phosphatase 7 Dusp7 1.661
    homeodomain interacting protein kinase 3 Hipk3 1.694
    insulin-like growth factor binding protein 5 Igfbp5 1.772
    protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta Ppp2r1b 2.509
    isoform
    protein tyrosine phosphatase-like (proline instead of catalytic arginine), Ptplb 2.38 
    member b
    STEROID BIOGENESIS
    retinol binding protein 4, plasma Rbp4 2.065
    TRANSCRIPTION
    CCAAT/enhancer binding protein (C/EBP), alpha Cebpa 2.168
    nuclear receptor subfamily 1, group D, member 2(Reverb-b) Nr1d2 1.794
    TRANSPORT
    transferrin Trf 1.907
    archain 1 Arcn1 1.617
    solute carrier family 1 (neutral amino acid transporter), member 5 Slc1a5 1.939
    RIKEN cDNA 1810073N04 gene 1810073N04Rik 2.326
    Down-regulated genes are in bold italics. (N = 3, each pooled from 3 mice, p < 0.05).
  • TABLE 3
    Gene targets regulated by GW1516 treatment or exercise training alone.
    FEATURE LOCUS DESCRIPTION GW Tr GW + Tr
    Hspb1 heat shock protein 1 1.815 1.965 —
    1451284_at Hspb7 heat shock protein family, 7 (cardiovascular) 3.414 1.753 —
    1422943_a_at Dnaja1 DnaJ (Hsp40) homolog, subfamily A, 1 — 1.545 —
    1421290_at Hsp110 heat shock protein 110 — 1.587 —
    1416288_at Serpinh1 serine (or cysteine) peptidase inhibitor, H, 1 — 2.198 —
    1423566_a_at Dnaja4 DnaJ (Hsp40) homolog, subfamily A, 4 1.756 1.545 —
    1417872_at Mt1 metallothionein 1 2.364 — —
    1424596_s_at Mt2 metallothionein 2 2.151 — —
    1416157_at Cryab crystallin, alpha B 1.561 1.52  —
    1423139_at Crygf crystallin, gamma F 1.801 3.56  —
    1448830_at Smad3 MAD homolog 3 (Drosophila) 1.841 1.886 —
    1450637_a_at Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 4.235 — —
    1416029_at Tnfrsf12a TNF receptor superfamily, 12a 1.759 1.782 —
    1426464_at Jun Jun oncogene — 1.521 —
    Data is average of N = 3 samples in each group (p < 0.05)
  • Thirty-two percent of the GW+Tr-regulated genes encode enzymes of metabolic pathways such as fatty acid biosynthesis/storage (e.g., FAS, SCD 1 & 2), uptake [e.g., FAT/CD36, fatty acid binding proteins (FABP) and LPL] and oxidation [e.g., adiponectin, hormone sensitive lipase (HSL), PDK4, UCP3]; and carbohydrate metabolism [e.g., fructose bisphosphate 2 (FBP2), phosphoenolpyruvate carboxykinase 1 (PEPCK1), lactate dehydrogenase B], which along with oxygen transporters and mitochondrial proteins form the largest class of genes directly linked to muscle performance (Ikeda et al., Biochem. Biophys. Res. Commun. 296:395-400, 2002; Achten and Jeukendrup, Nutrition. 20:716-27, 2004; Hittel et al., J. Appl. Physiol. 98: 168-79, 2005; Civitarese et al., CellMetab. 4:75-87, 2006; Nadeau et al., FASEB J 17:1812-9, 2006; Kiens, Physiol. Rev. 86:205-43, 2006; Yamauchi et al., Nat. Med. 8:1288-95, 2006). Unexpectedly, established PPARα target genes fatty acyl-CoA oxidase and medium chain acyl-CoA dehydrogenase (MCAD) were not represented in the signature. All but four of these metabolic genes were induced, which indicated a general increase in oxidative capacity of skeletal muscle in exercise-trained subjects that received GW1516 treatment.
  • Other genes regulated in quadriceps muscle by the combination of exercise and GW1516 treatment encoded proteins involved in pathways such as angiogenesis (e.g., angiopoietin-like 4 protein/also a known regulator of lipid metabolism), (e.g., adrenergic receptor β3, insulin-like growth factor, insulin-like growth factor binding protein 5), transcription (e.g., C/EBP α, Reverb β, NURR1) and substrate transport (e.g., transferrin, chloride channel 5) (Nagase et al., J. Clin. Invest. 97:2898-904, 1996; Singleton and Feldman, Neurobiol. Dis. 8:541-54, 2001; Adams, J. Appl. Physiol. 93:1159-67, 2002; Centrella et al., Gene. 342: 13-24, 2004; Lundby et al., Eur. J. Appl. Physiol. 96: 363-9, 2005; Mahoney et al., FASEB J. 19:1498-500, 2005; Mahoney et al., Phys. Med. Rehabil. Clin. N. Am. 16: 859-73, 2005; Ramakrishnan et al., J. Biol. Chem. 280:8651-9, 2005). Without wishing to be bound to a particular theory, such other genes are likely involved, at least in part, in muscle remodeling and increased endurance observed in GW1516-treated, exercise-trained subjects.
  • Interestingly, comparative expression analysis of the 48 gene subset of the endurance signature (Table 2), but not of either intervention alone, revealed a striking similarity to ‘untrained’ VP16-PPARδ transgenic mice. This observation confirms the primary dependence of the 48 genes on PPARδ and indicates that exercise-generated signals may function to synergize PPARδ transcriptional activity to levels comparable to transgenic over-expression. Therefore, exercise cues along with PPARδ agonist may function to hyper-activate receptor transcriptional activity to re-program of adult muscle.
  • Genes and/or proteins uniquely affected (e.g., up-regulated or down-regulated or not substantially regulated) by exercise in the presence of one or more pharmaceutical agents (e.g., PPARδ agonists) can be used as markers, for instance, of “drug doping” in exercise-trained subjects (e.g., athletes). It is expected that the unique set of 48 genes regulated by GW+Tr, but not GW1516 treatment or exercise training alone, can be used to identify exercised subjects who have received a variety performance-enhancing drugs.
    • Example 6 PPARδ Directly Interacts with Exercise-Activated Kinases, p44/42 MAPK and AMPK
  • Exercise training is known to activate kinases, such as p44/42 MAPK and AMPK, which regulate gene expression in skeletal muscle (Chen et al., Diabetes, 52:2205-12, 2003; Goodyear et al., Am. J. Physiol., 271:E403-8, 1996). AMPK affects skeletal muscle gene expression and oxidative metabolism (Chen et al., Diabetes. 52: 2205-12, 2003, Reznick et al., J. Physiol. 574: 33-9, 2006). The interaction between exercise-regulated kinases and PPARδ signaling is described in this Example.
  • The levels of phospho-p44/42 MAPK and phospho-AMPK αsubunit and total AMPK were determined in protein homogenates of quadriceps muscle by Western blot. Antibodies specific for phospho-p44/42 MAPK, phospho- and total-AMPK α1 antibodies were obtained from Cell Signaling. The phospho-specific AMPK αc1 antibody recognizes the key activating threonine in the activation loop.
  • Active forms of both kinases (phospho-p44/42 MAPK and phospho-AMPK αsubunit) were expressed at higher levels in the quadriceps muscles of exercised mice relative to the sedentary controls (FIG. 7A). Previous reports claim that PPARδ is not required for activation of AMPK by GW1516 in cultured cells (Kramer et al, Diabetes. 54(4):1157-63, 2005 and Kramer et al., J. Biol. Chem. 282(27):19313-2, 2007). In contrast, it was observed that GW1516 failed to activate p44/42 or AMPK in either sedentary or trained muscles, which indicated that PPARδ-regulated effects are downstream to the exercise-induced signals that activate these kinases. Furthermore, AMPK appears to be constitutively active in muscles of VP16-PPARδ transgenic mice in absence of exercise or drug (FIG. 7B). These results indicate that synergy is AMPK and PPARδ co-dependent.
  • If synergy is AMPK and PPARδ co-dependent, selective co-activation of AMPK and PPARδ would induce gene expression changes that mimic those triggered by combined exercise and PPARδ as well as VP16-PPARδ over-expression. To demonstrate this, transcriptional changes induced in skeletal muscle by combined exercise and GW1516 treatment (as described in Example 5) were compared to that of combined AMPK activator (the cell permeable AMP analog AICAR; 250 mg/kg/day, i.p.) and GW1516 (5 mg/kg/day, oral gavage) treatment for 6 days. Genome analysis was performed using the methods described in Example 5.
  • Simultaneous GW1516 and AICAR treatment for 6 days created a unique gene expression signature in the quadriceps of untrained C57B1/6J mice (FIG. 8A, which includes target genes associated with translation, protein processing, amino acid metabolism, fat metabolism, oxygen carriers, carbohydrate metabolism, signal transduction, transcription, transport, steroid biogenesis, heat shock response, angiogenesis, proliferation and apoptosis, cytokines, contractile proteins, stress, and others) that shares 40% of the genes with that of combined GW1516 treatment and exercise (FIG. 8B). Classification of the 52 genes common to the two signatures (combined PPARδ activation and exercise or PPARδ and AMPK co-activation) (listed in Table 4) revealed that the majority of the targets were linked to oxidative metabolism.
  • TABLE 4
    Targets common to exercise-PPARδ and AMPK-PPARδ gene signatures.
    DESCRIPTION LOCUS Tr + GW AI + GW
    ANGIOGENESIS
    angiopoietin-like 4 Angptl4 5.495 2.917
    APOPTOSIS
    cell death-inducing DFFA-like effector c Cidec 4.771 1.838
    cell death-inducing DNA fragmentation factor, alpha Cidea 49.625 1.842
    subunit-like effector A
    CARBOHYDRATE METABOLISM
    lactate dehydrogenase B Ldhb 2.541 1.917
    fructose bisphosphatase 2 Fbp2 2.808 2.478
    FAT METABOLISM
    stearoyl-Coenzyme A desaturase 1 Scd1 6.494 1.78
    fatty acid binding protein 3, muscle and heart Fabp3 1.833 1.5
    pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 2.27 2.486
    uncoupling protein 3 (mitochondrial, proton carrier) Ucp3 2.943 2.792
    adiponectin, C1Q and collagen domain containin Adipoq 3.082 1.56
    diacylglycerol O-acyltransferase 2 Dgat2 2.784 2.14
    solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 3.58 2.195
    lipase, hormone sensitive Lipe 3.032 1.746
    solute carrier family 25 (mitochondrial Slc25a20 1.704 1.697
    carnitine/acylcarnitine translocase), member 20
    CD36 antigen Cd36 1.584 1.513
    phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 3.518 1.781
    fatty acid synthase Fasn 6.323 2.24
    fatty acid binding protein 4, adipocyte Fabp4 2.189 1.81
    monoglyceride lipase Mgll 1.907 1.51
    acetyl-Coenzyme A acetyltransferase 2 Acat2 1.625 1.563
    acetyl-Coenzyme A dehydrogenase, long-chain Acadl 2.549 1.992
    resistin Retn 4.114 1.756
    malonyl-CoA decarboxylase Mlycd 1.781 1.962
    transketolase Tkt 2.256 1.983
    ATP citrate lyase Acly 2.458 1.91
    HEAT SHOCK
    heat shock protein 90 kDa alpha (cytosolic), class A member 1 Hsp90aa1 1.455 0.616
    DnaJ (Hsp40) homolog, subfamily B, member 1 Dnajb1 3.59 0.604
    CYTOKINES
    interferon, alpha-inducible protein 27 Ifi27 1.714 1.537
    OTHER
    sarcolipin Sln 0.363 4.576
    thyroid hormone responsive SPOT14 homolog (Rattus) Thrsp 2.685 1.766
    RIKEN cDNA 2310076L09 gene 2310076L09Rik 1.868 2.117
    myosin, heavy polypeptide 2, skeletal muscle, adult Myh2 2.194 1.797
    surfeit gene 4 Surf4 2.091 0.654
    acid phosphatase 5, tartrate resistant Acp5 3.91 1.477
    serine (or cysteine) proteinase inhibitor, clade A, member 1a Serpina1a 0.396 3.891
    cysteine dioxygenase 1, cytosolic Cdo1 3.266 1.678
    erythroid differentiation regulator 1 0.619 1.805
    RIKEN cDNA 1810073N04 gene 1810073N04Rik 2.326 1.628
    superoxide dismutase 3, extracellular Sod3 1.606 1.617
    complement factor D (adipsin) Cfd 2.828 1.5
    cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 2.941 1.743
    catalase Cat 1.728 1.902
    early growth response 1 Egr1 2.577 0.65
    OXYGEN CARRIER
    hemoglobin, beta adult minor chain|hemoglobin Y, beta- Hbb-b2|Hbb-y 1.626 1.503
    like embryonic chain
    STEROID BIOGENESIS
    retinol binding protein 4, plasma Rbp4 2.065 2.225
    SIGNAL TRANSDUCTION
    adreneyrgic receptor, beta 3 Adrb3 3.83 1.56
    protein tyrosine phosphatase-like (proline instead of catalytic Ptplb 2.38 1.569
    arginine), member b
    dual specificity phosphatase 7 Dusp7 1.661 1.672
    TRANSCRIPTION
    nuclear receptor subfamily 4, group A, member 2 Nr4a2 1.776 0.437
    TRANSPORT
    solute carrier family 1 (neutral amino acid transporter), Slc1a5 1.939 1.511
    member 5
    two pore channel 1 Tpcn1 2.842 1.487
    seminal vesicle secretion 5 Svs5 0.095 2.243
    Data is average of N = 3 samples in each group (p < 0.05).
  • Quantitative expression analysis of selective oxidative genes (eight of those listed in Table 4) was determined in quadriceps of mice treated with vehicle (V), GW1516 (GW, 5 mg/kg/day), AICAR (AI, 250 mg/kg/day) and the combination of the two drugs (GW+AI) for 6 days using the methods described in Example 1. As shown in FIGS. 9A-H, several of these biomarkers including PDK4, SCD1, ATP citrate lyase, HSL, mFABP and LPL were induced in a synergistic fashion by GW1516 and AICAR in the quadriceps (FIGS. 9C-9H). Intriguingly, synergism was undetectable in UCP3 and mCPT I (FIGS. 9A and B). These genes were induced in quadriceps of untrained VP16-PPARδ mice, where AMPK is constitutively active (Table 5).
  • TABLE 5
    Selective oxidative genes induced in muscle by combined
    PPARδ and AMPK activation as well as
    VP16-PPARδ over-expression
    Description Locus GW + AI VP-PPARδ
    ATP citrate lyase Acly 1.648 3.095
    carnitine palmitoyltransferase 1b, Cpt1b 1.371 1.678
    muscle
    fatty acid binding protein 3, muscle Fabp3 1.447 5.904
    and heart
    fatty acid synthase Fasn 2.24 2.749
    lipoprotein lipase Lpl 1.113 1.72
    lipase, hormone sensitive Lipe 1.746 2.203
    pyruvate dehydrogenase kinase, Pdk4 2.486 5.06
    isoenzyme 4
    stearoyl-Coenzyme A desaturase 1 Scd1 1.78 7.353
    uncoupling protein 3 Ucp3 2.792 4.107
  • Collectively, these results demonstrate that while interaction between AMPK and PPARδ may substantially contribute to re-programming of the skeletal muscle transcriptome during exercise, additional changes may involve cross-talk between other components of the exercise signaling network and PPARδ.
  • In summary, PPARδ and exercise synergistically regulate running endurance. Although not bound by theory, kinase activation may influence PPARδ signaling during exercise in establishing an “endurance gene expression signature” that effectively enhances performance.
    • Example 7 AMPK Increases Transcriptional Activation by PPARδ
  • The genetic synergism described in Example 6 indicates that AMPK directly regulates the transcriptional activity of PPARδ in skeletal muscles. To demonstrate this, an analysis of the effects of GW1516 and AICAR on gene expression in primary muscle cells isolated from wild type and PPARδ null mice was performed.
  • Primary muscle cells were isolated from wild type and PPARδ null mice as previously described (Rando and Blau, J. Cell. Biol. 125(6):1275-87, 1994). Skeletal muscle C2C12 cells were cultured in DMEM containing 20% serum and penicillin/streptomycin cocktail. For differentiation, cells at 80% confluence were switched to a differentiation medium (DMEM+2% serum) for 4 days to obtain differentiated myotubules. Cells were treated with vehicle, GW1516, AICAR, or GW1516+AICAR (GW: 0.1 μM; AICAR: 500 μM) for 24 hours. RNA expression of UCP3, PDK4, LPL, and HSL was determined using real time quantitative PCR as described in Example 1.
  • As shown in FIGS. 10A-D, synergism is dependent on PPARδ and lost in the null cells. Similar synergistic regulation of gene expression by GW1516 and AICAR was also observed in differentiated C2C12 cells. These results show that AMPK activation may enhance ligand-dependent transcriptional effects of PPARδ in muscles.
  • To more directly address this, reporter gene expression assays were utilized. AD 293 cells were cultured in DMEM containing 10% serum and an antibiotic cocktail. Cells were transfected with one or more of CMX-Flag, CMX-Flag PPARδ, CMX-Tk-PPRE, or CMX-βGAL, or an hAMPK (α1 and α2 subunits, Origene) expression vector using Lipofectamine™ 2000 in accordance with the manufacturer's instructions. Anti-Flag antibody-conjugated beads were incubated overnight at 4° C. with lysates from transfected cells. Flag-tagged protein or protein complexes were immunoprecipitated by separating the beads from non-bound materials. The beads were washed in ice-cold lysis buffer followed by extraction in Laemmli buffer. For co-immunoprecipitation experiments SDS was excluded from the lysis buffer. Western blotting was performed with antibodies specific for the Flag tag or AMPK α subunit(s).
  • Co-transfection of either catalytic AMPK α1 or α2 subunits, but not control vector, with PPARδ increased the basal (FIG. 10E) and GW1516-dependent transcriptional activity (FIG. 10F) of PPARδ in inducing a PPRE-driven reporter gene in AD293 cells. AMPK over-expression or GW1516 treatment did not change reporter activity in transfections excluding the PPARδ expression vector negating the possibility of an effect via RXR. Additional results indicate that AMPK may modulate PPARδ transcriptional activity by directly interacting with the receptor. In AD293 cells co-transfected with Flag-PPARδ and with either catalytic AMPK α1 or α2 subunits, both of the subunits co-immunoprecipitated as a complex with Flag-PPARδ (FIG. 10G). Furthermore, Flag-PPARδ also co-immunoprecipitated endogenous AMPKα subunits from AD293 cells confirming a direct physical interaction between the nuclear receptor and the kinase (FIG. 10H). Despite physical interaction, AMPK failed to increase PPARδ phosphorylation.
  • While potential AMPK phosphorylation sites were found in PPARδ, none of these sites were phosphorylated by AMPK in in vitro kinase assays. This was further confirmed by measuring the p32 labeling of PPARδ in AD 293 cells in the presence or absence of AMPK. AD 293 cells were transfected with PPARδ and hAMPk (α1 or α2 subunit) expression vectors as described above. Forty-eight hours after transfection, the cells were washed three times with phosphate-free DMEM and incubated with 32P-orthophosphate in phosphate-free DMEM for 20 hours (100 μCi/5 ml). Cells were washed three times with ice-cold phosphate-free DMEM and lysed in ice-cold lysis buffer.
  • As shown in FIG. 10I, overall PPARδ phosphorylation is not increased by AMPK in vivo. However, co-transfection of AMPKα2 and co-activator PGC1α (a known phosphorylation target of AMPK) co-operatively interact to further induce both the basal and ligand-dependent transcriptional activity of PPARδ (FIG. 10J). Strikingly, no significant physical interaction between Flag-PGC1α and AMPK (FIG. 10K) was detected, both of which independently interacted with PPARδ. Collectively, these observations indicate that AMPK may be present in a transcriptional complex with PPARδ where it can potentiate receptor activity via direct protein-protein interaction and/or by phosphorylating co-activators such as PGC1α.
  • These results indicate that AMPK directly interacts with PPARδ and dramatically increases basal and ligand-dependent transcription via the receptor. Despite physical interaction, AMPK does not phosphorylate PPARδ. AMPK and its substrate PGC1α synergistically increased PPARδ transcription, indicating indirect regulation of receptor by AMPK via co-regulator modification.
  • The conclusion that exercise-activated AMPK interacts with PPARδ in regulating gene expression in vivo is strengthened by the observation that treatment of animals with AICAR (AMPK activator) and GW1516 creates a gene signature in skeletal muscle that replicates up to 40% of the genetic effects of combined exercise and GW1516 treatment (see Table 4). Moreover, several candidate genes from this signature are synergistically induced by GW1516 and AICAR in wild type but not in PPARδ null primary muscle cells, demonstrating that the interactive effects of the two drugs are mediated through PPARδ. While 45% of the commonly regulated genes are linked to oxidative metabolism, additional common targets relevant to muscle performance include angiogenic, signal transduction and glucose sparing genes (Table 4). It is possible that the portion of the PPARδ-exercise signature that is independent of PPARδ-AMPK interaction (FIG. 8B) may depend on cross-talk between the receptor and other exercise signal transducers such as MAPK, calcineurin/NFAT and SIRT 1. These possibilities are summarized in FIG. 10L, where AMPK and additional components of the signaling network are proposed to interact with liganded PPARδ to generate a muscle endurance gene signature and enhanced endurance adaptation.
  • In summary, it is shown herein that synthetic PPARδ activation alone induces a set of genomic changes that fail to alter the preset muscle architecture and endurance levels in adult mice. However, the combination of PPARδ activation with exercise brings about novel transcriptional changes, potentially via interaction with kinases such as AMPK (as depicted in FIG. 10L), re-setting the muscle transcriptome to a phenotype that dramatically enhances muscle performance.
    • Example 8 Enhancing Exercise Effect in a Subject
  • This example describes methods that can be used to increase or enhance an exercise in a healthy mammalian subject. Although specific conditions are described, one skilled in the art will appreciate that minor changes can be made to such conditions.
  • Healthy adult human subjects perform aerobic exercise (e.g., running) for at least 30 minutes (e.g., 30-90 minutes) for at least 3-4 days per week (e.g., 3-7 days per week) for at least 2 weeks (e.g., at least 4-12 weeks). The exercise is performed at 40%-50% maximal heart rate, 50%-60% maximal heart rate, 60%-70% maximal heart rate, or 75%-80% maximal heart rate, where maximum heart rate for a human subject is calculated as: 220 bps−(age of the subject).
  • During or after performing aerobic exercise as described above, the subjects are orally administered GW1516 [(2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfanyl)phenoxy)acetic acid] at a dose of 1 to 20 mg per day, such as 2.5 or 10 mg per day. Subjects can continue to perform aerobic exercise while receiving GW1516. The subject can receive GW1516 for a period of at least 2 weeks, such as at least 4 weeks.
  • The exercise effect achieved in the treated subjects (e.g., running endurance) can be compared to such an effect in untreated subjects. Exercise effect can be measured using methods known in the art, such as measuring aerobic or running endurance (for example measuring distance run until exhaustion or amount of time to run a particular distance). In some instances, the exercise effect of interest is increased in treated subjects by at least 5%, such as at least 10% as compared to untreated subjects.
    • Example 9 Identifying Performance Enhancing Substances in an Exercise-Trained Subject
  • This example describes methods that can be used to identify performance-enhancing substances in an exercised-trained subject.
  • A biological sample obtained from a healthy adult human is analyzed to determine if the subject is taking a PES (e.g., GW1516) by analyzing expression of one or more of the molecules (nucleic acids or proteins) listed in Table 2 or Table 4. Suitable biological samples include samples containing genomic DNA or RNA (including mRNA) or proteins obtained from cells of a subject, such as those present in peripheral blood, urine, saliva, tissue biopsy, or buccal swab. For example, a biological sample of the subject can be assayed for a change in expression (such as an increase or decrease) of any combination of at least four molecules (nucleic acids or proteins) listed in Table 2 or 4, such as any combination of at least 10, at least 20, at least 30, or at least 40 of those listed in Table 2 or 4, for example all of those listed in Table 2 or 4.
    • Analyzing Nucleic Acid Molecules
  • Methods of isolating nucleic acid molecules from a biological sample are routine, for example using PCR to amplify the molecules from the sample, or by using a commercially available kit to isolate mRNA or cDNA. However, nucleic acids need not be isolated prior to analysis. Nucleic acids can be contacted with an oligonucleotide probe that will hybridize under stringent conditions with one or more nucleic acid molecule listed in Table 2 or 4. The nucleic acids which hybridize with the probe are then detected and quantified. The sequence of the oligonucleotide probe can bind specifically to a nucleic acid molecule represented by the sequences listed in Table 2 or 4.
  • Increased or decreased expression of the molecules listed in Table 2 or 4 can be detected by measuring the cellular levels of mRNA. mRNA can be measured using techniques well known in the art, including for instance Northern analysis, RT-PCR and mRNA in situ hybridization. Details of mRNA analysis procedures can be found, for instance, in provided examples and in Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
  • Oligonucleotides specific to sequences listed in Table 2 or 4 can be chemically synthesized using commercially available machines. These oligonucleotides can then be labeled, for example with radioactive isotopes (such as 32P) or with non-radioactive labels such as biotin (Ward and Langer et al., Proc. Natl. Acad. Sci. USA 78:6633-57, 1981) or a fluorophore, and hybridized to individual DNA samples immobilized on membranes or other solid supports by dot-blot or transfer from gels after electrophoresis. These specific sequences are visualized, for example by methods such as autoradiography or fluorometric (Landegren et al., Science 242:229-37, 1989) or calorimetric reactions (Gebeyehu et al., Nucleic Acids Res. 15:4513-34, 1987).
    • Analyzing Proteins
  • Proteins in the biological sample can also be analyzed. In some examples, proteins are isolated using routine methods prior to analysis.
  • In one example, surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry is used to detect changes in differential protein expression, for example by using the ProteinChip™ (Ciphergen Biosystems, Palo Alto, Calif.). Such methods are well known in the art (for example see U.S. Pat. No. 5,719,060; U.S. Pat. No. 6,897,072; and U.S. Pat. No. 6,881,586). SELDI is a solid phase method for desorption in which the analyte is presented to the energy stream on a surface that enhances analyte capture or desorption. Therefore, in a particular example, the chromatographic surface includes antibodies that recognize proteins listed in Table 2 or 4. Antigens present in the sample can recognize the antibodies on the chromatographic surface. The unbound proteins and mass spectrometric interfering compounds are washed away and the proteins that are retained on the chromatographic surface are analyzed and detected by SELDI-TOF. The MS profile from the sample can be then compared using differential protein expression mapping, whereby relative expression levels of proteins at specific molecular weights are compared by a variety of statistical techniques and bioinformatic software systems.
  • In another examples, the availability of antibodies specific to the molecules listed in Table 2 or 4 facilitates the detection and quantification of proteins by one of a number of immunoassay methods that are well known in the art, such as those presented in Harlow and Lane (Antibodies, A Laboratory Manual, CSHL, New York, 1988). Methods of constructing such antibodies are known in the art. Any standard immunoassay format (such as ELISA, Western blot, or RIA assay) can be used to measure protein levels. Immunohistochemical techniques can also be utilized for protein detection and quantification. For example, a tissue sample can be obtained from a subject, and a section stained for the presence of the desired protein using the appropriate specific binding agents and any standard detection system (such as one that includes a secondary antibody conjugated to horseradish peroxidase). General guidance regarding such techniques can be found in Bancroft and Stevens (Theory and Practice of Histological Techniques, Churchill Livingstone, 1982) and Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1998).
  • For the purposes of detecting or even quantifying protein or nucleic acid expression, expression in the test sample can be compared to levels found in cells from a subject who has not taken a PES. Alternatively, the pattern of expression identified in the test subject can be compared to that shown in Table 2 or 4.
  • For example, if the test sample shows a pattern of expression similar to that in Table 2 or 4 (e.g. the genes shown as upregulated and downregulated in Table 2 or 4 are observed in the subject to be upregulated and downregulated, respectively), this indicates that the subject is taking a PES, such as a PPARδ agonist (e.g. GW1516). In contrast, If the pattern of expression identified in the test subject is different to that shown in Table 2 or 4 (e.g. the genes shown as upregulated and downregulated in Table 2 or 4 are observed in the subject to be not differentially expressed or show a different pattern of regulation), this indicates that the subject is not taking a PES, such as a PPARδ agonist (e.g. GW1516).
  • A significant increase in the non-bolded proteins listed in Table 2 in the cells of a test subject compared to the amount of the same protein found in normal human cells is usually at least 2-fold, at least 3-fold, at least 4-fold or greater difference. Substantial overexpression of the non-bolded proteins listed in Table 2 in the subject's sample can be indicative of the subject taking a PES. Similarly, a significant decrease in the bolded proteins listed in Table 2 in the cells of a test subject compared to the amount of the same protein found in normal human cells is usually at least 2-fold, at least 3-fold, at least 4-fold or greater difference. Substantial underexpression of the bolded proteins listed in Table 2 in the subject's sample can be indicative of the subject taking a PES.
  • While this disclosure has been described with an emphasis upon particular embodiments, it will be obvious to those of ordinary skill in the art that variations of the particular embodiments may be used and it is intended that the disclosure may be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications encompassed within the spirit and scope of the disclosure as defined by the following claims:

Claims (25)

1. A method for enhancing an exercise effect in a subject, comprising
performing by a subject physical activity sufficient to produce an exercise effect; and
administering to the subject an effective amount of a PPARδ agonist, thereby enhancing the exercise effect in the subject.
2. The method of claim 1, wherein the subject is a mammal.
3. The method of claim 2, wherein the subject is a racing mammal.
4. The method of claim 3, wherein the racing mammal is a horse, a dog, or a human.
5. The method of claim 1, wherein the subject is an adult.
6. The method of claim 1, wherein the subject is an exercise-trained subject.
7. The method of claim 1, wherein the PPARδ agonist is GW1516.
8. The method of claim 1, wherein the PPARδ agonist is administered on the same day(s) on which the physical activity is performed.
9. The method of claim 1, wherein the physical activity is an aerobic exercise.
10. The method of claim 9, wherein the aerobic exercise is running.
11. The method of claim 9, wherein the exercise effect is improved running endurance.
12. The method of claim 11, wherein improved running endurance is improved running distance or improved running time or a combination thereof.
13. The method of claim 1, wherein the effective amount is from about 5 mg/kg per day to about 10 mg/kg per day in a single dose or in divided doses.
14. The method of claim 1, wherein administration comprises oral administration, intravenous injection, intramuscular injection, or subcutaneous injection.
15. The method of claim 1, wherein the exercise effect is increased fatty acid oxidation in at least one skeletal muscle of the subject.
16. The method of claim 1, wherein the exercise effect is body fat reduction.
17. The method of claim 16, wherein the body fat is white adipose tissue.
18. A method for identifying the use of performance-enhancing substances in an exercise-trained subject comprising determining in a biological sample taken from an exercise-trained subject the expression of one or more molecules listed in Tables 2 or 4.
19. The method of claim 18, wherein:
(i) expression is upregulated in one or more of adipose differentiation related protein; stearoyl-Coenzyme A desaturase 2; acetyl-Coenzyme A acetyltransferase 2; ATP citrate lyase; adiponectin, C1Q and collagen domain containing; diacylglycerol O-acyltransferase 2; lipase, hormone sensitive; monoglyceride lipase; resistin; CD36 antigen; fatty acid binding protein 4, adipocyte; lipoprotein lipase; microsomal glutathione S-transferase 1; GPI-anchored membrane protein 1; dual specificity phosphatase 7; homeodomain interacting protein kinase 3; insulin-like growth factor binding protein 5; protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; protein tyrosine phosphatase-like (proline instead of catalytic arginine); member b; CCAAT/enhancer binding protein (C/EBP), alpha; nuclear receptor subfamily 1, group D, member 2(Reverb-b); transferring; archain 1; solute carrier family 1 (neutral amino acid transporter), member 5; RIKEN cDNA 1810073N04 gene; haptoglobin; retinol binding protein 4, plasma; phosphoenolpyruvate carboxykinase 1, cytosolic; cell death-inducing DFFA-like effector c; interferon, alpha-inducible protein 27; carbonic anhydrase 3; cysteine dioxygenase 1, cytosolic; DNA segment, Chr 4, Wayne State University 53, expressed; dynein cytoplasmic 1 intermediate chain 2; Kruppel-like factor 3 (basic); thyroid hormone responsive SPOT14 homolog (Rattus); cytochrome P450, family 2, subfamily e, polypeptide 1; complement factor D (adipsin); and/or transketolase; or
(ii) expression is downregulated in one or more of gamma-glutamyl carboxylase; 3-oxoacid CoA transferase 1; solute carrier family 38, member 4; annexin A7; CD55 antigen, RIKEN cDNA 1190002H23 gene; fusion, derived from t(12;16) malignant liposarcoma (human); lysosomal membrane glycoprotein 2; and/or neighbor of Punc E11; or
(iii) a combination of (i) and (ii).
20. The method of claim 18, wherein determining expression comprises determining protein expression, determining expression of a gene encoding the protein, or a combination thereof.
21. The method of claim 20, comprising determining expression of a gene encoding the protein.
22. The method of claim 18, wherein the biological sample is a skeletal muscle biopsy.
23. A method of identifying an agent having potential to enhance exercise performance in a subject, comprising:
providing a first component comprising a PPARδ receptor or an AMPK-binding fragment thereof;
providing a second component comprising an AMP-activated protein kinase (AMPK), AMPKα1, AMPKα2, or a PPARδ-binding fragment of any thereof;
contacting the first component and the second component with at least one test agent under conditions that would permit the first component and the second component to specifically bind to each other in the absence of the at least one test agent; and
determining whether the at least one test agent affects specific binding of the first component and the second component to each other, wherein an effect on specific binding identifies the at least one test agent as an agent having potential to enhance exercise performance in a subject.
24. The method of claim 23, further comprising providing a third component comprising a PPARδ agonist; and contacting the first component, second component, and third component.
25. The method of claim 24, wherein the PPARδ agonist is GW1516.
US11/966,851 2006-12-29 2007-12-28 Methods for enhancing exercise performance Abandoned US20080187928A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/966,851 US20080187928A1 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance
PCT/US2008/088466 WO2009086526A2 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
CA2710764A CA2710764A1 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
US12/810,123 US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
AU2008345009A AU2008345009A1 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
JP2010540930A JP2011507970A (en) 2007-12-28 2008-12-29 Methods for improving muscle capacity and tension
EP08866040A EP2234622A4 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
US13/899,292 US20140005238A1 (en) 2006-12-29 2013-05-21 Methods for enhancing exercise performance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88277406P 2006-12-29 2006-12-29
US11/966,851 US20080187928A1 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/089124 Continuation-In-Part WO2008083330A2 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/810,123 Continuation-In-Part US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
US12/810,123 Division US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
US13/899,292 Division US20140005238A1 (en) 2006-12-29 2013-05-21 Methods for enhancing exercise performance

Publications (1)

Publication Number Publication Date
US20080187928A1 true US20080187928A1 (en) 2008-08-07

Family

ID=39589228

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/966,851 Abandoned US20080187928A1 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance
US12/810,123 Active 2030-06-21 US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
US13/899,292 Abandoned US20140005238A1 (en) 2006-12-29 2013-05-21 Methods for enhancing exercise performance

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/810,123 Active 2030-06-21 US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
US13/899,292 Abandoned US20140005238A1 (en) 2006-12-29 2013-05-21 Methods for enhancing exercise performance

Country Status (6)

Country Link
US (3) US20080187928A1 (en)
EP (1) EP2114396A4 (en)
JP (1) JP2010514804A (en)
AU (1) AU2007341981A1 (en)
CA (1) CA2672420A1 (en)
WO (1) WO2008083330A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306830A1 (en) * 2007-06-07 2008-12-11 Cliquality, Llc System for rating quality of online visitors
WO2010029527A1 (en) * 2008-09-11 2010-03-18 University College Dublin - National University Of Ireland, Dublin A method for predicting athletic performance potential
US20110097427A1 (en) * 2009-10-27 2011-04-28 Shyam Ramakrishnan Molecular Targets and Dietary Modulators of Exercise-Induced Muscle Damage
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
US20140147431A1 (en) * 2010-09-20 2014-05-29 The Regents Of The University Of California Compositions and Methods for Modulating Desnutrin-Mediated Adipocyte Lipolysis
US20150072985A1 (en) * 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
US9249470B2 (en) 2008-09-11 2016-02-02 University College Dublin-National University of Ireland Method for predicting the athletic performance potential of a subject
US20180067131A1 (en) * 2011-01-08 2018-03-08 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure
CN112912069A (en) * 2018-10-23 2021-06-04 国立研究开发法人科学技术振兴机构 PPAR delta activators
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710764A1 (en) * 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
US8930490B2 (en) 2009-01-27 2015-01-06 Apple Inc. Lifestream annotation method and system
US20120111936A1 (en) * 2009-01-27 2012-05-10 Brown Stephen J Semantic Note Taking System
US8645383B2 (en) 2009-01-27 2014-02-04 Stephen J. Brown Content management system using sources of experience data and modules for quantification and visualization
CN103298469A (en) 2010-08-31 2013-09-11 首尔大学校产学协力财团 Use of the fetal reprogramming of a PPAR delta agonist
US9005909B2 (en) * 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US20150005254A1 (en) 2011-06-27 2015-01-01 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
RU2017129378A (en) * 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. COMPOSITIONS AND METHODS FOR MODULATING METABOLIC WAYS
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CA2891335C (en) 2012-11-13 2021-05-04 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US10632175B2 (en) 2013-03-04 2020-04-28 Joslin Diabetes Center, Inc. Exercise-regulated adipokines as therapy for diabetes management
US9585876B2 (en) 2013-03-15 2017-03-07 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10487690B2 (en) 2014-08-18 2019-11-26 Rohr, Inc. Actively controlled cooling air exhaust door on an aircraft engine nacelle
US10780061B2 (en) 2014-09-26 2020-09-22 Daegu Gyeongbuk Institute Of Science And Technology Composition comprising farnesol and use thereof
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
JP6539511B2 (en) * 2015-06-17 2019-07-03 花王株式会社 Marker for judgment of motor function
RU2642673C1 (en) * 2017-06-27 2018-01-25 Ольга Александровна Логинова Composition for increasing operability and physical durability

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6534487B1 (en) * 1999-08-03 2003-03-18 Childrens Hospital Los Angeles Methods for suppressing appetite and enhancing exercise and recovery
US6713082B2 (en) * 1999-12-30 2004-03-30 Quest International B.V. Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US20050233328A1 (en) * 2001-12-03 2005-10-20 Constance Berghs Methods of identifying compounds that modulate protein activity
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20070248698A1 (en) * 2003-12-30 2007-10-25 Md Bioalpha Co., Ltd., Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5861274A (en) * 1990-03-22 1999-01-19 The Salk Institute For Biological Studies Nucleic acids encoding peroxisome proliferator-activated receptor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
US5776672A (en) * 1990-09-28 1998-07-07 Kabushiki Kaisha Toshiba Gene detection method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ES2201077T3 (en) * 1993-05-28 2004-03-16 Baylor College Of Medicine METHOD AND SPECTROMETER OF MASSES FOR DESORTION AND IONIZATION OF ANALYTS.
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
EP0769052A2 (en) * 1994-07-01 1997-04-23 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU721452B2 (en) 1996-02-02 2000-07-06 Merck & Co., Inc. Antidiabetic agents
ES2241036T3 (en) 1996-02-02 2005-10-16 MERCK &amp; CO., INC. PROCESS OF TREATMENT OF DIABETES AND ASSOCIATED PATHOLOGICAL STATES.
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
EP0882029B1 (en) 1996-02-02 2003-04-02 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
ES2258799T3 (en) 1996-12-23 2006-09-01 MERCK &amp; CO., INC. ANTIDIABETIC AGENTS.
US6090556A (en) * 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP3784162B2 (en) * 1998-01-14 2006-06-07 株式会社日立製作所 DNA fragment analysis
US6911307B1 (en) * 1998-12-08 2005-06-28 Proteus S.A. Method of detection in vitro of a target substance in a sample comprising the labelling of said substance with a reporter gene and with the sequences necessary for the expression of said reporter gene in vitro
JP3924976B2 (en) * 1999-02-17 2007-06-06 味の素株式会社 Gene frequency analysis method
WO2000066265A2 (en) * 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1089211B1 (en) * 1999-09-30 2005-11-16 Hitachi Software Engineering Co., Ltd. Method and apparatus for displaying gene expression patterns
AU2001269785A1 (en) 2000-06-09 2001-12-17 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids
US6811977B2 (en) * 2000-07-27 2004-11-02 California Institute Of Technology Rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping
WO2002009726A1 (en) * 2000-07-31 2002-02-07 Trustees Of Boston University Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
JP4505776B2 (en) * 2001-01-19 2010-07-21 凸版印刷株式会社 Gene detection system, gene detection apparatus equipped with the same, detection method, and gene detection chip
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
US6816790B2 (en) * 2002-12-31 2004-11-09 International Business Machines Corporation Method and apparatus for determining gene expression levels
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
AU2005238163A1 (en) 2004-04-28 2005-11-10 F. Hoffmann-La Roche Ag Pyrazole phenyl derivatives as PPAR activators
MXPA06013195A (en) * 2004-05-14 2007-02-14 Irm Llc Compounds and compositions as ppar modulators.
EP1781101A2 (en) 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
US7405236B2 (en) 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2006041197A1 (en) 2004-10-14 2006-04-20 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
DE102005020229A1 (en) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Use of indoline-phenylsulfonamide derivatives
US20070054965A1 (en) * 2005-09-05 2007-03-08 Kao Corporation AMPK activating agent
KR100826108B1 (en) 2006-08-04 2008-04-29 한국화학연구원 Furan-2-carboxylic acid?derivatives and process for the preparation thereof
US8519145B2 (en) * 2006-12-02 2013-08-27 Seoul National University Industry Foundation Aryl compounds as PPAR ligands and their use
EP2114396A4 (en) * 2006-12-29 2010-03-10 Salk Inst For Biological Studi Methods for enhancing exercise performance
CA2710764A1 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6534487B1 (en) * 1999-08-03 2003-03-18 Childrens Hospital Los Angeles Methods for suppressing appetite and enhancing exercise and recovery
US6713082B2 (en) * 1999-12-30 2004-03-30 Quest International B.V. Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US20050233328A1 (en) * 2001-12-03 2005-10-20 Constance Berghs Methods of identifying compounds that modulate protein activity
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20070248698A1 (en) * 2003-12-30 2007-10-25 Md Bioalpha Co., Ltd., Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kim et al, Diabetes, Obesity and Metabolism, 2011, 13, 584-593 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
US9192601B2 (en) 2006-12-29 2015-11-24 Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
US20080306830A1 (en) * 2007-06-07 2008-12-11 Cliquality, Llc System for rating quality of online visitors
US9249470B2 (en) 2008-09-11 2016-02-02 University College Dublin-National University of Ireland Method for predicting the athletic performance potential of a subject
WO2010029527A1 (en) * 2008-09-11 2010-03-18 University College Dublin - National University Of Ireland, Dublin A method for predicting athletic performance potential
US20110223600A1 (en) * 2008-09-11 2011-09-15 Emmeline Hill Method For Predicting Athletic Performance Potential
US8771943B2 (en) 2008-09-11 2014-07-08 University College Dublin—National University of Ireland, Dublin Method for predicting athletic performance potential
US20110097427A1 (en) * 2009-10-27 2011-04-28 Shyam Ramakrishnan Molecular Targets and Dietary Modulators of Exercise-Induced Muscle Damage
WO2011056549A1 (en) * 2009-10-27 2011-05-12 Access Business Group International Llc Molecular targets and dietary modulators of exercise-induced muscle damage
US20140147431A1 (en) * 2010-09-20 2014-05-29 The Regents Of The University Of California Compositions and Methods for Modulating Desnutrin-Mediated Adipocyte Lipolysis
US20180067131A1 (en) * 2011-01-08 2018-03-08 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure
US9487493B2 (en) * 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
US20150072985A1 (en) * 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
US9968613B2 (en) 2013-09-09 2018-05-15 Vtv Therapeutics Llc Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US10456406B2 (en) 2013-09-09 2019-10-29 Vtv Therapeutics Llc Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US11096946B2 (en) 2013-09-09 2021-08-24 Vtv Therapeutics Llc Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US20220072005A1 (en) * 2013-09-09 2022-03-10 Vtv Therapeutics Llc Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limb
CN112912069A (en) * 2018-10-23 2021-06-04 国立研究开发法人科学技术振兴机构 PPAR delta activators
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Also Published As

Publication number Publication date
CA2672420A1 (en) 2008-07-10
EP2114396A4 (en) 2010-03-10
US20140005238A1 (en) 2014-01-02
JP2010514804A (en) 2010-05-06
AU2007341981A1 (en) 2008-07-10
EP2114396A2 (en) 2009-11-11
WO2008083330A2 (en) 2008-07-10
US9192601B2 (en) 2015-11-24
WO2008083330A3 (en) 2008-10-23
US20110112047A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
US9192601B2 (en) Methods for enhancing muscle performance and tone
WO2009086526A2 (en) Methods for enhancing muscle performance and tone
Chow et al. Impact of endurance training on murine spontaneous activity, muscle mitochondrial DNA abundance, gene transcripts, and function
Welly et al. Comparison of diet vs. exercise on metabolic function & gut microbiota in obese rats
Fan et al. PPARδ promotes running endurance by preserving glucose
Narkar et al. AMPK and PPARδ agonists are exercise mimetics
Gurley et al. Increased skeletal muscle GLUT4 expression in obese mice after voluntary wheel running exercise is posttranscriptional
Mustafina et al. AGTR2 gene polymorphism is associated with muscle fibre composition, athletic status and aerobic performance
Liu et al. Lactylation, an emerging hallmark of metabolic reprogramming: Current progress and open challenges
Rinaldi et al. Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training
Tuniyazi et al. Changes of microbial and metabolome of the equine hindgut during oligofructose-induced laminitis
Tokinoya et al. Moderate‐intensity exercise increases renalase levels in the blood and skeletal muscle of rats
Sant’Anna et al. Physical exercise stimulates salivary secretion of cystatins
Chen et al. Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment
Reho et al. The stress of maternal separation causes misprogramming in the postnatal maturation of rat resistance arteries
Katayama et al. Hormonal regulation of thirst in the amphibious ray-finned fish suggests the requirement for terrestrialization during evolution
CN103547289A (en) Methods and compositions for treating alzheimer&#39;s disease
JP5990871B2 (en) Fatigue judgment method
Londoño et al. Transcriptional signatures regulated by TRPC1/C4-mediated Background Ca2+ entry after pressure-overload induced cardiac remodelling
Nedi et al. Tissue dependent differences in G-protein coupled receptor kinases associated with 5-HT4 receptor desensitization in the rat gastro-intestinal tract
Ohishi et al. Bortezomib alters sour taste sensitivity in mice
Huang et al. Exercise improves high-fat diet-induced metabolic disorder by promoting HDAC5 degradation through the ubiquitin–proteasome system in skeletal muscle
Li et al. Expression of the nociceptin/orphanin FQ receptor in the intestinal mucosa of IBS patients
Cui et al. Exercise suppresses mouse systemic AApoAII amyloidosis through enhancement of the p38 MAPK signaling pathway
Iida et al. Effects of exposure to oxytetracycline on the liver proteome of red seabream (Pagrus major) in a real administration scenario

Legal Events

Date Code Title Description
AS Assignment

Owner name: SALK INSTITUTE FOR BIOLOGICAL STUDIES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOWARD HUGHES MEDICAL INSTITUTE;REEL/FRAME:020738/0515

Effective date: 20080306

Owner name: SALK INSTITUTE FOR BIOLOGICAL STUDIES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, YONG-XU;DOWNES, MICHAEL;YU, RUTH T.;REEL/FRAME:020732/0422;SIGNING DATES FROM 20080111 TO 20080222

Owner name: HOWARD HUGHES MEDICAL INSTITUTE, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EVANS, RONALD M.;REEL/FRAME:020732/0462

Effective date: 20080111

Owner name: HOWARD HUGHES MEDICAL INSTITUTE, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NARKAR, VIHANG A.;REEL/FRAME:020732/0454

Effective date: 20080111

AS Assignment

Owner name: HOWARD HUGHES MEDICAL INSTITUTE, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EVANS, RONALD M.;NARKAR, VIHANG A.;SHAW, REUBEN J.;SIGNING DATES FROM 20101207 TO 20101208;REEL/FRAME:029372/0001

Owner name: SALK INSTITUTE FOR BIOLOGICAL STUDIES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOWNES, MICHAEL;YU, RUTH T.;REEL/FRAME:029371/0866

Effective date: 20101207

Owner name: SALK INSTITUTE FOR BIOLOGICAL STUDIES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOWARD HUGHES MEDICAL INSTITUTE;REEL/FRAME:029372/0041

Effective date: 20101207

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION